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ABSTRACT OF THE DISSERTATION 
The Regulation of Plasmodium falciparum Metabolism by Haloacid Dehalogenase Proteins 
Philip M Frasse 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Microbiology and Microbial Pathogenesis 
Washington University in St. Louis, 2021 
Professor Daniel E Goldberg MD, PhD, Chair 
Professor Audrey R Odom John MD, PhD, Co-Chair 
 
Malaria is an enormous financial and public health burden for much of the world, infecting 
over 200 million and killing over 400,000 people every year. While much progress has been made 
combating malaria in the past few decades, those advances have slowed in recent years, partially 
due to the emergence of resistance to all known antimalarials used to date. To achieve the goal of 
eliminating malaria as a major global health problem, new therapeutics need to be developed, 
targeting novel categories of parasite biology. One poorly understood area of parasite biology is 
the regulation of various metabolic pathways. We have recently identified a superfamily of 
proteins, named haloacid dehalogenase (HAD) proteins, that are implicated in resistance to 
metabolic inhibitors and regulation of essential metabolic pathways in Plasmodium falciparum 
malaria parasites. Here, we investigate how HAD2 (PF3D7_1226300) regulates metabolism of the 
isoprenoid biosynthesis pathway, using biochemical, metabolomic, and genetic tools. We find that 
HAD2 is a phosphatase with a preference for triose phosphates. We then investigate the related 
HAD proteins—HAD4 (PF3D7_1118400), Lipin (PF3D7_0303200), and HAD5 
(PF53D7_1017400)—for their roles in regulating parasite metabolism and the implications for 
 xxvii 
future drug design. We find that HAD4 and Lipin are dispensable for growth in asexual malaria 
parasites. Lipin disruption causes significant growth reduction and accumulation of lipid species, 
while HAD4 is a dispensable nucleotide phosphatase. We also find that HAD5 is a 
phosphomannomutase that is essential for parasite egress and invasion. We solve the three-
dimensional crystal structure of HAD5 and demonstrate our ability to selectively inhibit it 
compared to human phosphomannomutases. All of these findings add to our understanding of 
metabolic regulation in malaria parasites, illuminating key ways that targeting different metabolic 

































1.1 Malaria, and its primary causative agent, Plasmodium 
falciparum 
1.1.1 Perspectives on infectious disease research in the COVID-19 era 
Over the past year and a half, the world has been ravaged by a respiratory disease, 
COVID-19, caused by the virus SARS-CoV-2, which, in the year of 2020 killed approximately 
1.8 million people globally1. In the midst of this pandemic, with evolving virus variants, changes 
to public health policy, and a complete uprooting of everyday life, it is difficult to view this 
pandemic through the historical lens of infectious diseases as a whole. Communicable diseases 
have been an ever-present and ever-evolving reality that humanity has had to face. Globally, 
communicable diseases were responsible for roughly one quarter of all deaths in 2019, and this 
number is far higher for lower-income countries2. One of the oldest and most deadly infectious 
diseases is malaria, which has plagued humanity since at least 4700 years ago, with references to 
its quintessential cyclical fevers in the ancient Chinese medical text, Nei Ching and the Ebers 
Papyrus from 1534 BCE, and Plasmodium falciparum DNA has been isolated from 4000 year 
old mummies3–5. Malaria parasites even predate humanity, with Plasmodium spp. DNA isolated 
from 30 million-year old Culex mosquitos preserved in amber6. So how does malaria stack up to 
a modern-day emergent pathogen like SARS-CoV-2? To provide some perspective, in the 20th 
Century alone, malaria killed approximately 150-300 million people3, roughly equal to a 
COVID-19 pandemic every year of that century. However, it should be noted that recent decades 
have seen a great decline in malaria deaths, and we in affluent Western nations rarely hear or 
think about malaria as a result of the successful malaria elimination campaigns of the mid-20th 
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Century. Therefore, virtually all of the annual malaria cases and deaths occur in Africa, 
Southeast Asia, and South America7.  
Of course, this perspective should not be used to minimize the tragedy caused by 
COVID-19, nor to support notions that COVID-19 is an inconsequential “mild cold”. Indeed, 
lower- and middle-income countries (LMICs) have also been hit hard by COVID-19 and have 
been given far fewer resources and vaccine doses than affluent countries. 85% of globally 
administered vaccine doses have been given to citizens in high- and upper-middle-income 
countries as of June 14, 2021, despite accounting for just 53% of the global population. 
Meanwhile, low-income countries that account for 8.7% of the global population have 
administered just 0.3% of global vaccines as of June 14 (vaccination data compiled from national 
ministries of health by OurWorldInData.org8, population data from WorldBank.org9). Therefore, 
rather than trivialize the effects of COVID-19, let this subchapter serve as a reminder that 
although devastating infectious diseases like malaria have been largely eliminated from 
privileged nations like the USA, LMICs struggle with diseases on-par with COVID-19 every 
year, and those diseases have not taken a hiatus during the COVID-19 pandemic. Perhaps this 
outlook may rally some to harness their passion for funding and discovering cures and vaccines 
for COVID-19 and channel it toward diseases that continue to ravage communities abroad. 
1.1.2 Current and historical global health impact of malaria 
Malaria has shaped the lives, geopolitics, and even biology of humanity for millennia. 
References to malaria-like illnesses date back thousands of years to ancient Mesopotamia, China, 
and Egypt. Some believe that it was malaria that killed Alexander the Great (though others 
contend it was typhoid fever)10, and Alaric I, King of the Visigoths was also likely killed by the 
disease after he sacked the city of Rome in 410 CE11. DNA evidence has even been found of 
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malaria parasites in the graves of Roman children circa 450 CE, lending credence to the idea that 
malaria epidemics were a key factor in the ultimate fall of the Roman Empire in 476 CE12,13.  
While treatments for this disease were occasionally rooted in effective methodologies, 
such as herbal remedies containing active antimalarial compounds, other treatments were 
less...robust. One of the most famous methods of treating malaria came from the roman 
physician Quintus Serenus Sammonicus, who instructed patients to write “ABRACADABRA” 
on a talisman in eleven rows, removing one letter per row until only an “A” remained, and wear 
it around their necks14. Although this was probably not a particularly effective treatment, we 
therefore have malaria to thank for one of our most well-known magical words.  
Skipping ahead by a millennium or two, malaria continued to shape geopolitics into the 
20th Century, as the advent of World Wars and a more global society led to an influx of 
immunologically naïve soldiers into malaria-endemic regions, resulting in massive numbers of 
infections and greater spread of different strains and species of parasites, even introducing the 
parasites to non-endemic regions15. At least 1.5 million soldiers were believed to be infected in 
World War I, with up to 5% case fatality15. In addition to the inevitable non-combat deaths of 
these malaria patients, large swaths of military personnel were put out of commission by the 
cumbersome illness, thwarting military plans.15 
Although WWI provided a wake-up call to governments that malaria was more prevalent 
than they had appreciated, mitigation efforts did not prevent malaria from playing a role in the 
next World War as well, especially in the South Pacific Theater. Of note, the American 
campaign to prevent the Japanese invasion of the Philippines in 1942 was sidelined by malaria. 
Roughly 1/3 of the American and Filipino troops suffered from the disease, dramatically drawing 
out the war effort on that front. All-told, 60-65% of American soldiers in the South Pacific 
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reported contracting malaria, and there are some estimates that up to 90% of deployed Japanese 
troops at a time were rendered ineffective from the disease16.  
 Besides military difficulties, malaria has been shaping the lives and even the genetics of 
humanity for thousands of years. Several genetic polymorphisms are known to confer degrees of 
resistance to malaria and have been selected for in populations where malaria is endemic. These 
polymorphisms include mutations that give rise to sickle cell trait, alpha- and beta-thalassemia, 
glucose-6-phosphate dehydrogenase deficiency, and Duffy antigen negativity, among others17. In 
the case of sickle cell trait, while people who are homozygous for sickle cell allele of the beta-
globin gene are at risk of life-threatening sickle-cell anemia, termed Sickle Cell Disease (SCD), 
heterozygous carriers (who are said to have “sickle cell trait”) have a 50-90% reduction in 
malaria parasite density18, leading to a selection for that allele in malaria-endemic regions of sub-
Saharan Africa. Additionally, the Duffy antigen, Fy glycoprotein, which is required for 
Plasmodium vivax infection, is largely missing in sub-Saharan African populations, leading to 
near elimination of P. vivax malaria from that region.  These genetic selection factors have even 
further-reaching effects than current populations of Africa, as they are also common among 
people of African descent, such as African Americans, and can affect healthcare of these 
patients. Duffy antigen negativity, which is found in 65%-68% of African Americans, is 
associated with lower allograft procedure survival19, and SCD occurs in 1 out of every 365 
African Americans20. The presence of the sickle cell trait has even been controversially cited as 
an underlying cause of death in Black American men who died in police custody, relieving 
police of culpability in those deaths21 and highlighting the pervasive effects that malaria has had 
on modern society. 
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 By the mid 20th Century, decades of malaria-ridden wars led the United States to 
establish the Office of Malaria Control in War Areas, the predecessor to the Centers for Disease 
Control and Prevention (CDC). When WWII ended, the CDC (at the time, the Communicable 
Diseases Center) was established to commence the effort to eliminate malaria from the US: The 
National Malaria Eradication Program, which primarily consisted of vector control through the 
application of the insecticide dichlorodiphenyltrichloroethane (DDT). By 1949, the USA was 
declared free of malaria as a significant public health problem22.  Similar efforts were 
successfully implemented throughout Europe, leading to the elimination of malaria in Europe by 
197823. 
However, despite effective elimination efforts in the USA and Europe, malaria remains a 
part of daily life in much of the world. In 2019, there were an estimated 229 million cases of 
malaria throughout the world, leading to 409,000 deaths, two-thirds of which were children 
under the age of five7. Approximately 94% of the cases and deaths from malaria occurred in the 
WHO Africa region, with nearly ¼ of deaths and 1/3 of cases in Nigeria alone7. While all of 
these numbers have dropped significantly in the last few decades, there remains a great burden 
caused by malaria on these countries. The financial costs, as well as opportunity costs of constant 
illness, are dramatic in malaria endemic countries. A 2001 study came to the conclusion that 
between 1965 and 1995, malaria endemic countries exhibited a 70% reduction in income per 
capita compared to non-endemic countries after correcting for other factors24 . More recently, a 
similar analysis found a correlation between reduction of malaria incidence and an increase in 
gross domestic product per capita25. It is therefore quite clear that centuries of malaria 
endemicity have shaped the world as we know it, and there remains a huge burden of this disease 
that must be overcome to achieve true financial and healthcare equity across the globe. 
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1.1.3 Life cycle of malaria parasites 
Malaria is caused by protozoan, apicomplexan parasites of the genus Plasmodium. While 
there are dozens of species of these parasites, which are known to infect diverse animals from 
birds and reptiles to rodents and deer26–29, there are five Plasmodium species known to infect 
humans: P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi. Each species has its 
idiosyncrasies in disease and life cycle, but the deadliest and most common in modern times is P. 
falciparum, which is responsible for roughly 90% of the annual malaria deaths30. There also 
exists a robust and reliable culturing system to grow P. falciparum in the laboratory31,32, allowing 
for much of malaria research to be conducted on this species. P. falciparum parasites are 
therefore the focus of the research in this dissertation, and it can thus be assumed that mentions 
of “parasites” or “malaria” are specifically referring to P. falciparum parasites or P. falciparum-
caused malaria disease, unless otherwise specified. 
P. falciparum parasites have a complex life cycle, composed of several transcriptionally, 
metabolically, and morphologically distinct stages. At the beginning of a human infection, the 
sporozoite form of the parasite is injected into the bloodstream from an infected female 
Anopheles mosquito while taking a bloodmeal. These sporozoites migrate to the human liver, 
where they then invade and take-up residence within the hepatocytes. The parasites grow and 
replicate within hepatocytes, multiplying their numbers to develop into upwards of 40,000 
merozoites, capable of infecting red blood cells (RBCs). After 2-10 days, the merozoites are 
released out of the hepatocytes and into the blood stream, where they invade RBCs and 
commence their asexual replicative cycle.33 
The RBC invasion process involves protein-protein interactions between the merozoite and 
the RBC, and several of these interacting proteins have been identified and well-documented.34 
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As the merozoite invades the erythrocyte, a process that takes mere minutes, the RBC membrane 
invaginates and encloses around the parasite, forming a parasite-containing vacuole within the 
host cell, termed the parasitophorous vacuole (PV) surrounded by the parasitophorous vacuolar 
membrane (PVM). Within the RBC, the parasite grows for 48 hours, with morphologically 
distinguishable phases. Soon after invasion, stained parasites resemble a diamond ring under the 
microscope, and have been termed “rings”. As they grow and digest the RBC hemoglobin and 
other nutrients, the parasites start to encompass nearly the entire volume of the host cell, and 
form a distinctive digestive vacuole filled with crystallized heme from digested hemoglobin, 
termed hemozoin. These larger parasites are termed trophozoites and can further be informally 
subdivided by size into early- or late-trophozoites. Near the end of the 48-hour intraerythrocytic 
cycle, trophozoites undergo schizogony, a form of cell division where organelles and membranes 
divide to form roughly 16 to 32 daughter merozoite cells, still enclosed by the PVM. Finally, the 
parasites release proteins to degrade the PVM and subsequently the RBC membrane, releasing 
the daughter merozoites in a process called egress. These merozoites can then reinvade fresh 
RBCs and start the cycle anew. It is this 48-hour cycle, culminating with a large burst of 
egressing parasites, that causes the 48-hour cyclical fevers that are emblematic of P. falciparum 
malaria. 
Occasionally, intraerythrocytic parasites follow an alternate route of development, which 
ends in their maturation into the sexual stages of parasites: male or female gametocytes.35 The 
causative factors leading a parasite to develop into gametocytes rather than remaining asexual 
continues to be an active area of research. It is these gametocytes that are drawn up by 
mosquitoes during another bloodmeal, allowing them to develop further, undergo sexual 
reproduction, and grow in the midgut of the mosquito. Eventually, the progeny of that 
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reproduction develop once again into sporozoites and migrate to the mosquito salivary glands to 
be deposited into a new human host. 
1.1.4 Unique biology and metabolism of malaria parasites 
As a member of the apicomplexan phylum, Plasmodium falciparum is part of a unique 
branch of evolution, which is believed to be the result of a secondary endosymbiosis event36. 
Long ago, a eukaryotic algae cell engulfed a cyanobacterium in a primary endosymbiosis event, 
leading to a symbiotic relationship between the two. When that algal cell was itself engulfed by 
another eukaryote in a second endosymbiosis event, the resulting cell contained a unique 
organelle that formed from the membranes of the original cyanobacteria and algae and included a 
diverse set of genes. This is the evolutionary origin of apicomplexans like P. falciparum, and the 
unique endosymbiotic organelle is called the apicoplast37. This non-photosynthetic, four-
membraned, plastid-like organelle has its own self-replicating circular genome, and is the site of 
several metabolic pathways in the parasites, including the methyl-erythritol-phosphate (MEP) 
pathway to produce isoprenoids, fatty acid biosynthesis, and heme biosynthesis36,38. Not only are 
the evolutionary origins of apicomplexans intellectually intriguing, however, they also provide 
unique opportunities for therapeutically targeting these pathogens. Because of the algal or 
bacterial origins of many parasite genes and metabolic pathways, several parasitic proteins are 
more similar to those of plants and bacteria than they are to metazoans39. This can be seen 
specifically with the MEP pathway. 
The MEP pathway is a multiple-step enzymatic process of converting the glycolytic 
intermediates pyruvate and glyceraldehyde 3-phosphate (Gly3P) into isopentyl pyrophosphate 
(IPP) and dimethylallyl pyrophosphate (DMAPP)40. These products serve as the building blocks 
for all isoprenoids, including farnesyl and geranylgeranyl groups, which are post-translational 
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protein modifications, as well as dolichol, ubiquinone and more essential products41. In addition 
to malaria parasites, many bacteria and the chloroplasts of plants follow the MEP pathway to 
produce their IPP and DMAPP. However, other eukaryotes, including fungi and humans, follow 
an entirely distinct biosynthetic route involving mevalonate40,42. This provides an opportunity to 
develop antimalarial therapies that have a low risk of inadvertently targeting human enzymes. 
For many years, it was believed that the sole essential function of the apicoplast in 
intraerythrocytic parasites was isoprenoid production, as disruption of apicoplast biogenesis 
entirely can be rescued with the MEP pathway product, IPP43. However, it was recently 
demonstrated that at least one apicoplast-targeted gene, dephospho-CoA kinase, remains active 
and essential even after the apicoplast is disrupted44. Nonetheless, the MEP pathway remains one 
of the key essential functions of the apicoplast, and has great potential for parasite-specific 
therapeutic development. 
Even parasite genes in pathways are shared with humans, such as glycolysis, are sometimes 
sufficiently distinct from human orthologs due to our distant evolutionary paths, allowing for 
specific inhibitors to be made against parasite proteins without the risk of inhibiting human 
enzymes. For example, both humans and parasites encode the dihydrofolate reductase (DHFR) 
gene, an enzyme that reduces dihydrofolate to tetrahydrofolate, a necessary step in producing 
purines and some amino acids. Despite both species encoding DHFR, these enzymes are 
sufficiently unique to develop potent and specific inhibitors to parasite DHFR (PfDHFR) without 
inhibiting human DHFR (HsDHFR). Indeed, the previously used antimalarial pyrimethamine 
was widely used as a specific inhibitor of PfDHFR, until resistance emerged45. Similarly, 
compound WR99210 is a potent inhibitor of PfDHFR, but not HsDHFR. This allows HsDHFR 
to be introduced to parasites in the laboratory as a drug selection marker with WR99210 
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treatment when researchers are genetically editing parasites46. Thus, the unique metabolism and 
evolutionary distinctiveness of malaria parasites provides many opportunities for specific 
targeting of parasitic pathways.  
 
1.2 Antimalarial therapeutics 
1.2.1 History and targets of antimalarials 
For as long as malaria has plagued humankind, people across the world have searched for 
ways to combat this deadly febrile illness. In South America, generations of native peoples 
learned that the bark of the chinchona tree offered abatement from fevers. When Jesuit 
missionaries arrived in the Andes in the 17th Century CE., they learned of these healing 
properties of chinchona bark and brought that knowledge back to Europe. It wasn’t until 1820 
that the bitter-tasting active compound from the bark was isolated and named: quinine.47 
Quinine, and other alkaloid compounds from chinchona bark, as well as their synthetic 
derivatives, have long been some of the most widely used antimalarial agents to this day. They 
are believed to interfere with the parasite’s ability to safely digest hemoglobin, preventing the 
formation of hemozoin crystals and causing the accumulation of toxic free heme in the 
parasite.48–50 
 A similar story describes the discovery of another antimalarial game-changer. For 
thousands of years, ancient Chinese herbalists knew of the healing properties of sweet 
wormwood (Artemisia annua), which they called Qinghao. In the 1960s, the Chinese 
government established a project to screen plants for antimalarial compounds, and by 1971, Dr. 
Youyou Tu and colleagues extracted the active component from the Artemisia plant, named 
artemisinin, and showed its efficacy in treating malaria, for which Dr. Tu was awarded the Nobel 
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Prize in 2015. Artemisinin and its derivatives then began use in the mid 1990s as an antimalarial 
therapy, and they continue to be used as a primary component of therapies, particularly in 
Southeast Asia, where they are used with other partner drugs in artemisinin combination 
therapies (ACTs). While the mechanism of action and mechanisms of resistance of artemisinin 
and its derivatives is an area of active research, it appears that these compounds kill parasites by 
causing non-specific damage through alkylating several proteins and cellular structures in the 
parasite.51–55 
 Many other antimalarial compounds have also been developed and administered, 
including drugs that target folate metabolism (proguanil, pyrimethamine/sulfadoxine), 
mitochondrial electron transport (atovaquone), and other inhibitors of heme detoxification 
(lumefantrine). Several metabolic pathways in the parasite are under active investigation for drug 
development, some of which have even gone through initial clinical trial stages, including drugs 
targeting pyrimidine synthesis enzyme dihydroorotate dehydrogenase (DHODH)56 and the MEP 
pathway enzyme deoxy-xylulose-5-phosphate reductase (DXR)57. There also remains much 
active research into antimalarial compounds with unknown functions and unknown cellular 
targets. One frequently used repository of such compounds is the Malaria Box, a set of 400 
compounds with antimalarial activity, funded through the Medicines for Malaria Venture 
(MMV).58–61 
1.2.2 Rise of antimalarial resistance 
The recurring story of antimalarial therapies is the resistance that has invariably emerged 
to all antimalarials known to date. One of the most successful antimalarials, chloroquine (CQ), 
which was first used in 1934, first faced resistance in the field by the late 1950s, and continued to 
spread throughout Africa, Asia, and South America through the 1960s and 1970s62,63. Parasites 
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had developed mutations in the PfCRT gene or PfMDR1, which allowed these proteins to shuttle 
chloroquine out of the parasite’s digestive vacuole, its locus of action.64–68 
Following the replacement of chloroquine with sulphadoxine-pyrimethamine (SP), 
resistance quickly emerged to that treatment as well. This time, the resistance was obtained 
primarily through target site mutation, with multiple mutations in the DHFR and DHPS 
(dihydropteroate synthase) genes emerging soon after SP’s widespread use.69–73 
 With the introduction of artemisinin and ACTs in the 1990s, there was renewed hope as 
these drugs quickly became the first-line of defense74–76. However, as before, treatment failures 
were observed as early as the mid 2000s77. This time, parasites developed a unique form of 
resistance, termed “delayed clearance”, wherein parasites would eventually succumb to drug 
treatment, but it took longer to achieve that clearance.78 Thus, this form of resistance would 
theoretically be acceptable if patients were treated for longer, but difficulties with accessibility 
and patient compliance make this resistance concerning. The delayed clearance phenotype is a 
result of mutations to the Kelch13 (K13) gene in P. falciparum.79–83 Several studies have 
investigated the natural role for K13 in the parasites, and how mutation confers resistance84–86, 
but the most recent prevailing evidence points toward K13 involvement in endocytosis. It is the 
iron released from hemoglobin endocytosis and digestion that activates artemisinin, and thus 
K13 mutation slows down endocytosis and limits artemisinin activity51,87. While these mutations, 
and thus the treatment failures, are widespread in Southeast Asia80,88, other regions of the world 
have thus-far been mostly spared. However, there have been some potentially concerning reports 
of K13 mutations in African parasite isolates recently89,90. If these became widespread, it could 
be devastating for the region, which already bears the brunt of P. falciparum cases and deaths7.  
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1.2.3 Strategies to overcome antimalarial resistance 
One of the most commonly implemented methods to prevent antimalarial resistance is the 
use of combination therapies. As previously mentioned, sulfadoxine-pyrimethamine served as a 
one-two hit against the folate biosynthesis pathway, but unfortunately these targets were easily 
able to evolve resistance. More recently, ACTs have taken the field by storm, by combining the 
potent, but short-acting artemisinin derivatives with a longer-lasting partner drug such as 
piperaquine or lumefantrine.91  
 Another strategy that has been put forward is to cycle through different drugs to take 
advantage of waning resistance.92 This idea has been propelled by the finding that chloroquine 
resistance, and particularly the PfCRT K76T mutations associated with CQ resistance, have been 
diluted out of the parasite population following the discontinuation of CQ in certain regions. In 
the absence of selective pressure from widespread CQ, sensitivity has re-emerged.93,94 This 
finding could be to our advantage, cycling through different drug regimens as parasites develop 
and lose resistance. 
 Of course, one of the most commonly discussed strategies in antimalarial efforts is to 
develop new therapeutics that the parasites have not been exposed to. This consists of new 
derivatives of older drugs, which was seen with the advent of quinine derivatives such as 
chloroquine and primaquine95, as well as the artemisinin derivatives dihydroartemisinin and 
artemether96. While this strategy has certainly proven useful, providing a wealth of new 
antimalarials to our repertoire with varying degrees of drug-like properties, parasites continue to 
develop resistance easily. 
Therefore, the final method of combatting antimalarial resistance is, of course, the 
development of new drugs that target novel pathways. This is an enticing strategy against 
 15 
malaria parasites, as they harbor unique, essential metabolic pathways97. Some of the metabolic 
pathways that have shown potential include the shikimate pathway98,99, the MEP pathway40,57,100, 
and pyrimidine synthesis56,101. However, target-based approaches to drug discovery can prove 
difficult; while it is relatively simple to identify essential and unique potential targets, developing 
a compound de novo to inhibit that target is not trivial. Therefore, much of the work being done 
on the novel drug target front is through identification of the targets of Malaria Box compounds, 
followed by compound optimization60,61,102.  
1.2.4 Vaccines against malaria 
The Holy Grail of tools to combat infectious diseases is, of course, the vaccine. 
Unfortunately, an effective malaria vaccine has remained elusive, despite decades of attempts. 
Part of the reason for this lack of success is the complex parasite life cycle, with a variety of 
antigens that change throughout the parasite’s life cycle, and even some surface antigens that can 
be mixed and matched within the intraerythrocytic stages.103 Furthermore, the parasites live 
within host cells and sequester those infected RBCs in small blood vessels, largely shielding 
them from the immune system104,105. This may be why the most successful vaccine candidate to 
date, the RTS,S subunit vaccine, targets the circumsporozoite protein (CSP) on an extracellular 
stage of the parasites, the sporozoite106,107. However, this vaccine remains suboptimal, with ≤ 
55% efficacy in children up to 17 months old, and this efficacy wanes over time107. By contrast, 
the World Health Organization (WHO) has called for efficacy of at least 75% for a vaccine to be 
sufficient for widespread use108,109.  
 Recently, a new vaccine candidate, R21/MM completed its phase II clinical trial with 
very promising results, demonstrating up to 77% efficacy when administered with a high dose of 
adjuvant110,111, surpassing the WHO guidelines. The R21 vaccine improved upon RTS,S by 
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increasing the relative concentration of CSP antigen compared to other antigens present on the 
vaccine particle, which appeared to be effective. While we will still await further phase II trials 
in a second malaria season, as well as phase III trials, these results show much promise for the 
field. 
 To hedge bets in case the CSP-targeting vaccines face future challenges, many labs 
continue to search for other potential vaccine targets that may help with future efforts to combat 
escape mutants and non-falciparum malaria species. Clinical trials are already underway that 
target antigens from sporozoites112–114, blood stages115–117, and sexual stages of the parasites118–
120. And we are constantly searching for new antigens that may serve as vaccine candidates.  
 While the field continues to make progress on the development of new therapeutics and 
vaccines, and the cases and deaths from malaria have greatly declined in recent decades, the road 
to global malaria eradication remains long. It is therefore prudent that we advance our 
understanding of the cellular and metabolic processes within malaria parasites, which will allow 
further development of novel vaccines and therapies. 
 
1.3 The Haloacid dehalogenase-like hydrolase (HAD) 
Superfamily of proteins 
1.3.1 Introduction to HAD proteins 
Haloacid Dehalogenase (HAD) and HAD-like proteins (IPR023214 and IPR036412) are 
a vast and varied superfamily of proteins found ubiquitously throughout life121,122. Although the 
superfamily is named for founding members that catalyze haloacid dehalogenase activity123,124 
the majority of these proteins actually catalyze phosphatase and phosphoryl-transferase 
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reactions121. These enzymes canonically consist of a two-domain structure, the first being a 
catalytic core domain containing a Rossmannoid fold. Distinct from other Rossmannoid fold-
comprised proteins, HAD proteins also contain two structural motifs, termed the “squiggle” and 
“flap”, and four conserved sequence motifs (I-IV).125 The first of these conserved sequence 
motifs is the DXD di-aspartate catalytic site which coordinates a Mg2+ ion to facilitate catalysis. 
In addition to the catalytic core domain, the other notable feature of HAD proteins is the Cap 
domain, which is linked to the core domain through a hinge-like mechanism that allows the cap 
to close upon a substrate in the active site126. HAD enzyme cap domains can be categorized into 
C1 or C2, depending on the location of their insertion between other structural motifs of the 
enzyme, or C0 if the cap is a simple beta hairpin loop.121 An analogous way of categorizing the 
HAD superfamily is to divide them subfamilies (I, II, and III) based their cap domain, with 
subfamilies I and II corresponding to C1 and C2 caps, respectively, and subfamily III 
corresponding to C0 caps127.  
HAD proteins have been observed catalyzing a diverse array of reactions across life. The 
majority of documented HAD proteins are small-molecule phosphatases, and several efforts have 
been made to characterize the substrate profiles of HAD proteins from various organisms, 
including the model organisms of Escherichia coli and Saccharomyces cerevisiae128,129. Other 
documented HAD proteins catalyze phosphomutase and phospho-transferase reactions upon 
small metabolites130,131. Yet other HAD proteins have also been characterized as protein-
phosphatases132,133. While there have not been many conclusive links between subfamily 
categorization and substrate profile, Subfamily III proteins, marked by small C0 cap domains, 
appear capable of accommodating larger substrates like tRNA134, or tyrosine-phosphates on 
polypeptides135. However, this is not cut-and-dry, as there are Subfamily III enzymes that 
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dephosphorylate smaller substrates136, as well as Subfamily II members that catalyze protein 
phosphatase activity132. Some HAD protein have even been demonstrated to catalyze 
dephosphorylation both of proteins and small metabolites, prompting the suggestion that small-
molecule phosphatase HAD enzymes may also conduct “moonlighting” activity as protein 
phosphatases.133 
1.3.2 HAD Proteins in P. falciparum 
Genome-wide searching of P. falciparum for proteins that contain HAD or HAD-like 
domains reveals approximately 23 protein-coding sequences (Fig. 1). Some of these, such as P-
type ATPases and guanylyl cyclases, have been previously studied for their cellular functions137–
140, while others remain uncharacterized. In recent years, a handful of these uncharacterized 
HADs have begun catching our interest for the roles they play in parasite metabolism.  
 In 2014, Guggisberg et al. published a study141 documenting the discovery and 
characterization of PfHAD1, the first of the uncharacterized metabolic HADs to be described in 
P. falciparum. That study found that parasites lacking PfHAD1 were resistant to fosmidomycin 
(FSM), a competitive inhibitor of the methyl-erythritol phosphate (MEP) pathway of isoprenoid 
biosynthesis. Mutation of HAD1 led to an increase in metabolism through the MEP pathway, 
marked by elevated levels of the MEP pathway starting substrate, deoxyxylulose 5-phosphate 
(DOXP), thus outcompeting FSM. In 2018, Dumont et al.142 found another P. falciparum HAD 
protein, the phosphoglycolate phosphatase (PGP; PF3D7_0715000), that affected MEP pathway 
metabolism. When PGP was knocked out, dramatic changes were seen in parasite metabolism, 
particularly in the pentose phosphate pathway and flavin mononucleotide metabolism. 
Furthermore, PGP-knockout parasites were hypersensitized to FSM by decreasing metabolic flux 
toward the MEP pathway intermediates, the opposite effect seen with HAD1. Finally, another 
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HAD protein, termed PfHAD2, was also found in resistance screens described by Guggisberg et 
al., and will be examined in the next chapter. All three of these enzymes are members of HAD 
Subfamily II. The implication of three Subfamily II members in FSM resistance begged the 
question: is there something inherent about this subfamily of proteins that links them to MEP 
pathway metabolism? Alternatively, is the MEP pathway uniquely sensitive to metabolic 
perturbations, such that many metabolic disruptions might confer changes to FSM sensitivity? If 
so, this would support further investigation of this pathway as an antimalarial target, pairing 
FSM with other antimalarial drugs that target metabolism for FSM hypersensitization.  
1.3.3 Hypotheses on the mechanism(s) of HAD protein function 
Although increasing evidence indicates that HAD protein family members, and 
specifically HAD subfamily II members, modulate metabolic homeostasis in P. falciparum, the 
cellular mechanism by which HAD enzymes control metabolism remains yet undefined. In a 
2019 Microbiology Insights commentary143 on the 2018 mBio paper from Guggisberg et al.144, 
we proposed 2 hypothetical models of how HAD protein family members may regulate cellular 
metabolite levels (Figure 2). In the first model, HAD proteins regulate metabolism directly by 
enzymatically converting substrates that would otherwise directly feed into biosynthetic 
pathways (Fig. 2A). Thus, loss of HAD activity causes a build-up of phosphosubstrate levels, 
leading to increased availability of these compounds for downstream metabolic reactions. To 
date, however, most of the genetic changes described in HADs not only reduce catalytic activity 
but also lead to substantial reduction of overall HAD protein levels. Therefore, the metabolic 
changes in had mutants may be due to the loss of HAD activity or, alternatively, due in part to 
some non-catalytic “moonlighting” function of HADs. In this alternative model of HAD-
mediated metabolic regulation, enzymatic activity serves as a molecular switch between “active” 
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and “inactive” conformational states (Fig. 2B). Following the paradigm established by small 
GTPases (such as Ras and Rab homologs),145 the conformational change in a given HAD might 
modulate localization or protein-protein interactions to mediate a regulatory effect. In support of 
this alternative model, structural studies of substrate-bound HAD1 by Park et al.126 found that 
HAD1 undergoes a large conformational change (from an “open” to “closed” conformation) 
during cap domain closure on substrate binding. It remains to be seen if the intriguing P. 
falciparum HAD proteins act through one or both of these mechanisms to exert their effect on 
parasite metabolism and cellular function. 
 
1.4 Aim and Scope of the Dissertation 
With the growing appreciation for the diverse roles that HAD proteins play in cell 
biology and metabolism, and recent findings of their roles in P. falciparum parasites, we sought 
to further understand a subset of HAD proteins in these parasites. Due to its emergence in FSM-
resistance screens and strong homology to HAD1, HAD2 was chosen as the first protein to 
explore for interesting and important parasite biology and is covered in Chapter 2. Based on 
phylogeny and membership in related HAD subfamilies to HAD1 and PGP, PF3D7_1118400 
(HAD4) and PF3D7_1017400 (HAD5) were next chosen as interesting HAD proteins to 
investigate. Investigation of HAD4 is described in Chapter 3 alongside another HAD protein 
termed Lipin, while HAD5 is characterized in Chapter 4. Other related HAD enzymes that are 
outside the scope of this dissertation include HAD6 (ISN1; PF3D7_1206100), which has 
recently been characterized as an IMP-specific nucleotidase146, many P-type ATPases, and 
several more (Fig. 1). 
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This dissertation therefore aims to further characterize the growing list of Subfamily II 
and related HAD phosphatases in P. falciparum by investigating the above genes through 
genetic, biochemical, and metabolomic approaches. It also aims to further understand the link 
between the MEP pathway of isoprenoid biosynthesis (and specifically FSM sensitivity) and 
HAD proteins. Understanding these metabolic regulatory processes, particularly as they relate to 
essential metabolic functions of the parasite, may give insight into how these processes could be 










Figure 1. Phylogenetic tree of HAD superfamily (IPR023214) proteins from P. falciparum.  
Protein names are given in parentheses, if applicable. HAD1, HAD2, and PGP all fall within 
Subfamily II of HAD proteins, and cluster near each other phylogenetically. Proteins are color-
coordinated by the presence of InterPro domains: HAD Subfamily I (IPR006439), HAD 
Subfamily II (IPR006379 and IPR006357), HAD Subfamily III (IPR006549), P-type ATPase 
(IPR006539 and IPR008250), and FCP1 homology domain (IPR004274). Phylogenetic analysis 





Figure 2. Model of hypothetical mechanisms of HAD-mediated metabolic regulation.  
(A) HAD proteins catalyze the bulk flow of metabolites from one state to another. (B) Binding 
and hydrolyzing substrates induces conformational changes that dictate the regulatory functions 







1. Team, W. E. R. COVID-19 Weekly Epidemiological Update - 5 January 2021. (2021). 
2. The top 10 causes of death. World Health Organization (2020). Available at: 
https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. 
(Accessed: 14th May 2021) 
3. Carter, R. & Mendis, K. N. Evolutionary and historical aspects of the burden of malaria. 
Clinical Microbiology Reviews 15, 564–594 (2002). 
4. Azab, M. An interview with Dr. Magda Azab. Trop. Parasitol. 3, 170 (2013). 
5. Taylor, G., Rutland, P. & Molleson, T. A sensitive polymerase chain reaction method for 
the detection of Plasmodium species DNA in ancient human remains – ScienceOpen. Anc. 
Biomol. 1, 193–203 (1997). 
6. Poinar, G. Plasmodium dominicana n. sp. (Plasmodiidae: Haemospororida) from Tertiary 
Dominican amber. doi:10.1007/s11230-004-6354-6 
7. World Health Organization. World Malaria Report 2020: 20 years of global progress and 
challenges. (2020). 
8. Coronavirus (COVID-19) Vaccinations - Statistics and Research - Our World in Data. 
Available at: https://ourworldindata.org/covid-vaccinations. (Accessed: 15th June 2021) 
9. Data for High income, Upper middle income, Lower middle income, Low income | Data. 
Available at: https://data.worldbank.org/?locations=XD-XT-XN-XM. (Accessed: 15th June 
2021) 
10. Cunha, B. A. The death of Alexander the Great: Malaria or typhoid fever? Infectious 
Disease Clinics of North America 18, 53–63 (2004). 
 25 
11. Galassi, F. M. et al. The sudden death of Alaric i (c. 370-410 AD), the vanquisher of Rome: 
A tale of malaria and lacking immunity. Eur. J. Intern. Med. 31, 84–87 (2016). 
12. Thompson, A. BBC - History - Ancient History in depth: Malaria and the Fall of Rome. BBC 
(2011). Available at: https://www.bbc.co.uk/history/ancient/romans/malaria_01.shtml. 
(Accessed: 15th June 2021) 
13. Sallares, R. & Gomzi, S. Biomolecular Archaeology of Malaria. Anc. Biomol. 3, 195–213 
(2001). 
14. Hempelmann, E. & Krafts, K. Bad air, amulets and mosquitoes: 2,000 years of changing 
perspectives on malaria. Malar. J. 12, 232 (2013). 
15. Brabin, B. J. Malaria’s contribution to World War One - The unexpected adversary. 
Malaria Journal 13, 1–22 (2014). 
16. Malaria in World War II - Army Heritage Center Foundation. Available at: 
https://www.armyheritage.org/soldier-stories-information/malaria-in-world-war-ii/. 
(Accessed: 14th May 2021) 
17. Kariuki, S. N. & Williams, T. N. Human genetics and malaria resistance. Human Genetics 
139, 801–811 (2020). 
18. Williams, T. N. et al. Sickle cell trait and the risk of Plasmodium falciparum malaria and 
other childhood diseases. J. Infect. Dis. 192, 178–186 (2005). 
19. Akalin, E. & Neylan, J. F. The influence of Duffy blood group on renal allograft outcome in 
African Americans. Transplantation 75, 1496–1500 (2003). 
20. Data & Statistics on Sickle Cell Disease | CDC. Available at: 
https://www.cdc.gov/ncbddd/sicklecell/data.html. (Accessed: 14th May 2021) 
 26 
21. LaForgia, M. & Valentino-DeVries, J. How a Genetic Trait in Black People Can Give the 
Police Cover. The New York Times (2021). Available at: 
https://www.nytimes.com/2021/05/15/us/african-americans-sickle-cell-
police.html?action=click&module=Top Stories&pgtype=Homepage. (Accessed: 15th May 
2021) 
22. Prevention, C.-C. for D. C. and. CDC - Malaria - About Malaria - History - Elimination of 
Malaria in the United States (1947-1951). (2019). 
23. Piperaki, E. T. & Daikos, G. L. Malaria in Europe: emerging threat or minor nuisance? 
Clinical Microbiology and Infection 22, 487–493 (2016). 
24. Gallup, J. L. & Sachs, J. D. The Economic Burden of Malaria. Am. J. Trop. Med. Hyg. 
(2001). 
25. Sarma, N., Patouillard, E., Cibulskis, R. E. & Arcand, J. L. The economic burden of Malaria: 
Revisiting the evidence. Am. J. Trop. Med. Hyg. 101, 1405–1415 (2019). 
26. Valkiunas, G. & Iezhova, T. A. Keys to the avian malaria parasites. Malaria Journal 17, 212 
(2018). 
27. Guggisberg, A. M., Sayler, K. A., Wisely, S. M. & Odom John, A. R. Natural History of 
Plasmodium odocoilei Malaria Infection in Farmed White-Tailed Deer. mSphere 3, 
e00067-18 (2018). 
28. Silva, J. C. et al. Genome sequences reveal divergence times of malaria parasite lineages. 
Parasitology 138, 1737–1749 (2011). 
29. Boundenga, L. et al. Rodent malaria in Gabon: Diversity and host range. Int. J. Parasitol. 
Parasites Wildl. 10, 117–124 (2019). 
 27 
30. Snow, R. W. Global malaria eradication and the importance of Plasmodium falciparum 
epidemiology in Africa. BMC Medicine 13, EE (2015). 
31. Haynes, J. D., Diggs, C. L., Hines, F. A. & Desjardins, R. E. Culture of human malaria 
parasites Plasmodium falciparum. Nature 263, 767–769 (1976). 
32. Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science (80-. ). 
193, 673–675 (1976). 
33. Cowman, A. F., Healer, J., Marapana, D. & Marsh, K. Malaria: Biology and Disease. Cell 
167, 610–624 (2016). 
34. Weiss, G. E. et al. Revealing the Sequence and Resulting Cellular Morphology of 
Receptor-Ligand Interactions during Plasmodium falciparum Invasion of Erythrocytes. 
PLoS Pathog. 11, 1004670 (2015). 
35. Talman, A. M., Domarle, O., McKenzie, F. E., Ariey, F. & Robert, V. Gametocytogenesis: 
The puberty of Plasmodium falciparum. Malaria Journal 3, 24 (2004). 
36. Vaishnava, S. & Striepen, B. The cell biology of secondary endosymbiosis - How parasites 
build, divide and segregate the apicoplast. Molecular Microbiology 61, 1380–1387 
(2006). 
37. Janouškovec, J., Horák, A., Oborník, M., Lukeš, J. & Keeling, P. J. A common red algal 
origin of the apicomplexan, dinoflagellate, and heterokont plastids. Proc. Natl. Acad. Sci. 
U. S. A. 107, 10949–10954 (2010). 
38. Ralph, S. A. et al. Metabolic maps and functions of the Plasmodium falciparum 
apicoplast. Nature Reviews Microbiology 2, 203–216 (2004). 
39. Nkrumah, L. J. et al. Efficient site-specific integration in Plasmodium falciparum 
 28 
chromosomes mediated by mycobacteriophage Bxb1 integrase. Nat. Methods 3, 615–
621 (2006). 
40. Guggisberg, A. M., Amthor, R. E. & Odom, A. R. Isoprenoid Biosynthesis in Plasmodium 
falciparum. Eukaryot. Cell 13, 1348–1359 (2014). 
41. Imlay, L. & Odom, A. R. Isoprenoid Metabolism in Apicomplexan Parasites. Current 
Clinical Microbiology Reports 1, 37–50 (2014). 
42. Kuzuyama, T. Mevalonate and nonmevalonate pathways for the biosynthesis of isoprene 
units. Biosci. Biotechnol. Biochem. 66, 1619–1627 (2002). 
43. Yeh, E. & DeRisi, J. L. Chemical rescue of malaria parasites lacking an apicoplast defines 
organelle function in blood-stage plasmodium falciparum. PLoS Biol. 9, (2011). 
44. Swift, R. P., Rajaram, K., Liu, H. B. & Prigge, S. T.  Dephospho‐CoA kinase, a nuclear‐
encoded apicoplast protein, remains active and essential after Plasmodium falciparum 
apicoplast disruption . EMBO J. (2021). doi:10.15252/embj.2020107247 
45. Chulay, J. D., atkins, W. M. & Sixsmith, D. G. Synergistic antimalarial activity of 
pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am. J. Trop. 
Med. Hyg. 33, 325–330 (1984). 
46. Rieckmann, K. H., Yeo, A. E. & Edstein, M. D. Activity of PS-15 and its metabolite, 
WR99210, against Plasmodium falciparum in an in vivo-in vitro model. Trans. R. Soc. 
Trop. Med. Hyg. 90, 568–571 (1996). 
47. Achan, J. et al. Quinine, an old anti-malarial drug in a modern world: Role in the 
treatment of malaria. Malaria Journal 10, 144 (2011). 
48. Egan, T. J. et al. Structure-function relationships in aminoquinolines: Effect of amino and 
 29 
chloro groups on quinoline-hematin complex formation, inhibition of β- hematin 
formation, and antiplasmodial activity. J. Med. Chem. 43, 283–291 (2000). 
49. Kaschula, C. H. et al. Structure - Activity relationships in 4-aminoquinoline 
antiplasmodials. The role of the group at the 7-position. J. Med. Chem. 45, 3531–3539 
(2002). 
50. Corrêa Soares, J. B. R. et al. Interference with hemozoin formation represents an 
important mechanism of schistosomicidal action of antimalarial quinoline methanols. 
PLoS Negl. Trop. Dis. 3, (2009). 
51. Birnbaum, J. et al. A Kelch13-defined endocytosis pathway mediates artemisinin 
resistance in malaria parasites. Science (80-. ). 367, 51–59 (2020). 
52. Talman, A. M., Clain, J., Duval, R., Ménard, R. & Ariey, F. Artemisinin Bioactivity and 
Resistance in Malaria Parasites. Trends in Parasitology 35, 953–963 (2019). 
53. O’Neill, P. M., Barton, V. E. & Ward, S. A. The molecular mechanism of action of 
artemisinin - The debate continues. Molecules 15, 1705–1721 (2010). 
54. Hou, H. ping et al. Effects and Mechanism of Action of Artemisinin on Mitochondria of 
Plasmodium berghei. Chin. J. Integr. Med. 26, 277–282 (2020). 
55. Meshnick, S. R. Artemisinin: Mechanisms of action, resistance and toxicity. in 
International Journal for Parasitology 32, 1655–1660 (Pergamon, 2002). 
56. Kokkonda, S. et al. Lead optimization of a pyrrole-based dihydroorotate dehydrogenase 
inhibitor series for the treatment of malaria. J. Med. Chem. 63, 4929–4956 (2020). 
57. Wang, X. et al. MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors 
against Malaria. J. Med. Chem. 61, 8847–8858 (2018). 
 30 
58. Spangenberg, T. et al. The Open Access Malaria Box: A Drug Discovery Catalyst for 
Neglected Diseases. PLoS One 8, (2013). 
59. Lucantoni, L., Duffy, S., Adjalley, S. H., Fidock, D. A. & Avery, V. M. Identification of MMV 
malaria box inhibitors of Plasmodium falciparum early-stage gametocytes using a 
luciferase-based high-throughput assay. Antimicrob. Agents Chemother. 57, 6050–6062 
(2013). 
60. Malebo, H. M. et al. In vitro multistage malaria transmission blocking activity of selected 
malaria box compounds. Drug Des. Devel. Ther. 14, 1593–1607 (2020). 
61. Chirawurah, J. D. et al. Antimalarial activity of Malaria Box Compounds against 
Plasmodium falciparum clinical isolates. Int. J. Parasitol. Drugs Drug Resist. 7, 399–406 
(2017). 
62. Payne, D. Spread of chloroquine resistance in Plasmodium falciparum. Parasitology 
Today 3, 241–246 (1987). 
63. Wellems, T. E. & Plowe, C. V. Chloroquine-resistant malaria. Journal of Infectious Diseases 
184, 770–776 (2001). 
64. Foote, S. J. et al. Several alleles of the multidrug-resistance gene are closely linked to 
chloroquine resistance in Plasmodium falciparum. Nature 345, 255–258 (1990). 
65. Wellems, T. E., Walker-Jonah, A. & Panton, L. J. Genetic mapping of the chloroquine-
resistance locus on Plasmodium falciparum chromosome 7. Proc. Natl. Acad. Sci. U. S. A. 
88, 3382–3386 (1991). 
66. Ecker, A., Lehane, A. M., Clain, J. & Fidock, D. A. PfCRT and its role in antimalarial drug 
resistance. Trends in Parasitology 28, 504–514 (2012). 
 31 
67. Reiling, S. J. & Rohrbach, P. Monitoring PfMDR1 transport in Plasmodium falciparum. 
Malar. J. 14, 270 (2015). 
68. Duraisingh, M. T. & Cowman, A. F. Contribution of the pfmdr1 gene to antimalarial drug-
resistance. Acta Trop. 94, 181–190 (2005). 
69. Eskandarian, A. A., Keshavarz, H., Basco, L. K. & Mahboudi, F. Do mutations in 
Plasmodium falciparum dihydropteroate synthase and dihydrofolate reductase confer 
resistance to sulfadoxine-pyrimethamine in Iran? Trans. R. Soc. Trop. Med. Hyg. 96, 96–
98 (2002). 
70. Cowman, A. F., Morry, M. J., Biggs, B. A., Cross, G. A. M. & Foote, S. J. Amino acid changes 
linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase 
gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 85, 9109–9113 (1988). 
71. Vasconcelos, K. F. et al. Mutations in Plasmodium falciparum Dihydrofolate Reductase 
and Dihydropteroate Synthase of Isolates from the Amazon Region of Brazil. Mem. Inst. 
Oswaldo Cruz 95, 721–728 (2000). 
72. Triglia, T., Menting, J. G. T., Wilson, C. & Cowman, A. F. Mutations in dihydropteroate 
synthase are responsible for sulfone and sulfonamide resistance in Plasmodium 
falciparum. Proc. Natl. Acad. Sci. U. S. A. 94, 13944–13949 (1997). 
73. Gatton, M. L., Martin, L. B. & Cheng, Q. Evolution of resistance to sulfadoxine-
pyrimethamine in Plasmodium falciparum. Antimicrob. Agents Chemother. 48, 2116–
2123 (2004). 
74. White, N. J. Artemisinin: Current status. Trans. R. Soc. Trop. Med. Hyg. 88, 3–4 (1994). 
75. White, N. J. The Treatment of Malaria. N. Engl. J. Med. 335, 800–806 (1996). 
 32 
76. Klayman, D. L. Qinghaosu (artemisinin): An antimalarial drug from China. Science (80-. ). 
228, 1049–1055 (1985). 
77. Noedl, H. et al. Evidence of Artemisinin-Resistant Malaria in Western Cambodia. N. Engl. 
J. Med. 359, 2619–2620 (2008). 
78. Dondorp, A. M. et al.  Artemisinin Resistance in Plasmodium falciparum Malaria . N. Engl. 
J. Med. 361, 455–467 (2009). 
79. Mbengue, A. et al. A molecular mechanism of artemisinin resistance in Plasmodium 
falciparum malaria. Nature 520, 683–687 (2015). 
80. Ashley, E. A. et al. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. N. 
Engl. J. Med. 371, 411–423 (2014). 
81. Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum 
malaria. Nature 505, 50–55 (2014). 
82. Ménard, D. et al.  A Worldwide Map of Plasmodium falciparum K13-Propeller 
Polymorphisms . N. Engl. J. Med. 374, 2453–2464 (2016). 
83. Straimer, J. et al. Drug resistance. K13-propeller mutations confer artemisinin resistance 
in Plasmodium falciparum clinical isolates. Science 347, 428–31 (2015). 
84. Tilley, L., Straimer, J., Gnädig, N. F., Ralph, S. A. & Fidock, D. A. Artemisinin Action and 
Resistance in Plasmodium falciparum. Trends in Parasitology 32, 682–696 (2016). 
85. Wicht, K. J., Mok, S. & Fidock, D. A. Molecular Mechanisms of Drug Resistance in 
Plasmodium falciparum Malaria. Annual Review of Microbiology 74, 431–454 (2020). 
86. Rosenthal, M. R. & Ng, C. L. Plasmodium falciparum Artemisinin Resistance: The Effect of 
Heme, Protein Damage, and Parasite Cell Stress Response. ACS Infectious Diseases 6, 
 33 
1599–1614 (2020). 
87. Yang, T. et al. Decreased K13 Abundance Reduces Hemoglobin Catabolism and 
Proteotoxic Stress, Underpinning Artemisinin Resistance. Cell Rep. 29, 2917-2928.e5 
(2019). 
88. Woodrow, C. J. & White, N. J. The clinical impact of artemisinin resistance in Southeast 
Asia and the potential for future spread. FEMS Microbiology Reviews 41, 34–48 (2017). 
89. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) 
with parasite clearance rates after artemisinin-based treatments-a WWARN individual 
patient data meta-analysis. BMC Med. 17, 1 (2019). 
90. Uwimana, A. et al. Emergence and clonal expansion of in vitro artemisinin-resistant 
Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat. Med. 26, 1602–
1608 (2020). 
91. Cui, L. & Su, X. Z. Discovery, mechanisms of action and combination therapy of 
artemisinin. Expert Review of Anti-Infective Therapy 7, 999–1013 (2009). 
92. Nguyen, T. D. et al. Optimum population-level use of artemisinin combination therapies: 
A modelling study. Lancet Glob. Heal. 3, e758–e766 (2015). 
93. Dagnogo, O. et al. Towards a re-emergence of chloroquine sensitivity in Côte d’Ivoire? 
Malar. J. 17, 413 (2018). 
94. Mita, T. et al. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium 
falciparum chloroquine resistance transporter gene mutation K76T following the 
discontinuance of chloroquine use in Malawi. Am. J. Trop. Med. Hyg. 68, 413–415 (2003). 
95. Al-Bari, A. A. Chloroquine analogues in drug discovery: New directions of uses, 
 34 
mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J. 
Antimicrob. Chemother. 70, 1608–1621 (2014). 
96. Krishna, S., Bustamante, L., Haynes, R. K. & Staines, H. M. Artemisinins: their growing 
importance in medicine. Trends in Pharmacological Sciences 29, 520–527 (2008). 
97. Nigussie, D., Beyene, T., Shah, N. A. & Belew, S. New Targets in Malaria Parasite 
Chemotherapy: A Review. (2015). doi:10.4172/2470-6965/1000S1-007 
98. Mcconkey, G. A. Targeting the shikimate pathway in the malaria parasite Plasmodium 
falciparum. Antimicrob. Agents Chemother. 43, 175–177 (1999). 
99. Derrer, B., Macheroux, P. & Kappes, B. The shikimate pathway in apicomplexan parasites: 
implications for drug development. Front. Biosci. (Landmark Ed. 18, 944–69 (2013). 
100. Zhang, B. et al. A second target of the antimalarial and antibacterial agent fosmidomycin 
revealed by cellular metabolic profiling. Biochemistry 50, 3570–3577 (2011). 
101. Kokkonda, S. et al. Isoxazolopyrimidine-Based Inhibitors of Plasmodium falciparum 
Dihydroorotate Dehydrogenase with Antimalarial Activity. ACS Omega 3, 9227–9240 
(2018). 
102. Imlay, L. S. et al. Plasmodium IspD (2-C-Methyl-D-erythritol 4-Phosphate 
Cytidyltransferase), an Essential and Druggable Antimalarial Target. ACS Infect. Dis. 1, 
157–167 (2015). 
103. Hviid, L. & Jensen, A. T. R. PfEMP1 - a parasite protein family of key importance in 
plasmodium falciparum malaria immunity and pathogenesis. Adv. Parasitol. 88, 51–84 
(2015). 
104. Belachew, E. B. Immune Response and Evasion Mechanisms of Plasmodium falciparum 
 35 
Parasites. Journal of Immunology Research 2018, (2018). 
105. Dinko, B. & Pradel, G. Immune evasion by &lt;i&gt;Plasmodium falciparum&lt;/i&gt; 
parasites: converting a host protection mechanism for the parasite′s benefit. Adv. Infect. 
Dis. 06, 82–95 (2016). 
106. Casares, S., Brumeanu, T. D. & Richie, T. L. The RTS,S malaria vaccine. Vaccine 28, 4880–
4894 (2010). 
107. Laurens, M. B. RTS,S/AS01 vaccine (MosquirixTM): an overview. Hum. Vaccines 
Immunother. 16, 480–489 (2019). 
108. Malaria Vaccine Technology Roadmap. (2006). 
109. 2013 Update to the Malaria Vaccine Technology Roadmap. (2013). 
110. Moorthy, V. & Binka, F. R21/Matrix-M: a second malaria vaccine? The Lancet 397, 1782–
1783 (2021). 
111. Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant 
Matrix-M, with seasonal administration to children in Burkina Faso: a randomised 
controlled trial. Lancet 397, 1809–1818 (2021). 
112. Roestenberg, M. et al. A double-blind, placebo-controlled phase 1/2a trial of the 
genetically attenuated malaria vaccine PfSPZ-GA1. Sci. Transl. Med. 12, (2020). 
113. Mordmüller, B. et al. Sterile protection against human malaria by chemoattenuated 
PfSPZ vaccine. Nature 542, 445–449 (2017). 
114. Molina-Franky, J. et al. Plasmodium falciparum pre-erythrocytic stage vaccine 
development. Malaria Journal 19, (2020). 
115. Ellis, R. D. et al. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1 42-
 36 
C1/alhydrogel with and without CPG 7909 in malaria naïve adults. PLoS One 5, (2010). 
116. Blank, A. et al. Immunization with full-length Plasmodium falciparum merozoite surface 
protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-
human trial. NPJ vaccines 5, 10 (2020). 
117. Chitnis, C. E. et al. Phase I clinical trial of a recombinant blood stage vaccine candidate for 
Plasmodium falciparum malaria based on MSP1 and EBA175. PLoS One 10, (2015). 
118. Chan, J. A. et al. Malaria vaccine candidates displayed on novel virus-like particles are 
immunogenic and induce transmission-blocking activity. PLoS One 14, (2019). 
119. Lee, S. M. et al. The Pfs230 N-Terminal fragment, Pfs230D1+: Expression and 
characterization of a potential malaria transmission-blocking vaccine candidate. Malar. J. 
18, 356 (2019). 
120. Theisen, M., Jore, M. M. & Sauerwein, R. Towards clinical development of a Pfs48/45-
based transmission blocking malaria vaccine. Expert Review of Vaccines 16, 329–336 
(2017). 
121. Burroughs, A. M., Allen, K. N., Dunaway-Mariano, D. & Aravind, L. Evolutionary Genomics 
of the HAD Superfamily: Understanding the Structural Adaptations and Catalytic Diversity 
in a Superfamily of Phosphoesterases and Allied Enzymes. J. Mol. Biol. 361, 1003–1034 
(2006). 
122. Koonin, E. V. & Tatusov, R. L. Computer Analysis of Bacterial Haloacid Dehalogenases 
Defines a Large Superfamily of Hydrolases with Diverse Specificity. J. Mol. Biol. 244, 125–
132 (1994). 
123. Van der Ploeg, J., van Hall, G. & Janssen, D. B. Characterization of the haloacid 
 37 
dehalogenase from Xanthobacter autotrophicus GJ10 and sequencing of the dhlB gene. J. 
Bacteriol. 173, 7925–7933 (1991). 
124. Weightman, A. J., Weightman, A. L. & Slater, J. H. Stereospecificity of 2-
monochloropropionate dehalogenation by two dehalogenases of Pseudomonas putida 
PP3: evidence for two different dehalogenation mechanisms. J. Gen. Microbiol. 128, 
1755–1762 (1982). 
125. Aravind, L., Galperin, M. Y. & Koonin, E. V. The catalytic domain of the P-type ATPase has 
the haloacid dehalogenase fold. Trends Biochem. Sci. 23, 127–129 (1998). 
126. Park, J., Guggisberg, A. M., Odom, A. R. & Tolia, N. H. Cap-domain closure enables diverse 
substrate recognition by the C2-type haloacid dehalogenase-like sugar phosphatase 
Plasmodium falciparum HAD1. Acta Crystallogr. D Biol. Crystallogr. 71, 1824–34 (2015). 
127. Allen, K. N. & Dunaway-Mariano, D. Phosphoryl group transfer: Evolution of a catalytic 
scaffold. Trends in Biochemical Sciences 29, 495–503 (2004). 
128. Kuznetsova, E. et al. Genome-wide analysis of substrate specificities of the Escherichia 
coli haloacid dehalogenase-like phosphatase family. J. Biol. Chem. 281, 36149–61 (2006). 
129. Kuznetsova, E. et al. Functional Diversity of Haloacid Dehalogenase Superfamily 
Phosphatases from Saccharomyces cerevisiae: BIOCHEMICAL, STRUCTURAL, AND 
EVOLUTIONARY INSIGHTS. J. Biol. Chem. 290, 18678–98 (2015). 
130. Singh, S. K. et al. The thrH Gene Product of Pseudomonas aeruginosa Is a Dual Activity 
Enzyme with a Novel Phosphoserine:Homoserine Phosphotransferase Activity. J. Biol. 
Chem. 279, (2004). 
131. Kedzierski, L. et al. Structure of Leishmania mexicana Phosphomannomutase Highlights 
 38 
Similarities with Human Isoforms. J. Mol. Biol. 363, (2006). 
132. Gohla, A., Birkenfeld, J. & Bokoch, G. M. Chronophin, a novel HAD-type serine protein 
phosphatase, regulates cofilin-dependent actin dynamics. Nat. Cell Biol. 7, 21–29 (2005). 
133. Gohla, A. Do metabolic HAD phosphatases moonlight as protein phosphatases? Biochim. 
Biophys. Acta - Mol. Cell Res. 1866, 153–166 (2019). 
134. Galburt, E. A., Pelletier, J., Wilson, G. & Stoddard, B. L. Structure of a tRNA repair enzyme 
and molecular biology workhorse: T4 polynucleotide kinase. Structure 10, 1249–1260 
(2002). 
135. Selengut, J. D. MDP-1 is a new and distinct member of the haloacid dehalogenase family 
of aspartate-dependent phosphohydrolases. Biochemistry 40, 12704–12711 (2001). 
136. Wu, J. & Woodard, R. W. Escherichia coli YrbI is 3-deoxy-D-manno-octulosonate 8-
phosphate phosphatase. J. Biol. Chem. 278, 18117–18123 (2003). 
137. Kenthirapalan, S., Waters, A. P., Matuschewski, K. & Kooij, T. W. A. Copper-transporting 
ATPase is important for malaria parasite fertility. Mol. Microbiol. 91, 315–325 (2014). 
138. Taylor, C. J., McRobert, L. & Baker, D. A. Disruption of a Plasmodium falciparum cyclic 
nucleotide phosphodiesterase gene causes aberrant gametogenesis. Mol. Microbiol. 69, 
110–118 (2008). 
139. Carucci, D. J. et al. Guanylyl cyclase activity associated with putative bifunctional integral 
membrane proteins in Plasmodium falciparum. J. Biol. Chem. 275, 22147–22156 (2000). 
140. Krishna, S. et al. A family of cation ATPase-like molecules from Plasmodium falciparum. J. 
Cell Biol. 120, 385–398 (1993). 
141. Guggisberg, A. M. et al. A sugar phosphatase regulates the methylerythritol phosphate 
 39 
(MEP) pathway in malaria parasites. Nat. Commun. 5, 4467 (2014). 
142. Dumont, L. et al. The metabolite repair enzyme phosphoglycolate phosphatase regulates 
central carbon metabolism and fosmidomycin sensitivity in plasmodium falciparum. 
MBio 10, e02060-19 (2019). 
143. Frasse, P. M. & Odom John, A. R. Haloacid Dehalogenase Proteins: Novel Mediators of 
Metabolic Plasticity in Plasmodium falciparum. Microbiol. Insights (2019). doi:DOI: 
10.1177/1178636119848435 
144. Guggisberg, A. M. et al. Suppression of Drug Resistance Reveals a Genetic Mechanism of 
Metabolic Plasticity in Malaria Parasites. MBio 9, e01193-18 (2018). 
145. Mishra, A. K. & Lambright, D. G. Invited review: Small GTPases and their GAPs. 
Biopolymers 105, 431–448 (2016). 
146. Carrique, L. et al. Structure and catalytic regulation of Plasmodium falciparum IMP 






Chapter 2: HAD2, an inorganic phosphate-



















Below is a compilation of data from both the publication Guggisberg et al., 2018 in 
mBio1, as well as subsequent and parallel findings that have not been formulated into a complete 
publication yet. Much of the data presented in the mBio publication was performed before my 
time and is considered background information, and it is therefore omitted from this thesis 
chapter. This chapter therefore focuses less on the original discovery of HAD2 as a mediator of 
FSM-resistance and more on attempts to understand the mechanism of that phenomenon and the 
cellular function of HAD2. All data presented here was produced by myself except for 




HAD2 is a Plasmodium falciparum enzyme of the haloacid dehalogenase (HAD) 
superfamily of proteins. Premature stop codon mutations in HAD2 confer resistance to the 
inhibitor of parasite isoprenoid biosynthesis, fosmidomycin (FSM), at the expense of diminished 
growth. To understand how loss of HAD2 confers FSM resistance, we characterize the 
biochemical and metabolic role of HAD2 in parasites. Using whole-parasite metabolic profiling 
and biochemical assays of recombinant HAD2, we provide evidence that HAD2 is a small 
metabolite phosphatase, with some specificity for triose phosphates and fructose 1,6-
bisphosphate. We also explore the role that serine phosphorylation plays in regulation of HAD2 
activity and substrate specificity. Finally, we demonstrate that HAD2 is highly sensitive to free 
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phosphate inhibition, which may indicate a role for HAD2 in regulating intracellular phosphate 
levels for the parasite. 
 
2.2 Introduction 
2.2.1 The identification of HAD2, and its complex relationship with glycolysis1 
Malaria is caused by infection with unicellular eukaryotic parasites of the 
genus Plasmodium. The species Plasmodium falciparum is responsible for most life-threatening 
malarial disease. As an obligate intracellular parasite of human erythrocytes, Plasmodium 
falciparum has unique metabolic features that may be exploited to discover new drug targets and 
develop new therapies. In the red blood cell niche, Plasmodium parasites are highly dependent 
on glucose metabolism. Infection with Plasmodium spp. results in a nearly 100-fold increase in 
glucose import in red blood cells2–4. Despite these energy requirements, the parasite 
demonstrates little aerobic respiration via the tricarboxylic acid (TCA) cycle. Instead, it relies on 
anaerobic glycolysis to produce ATP5–8. 
Besides ATP production, glucose also has a number of anabolic fates in P. falciparum. 
One such fate is the synthesis of isoprenoids. Isoprenoids are a large class of hydrocarbons with 
extensive structural and functional diversity9. In the malaria parasite, isoprenoids perform several 
important functions, including protein prenylation, dolichylation, and synthesis of GPI anchors10–
12. Despite this diversity, all isoprenoids are synthesized from a common five-carbon building 
block, isopentyl pyrophosphate (IPP). Evolution has produced two distinct routes for IPP 
synthesis: the mevalonate pathway, found in archaea, fungi, animals, and the cytoplasm of 
plants; and the methylerythritol phosphate (MEP) pathway, found in most eubacteria, plant 
chloroplasts, and apicomplexan parasites such as P. falciparum13. Because it is both essential for 
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the parasite and absent from the human host, the MEP pathway is a compelling target for 
antimalarial development. The antibiotic and antimalarial fosmidomycin (FSM) is a competitive 
inhibitor of the first committed enzymatic step of the MEP pathway, catalyzed by 1-deoxy-D-
xylulose-5-phosphate reductoisomerase (DXR; EC 1.1.1.267)14–16. FSM has been validated as a 
specific inhibitor of the MEP pathway in P. falciparum17and is a valuable chemical tool to study 
MEP pathway biology and essential metabolism in the parasite. In this study, we found that FSM 
is also a useful tool for probing glycolytic metabolism upstream of the essential MEP pathway. 
Parasites are likely to control the proportion of glucose used for energy production versus 
production of secondary metabolites, such as isoprenoids. We previously used a screen for FSM 
resistance to identify HAD1, a metabolic regulator whose loss results in increased levels of MEP 
pathway intermediates and resistance to MEP pathway inhibition. HAD1 is a cytoplasmic sugar 
phosphatase that dephosphorylates a number of sugar phosphate intermediates upstream of the 
MEP pathway18,19. Hypomorphic mutation of HAD1 allows buildup of those upstream 
intermediates, culminating in increased availability of 1-deoxy-D-xylulose-5-phosphate (DOXP). 
This increased substrate availability outcompetes the inhibitor FSM to confer resistance.  
HAD1 belongs to the haloacid dehalogenase-like hydrolase (HAD) enzyme superfamily 
and, more specifically, to the IIB and Cof-like hydrolase subfamilies20. While HADs are found in 
all kingdoms of life, HAD1 is most closely related to bacterial members of this superfamily18,21, 
which have been implicated in metabolic regulation, stress response, and phosphate 
homeostasis22–26. However, most members of this superfamily remain uncharacterized. 
We next described the discovery of HAD2 (PF3D7_1226300), a second HAD family 
member in P. falciparum1. We found that HAD2 is a cytosolic phosphatase required for 
metabolic homeostasis. Loss of HAD2 by acquiring a premature stop codon, R157X, 
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dysregulates glycolysis and misroutes metabolites toward the MEP pathway, conferring drug 
resistance. In our study, we harnessed a fitness defect in HAD2R157X parasite strains to employ an 
innovative screen for suppression of drug resistance in the parasite. Selection for suppression of 
drug resistance identified mutations in PFK9, which encodes the canonical glycolytic regulatory 
enzyme phosphofructokinase (PFK). Reduction in PFK9 activity rescued the metabolic 
dysregulation in our resistant mutants and restored FSM sensitivity. Our unique approach thus 
revealed PFK9 as a site of exceptional metabolic plasticity in the parasite and uncovers a novel 
genetic mechanism by which P. falciparum malaria parasites may adapt to metabolic stress and 
drug selective pressure. 
2.2.2 Hypotheses on HAD2 function and regulatory mechanisms 
Having identified HAD2 as a small molecule phosphatase with some promiscuity in its 
substrate use1, we sought to further characterize how HAD2 functions in a cellular environment, 
what its in vivo substrate(s) is/are, and how its activity is regulated. HAD2 is highly homologous 
to HAD1, as it is also a member of the IIB and Cof-like hydrolase subfamilies of HAD 
proteins20. Because HAD1 is a sugar phosphatase, and unpublished metabolomic work of HAD1-
overexpressing parasites indicates that its primary natural substrate is glycerol 1-phosphate, we 
hypothesized that HAD2 would also have sugar phosphatase activity. In this work, we 
demonstrate that HAD2 has promiscuous activity against several small phosphometabolites, and 
observe a preference toward triose phosphates. 
 One distinction between HAD2 and HAD1 is the proteomic description of two 
phosphorylated serine residues (Ser4 and Ser9) near the N-terminus of HAD227. The 
phosphorylation by kinases and dephosphorylation by phosphatases of proteins have long been 
known as mechanisms of enzymatic regulation28,29. These phosphorylated serines therefore may 
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regulate the enzymatic function of HAD2. Understanding this regulation, and which kinase(s) or 
phosphatase(s) carry it out, may be a useful tool in future efforts to therapeutically target the 
MEP pathway. We therefore investigate these two serine residues in HAD2 by generating 
recombinant enzyme that ablates phosphorylation with serine-to-alanine mutation, or enzyme 
that mimics serine phosphorylation with serine-to-aspartate mutation. We demonstrate that 
phosphorylation of Ser4 and Ser9 may confer subtle increases to HAD2 phosphatase activity and 
modest changes in substrate specificity.  
 Finally, we demonstrate that HAD2 is highly sensitive to inhibition by physiologically 
relevant levels of inorganic phosphate (Pi). While this has been seen in other phosphatases, 
including HAD1 and HAD430, the high sensitivity of HAD2 to low concentrations of free 




2.3.1 HAD2 is a functional phosphometabolite phosphatase. 
We have previously established that P. falciparum HAD1 is a promiscuous sugar 
phosphatase, with activity against a wide range of phosphometabolites. Similarly, P. 
vivax HAD2 (PVX_123945) has been enzymatically characterized and found to possess 
phosphatase activity against various monophosphorylated substrates, including glycerol 2-
phosphate (Glc2P) and pyridoxal-5’-phosphate (PLP)31. Recombinant PvHAD2 also utilizes 
additional monophosphorylated substrates, such as adenosine monophosphate (AMP) and 
glycerol 1-phosphate (Glc1P), with moderate activity. 
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On the basis of the previous characterization of a close Plasmodium homolog, as well as 
sequence homology to HAD1 and other HAD proteins, we predicted that PfHAD2 would also 
function enzymatically as a phosphatase. We successfully purified recombinant PfHAD2 
in Escherichia coli and confirmed the phosphatase activity of recombinant PfHAD2 using para-
nitrophenyl phosphate (pNPP), a promiscuous, chromogenic phosphosubstrate (Fig. 1A)21,32,33. 
Because E. coli expresses a number of HAD-like phosphatases21, we confirmed that the 
phosphatase activity was specific to purified PfHAD2 by expression and purification of a 
catalytically inactive mutant (HAD2D26A). The Asp26 residue was chosen for mutagenesis 
because the corresponding residue in PfHAD1 (Asp27) has been previously shown to be required 
for catalysis19. 
We also established the activity of PfHAD2 against a panel of phosphorylated substrates 
and determined that its substrate profile closely mirrors that of PvHAD2 (Fig. 1B). Overall, we 
found that PfHAD2 is a phosphatase with activity against small phosphosubstrates, such as 
Glc2P. These data suggest that, like HAD1 and related HADs in microbes and plants21,33,34, 
HAD2 is a phosphatase with the potential to utilize a variety of monophosphorylated 
phosphometabolites. 
2.3.2 HAD2 enzymatic activity is strongly inhibited by free phosphate 
We have previously seen that HAD1 (as-yet unpublished) and HAD430 are both inhibited 
by high concentrations of inorganic phosphate (Pi) in the reaction buffer, acting as a feedback-
inhibitory mechanism to regulate enzyme function. To test whether HAD2 was also subject to Pi 
inhibition, we tested HAD2 activity in our pNPP assay with varying concentrations of Pi. 
Changing the concentration of the pNPP substrate along with the concentration of Pi, we found 
that HAD2 is competitively inhibited by free phosphate (Fig. 2A). We observed that HAD1 was 
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inhibited by free phosphate with a half-maximal inhibitory concentration (IC50) of ~5 mM. By 
contrast, we found that HAD2 was 5- to 10-fold more sensitive to inorganic phosphate inhibition 
than HAD1 (Fig. 2B), with a mean ± SEM IC50 of 0.46 ± 0.15 mM. Notably, parasites’ 
intracellular phosphate concentration is linked to that of the extracellular media, equilibrating in 
a matter of hours (Dr. Simon Cobbold, personal communication). Therefore, under typical 
culturing conditions, and in plasma, in which [Pi] equals 1-5 mM, we would expect the majority 
of HAD2 activity to be inhibited, as it is 2-10x the enzyme’s IC50. Furthermore, parasites exhibit 
diminished growth when grown in low concentrations of Pi, and HAD2 mutant parasites are 
hypersensitive to this (Fig. 2C). This suggests that the metabolic role of HAD2 could be linked to 
maintaining the balance of phosphate in the parasites, so that loss of HAD2 dysregulated 
phosphate homeostasis. 
2.3.3 Phosphorylation of HAD2 may modestly enhance enzymatic function 
To probe the question of how phosphorylation affects enzymatic function of HAD2, we 
generated recombinant HAD2 mutant enzymes that could mimic either an unphosphorylated or 
phosphorylated state, in addition to the wild-type (WT) sequence. We predict that the WT 
enzyme is likely in its unphosphorylated state, as the necessary protein kinase is likely absent 
from the E. coli cells used to generate the enzyme. However, to ensure an unphosphorylated 
state, we generated a mutant in which both Ser4 and Ser9 are mutated to alanine, termed 
“S4AS9A”. In contrast, due to its structural resemblance to phosphorylated serine, aspartic acid 
has previously been used to mimic the phosphorylated state of enzymes35,36. We therefore also 
generated a double-phospho-mimetic mutant in which both Ser4 and Ser9 are replaced with 
aspartic acid residues, termed “S4DS9D”. These two enzymes were then compared to each other 
and to WT for differences in enzymatic activity.  
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 When testing these enzymes for phosphatase activity against the robust substrate, Glc2P, 
we find that WT and S4AS9A enzymes had similar activities, while the S4DS9D enzyme 
exhibited a modest but significant increase in activity (Fig. 3). One caveat to this approach is that 
comparisons between different enzyme preparations can yield differing results, depending on the 
relative purification of the enzymes. Other metrics that are less dependent on exact concentration 
of active enzyme, such as Michaelis-Menten kinetics and relative activity against other 
substrates, may be more informative than this approach. 
 To further evaluate the potential regulatory role of serine phosphorylation on HAD2, we 
reasoned that perhaps inorganic phosphate inhibition of HAD2 was dependent upon serine 
phosphorylation. We therefore evaluated our recombinant S4AS9A and S4DS9D enzymes for 
inorganic phosphate inhibition. As shown in Fig. 2D, however, there was no statistically 
significant difference in phosphate inhibition between the WT enzyme (presumed to be 
unphosphorylated), the phospho-ablated, and the phospho-mimetic. We conclude that inorganic 
phosphate inhibition of HAD2 is independent of phosphorylation status of the enzyme.  
2.3.4 Metabolomic Analysis of HAD2 mutant parasites 
To investigate the mechanism by which HAD2 mutation confers FSM resistance, as well 
as the natural function of HAD2, we collaborated with Drs. Malcolm McConville and Simon 
Cobbold at the University of Melbourne to perform metabolic profiling on our parasites. This 
profiling was performed with the FSM-resistant parasites with HAD2R157X mutations from our 
resistance screen, termed “E2-D2”. Additionally, we profiled parasites in which FSM had been 
removed and suppressor mutations arose in PFK9, termed “E2-D2S”, signifying that they are 
descended from E2-D2, but are again FSM-sensitive. Finally, the E2-D2S parasites were 
complemented with a copy of HAD2-GFP, under a constitutive HSP110 promoter. These 
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parasites are termed “E2-A8”. Parasites were fed 13C-glucose over a period of 0-30 minutes, with 
time points taken to measure metabolic uptake of 13C in a variety of metabolites using LC-MS, 
comparing the pool size of each metabolite to that of wild-type 3D7 parasites. As shown in 
Figure 4, dramatic changes were seen in E2-D2 parasites compared to wild-type. Some of the 
most striking changes occurred in nucleotide phosphates, which were decreased in E2-D2 
parasites, and increases in certain glycolytic and pentose phosphate pathway metabolites, such as 
fructose 1,6-bisphosphate and the bisphosphates of both octulose and sedoheptulose. Based on 
these data from HAD2R157X parasites, we hypothesized that perhaps HAD2 dephosphorylates 
sugar phosphates, as has been shown for HAD1, and somehow promotes the synthesis of 
nucleotide phosphates. One caveat to these parasites, however, is that HAD2 mutation is not the 
sole polymorphism difference between E2-D2 parasites and wild-type, so other polymorphisms 
in the genome might account for some of these metabolic changes. 
 We next investigated E2-D2S parasites, which had developed suppressor mutations in 
PFK9 compared to E2-D2. These parasites had mostly inverted metabolic signatures compared 
to E2-D2 parasites, in regard to nucleotide phosphates and the pentose phosphate pathway. 
Unfortunately, as PFK9 is such an important regulator of carbon metabolism as a whole, it was 
difficult to fit a model to the effects we observed. 
 Finally, E2-A8 parasites were metabolically profiled. Because these parasites were 
transgenically generated from E2-D2S parasites, rather than evolved in a screen, the comparison 
between E2-A8 and E2-D2S is the cleanest comparison we currently have available to assess 
HAD2 metabolic effects. While there are not many differences between these strains, one 
notable exception is again seen with octulose 1,8-bisphosphate (OBP) and sedoheptulose 1,7-
bisphosphate (SBP). Both of these metabolites were elevated in the original E2-D2 strain, and 
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are decreased upon complementation with HAD2-GFP in the E2-A8 strain. This suggests that 
these metabolites could be the natural substrates for HAD2. 
2.3.5 HAD2 has a preference for triose phosphates in vitro 
Because the substrate profile in Figure 1 was limited and guided mostly by the findings 
from the P. vivax homolog, we sought to expand our substrate profile analysis of HAD2 to more 
phospho-metabolites. Furthermore, while Glc2P is the substrate with highest activity, it is not a 
naturally occurring metabolite, so the natural substrate(s) of HAD2 in parasites remained 
undetermined. Moreover, our metabolic data revealed specific substrates of interest that could 
potentially serve as HAD2 substrates, which needed to be validated in vitro. We therefore tested 
the enzymatic activity of WT HAD2 against a wide panel of potential substrates (Fig. 5). Again, 
it is clear that the substrate for which HAD2 has highest activity is Glc2P. While no single 
natural substrate stands out above the rest, and indeed HAD2 may act upon multiple substrates 
within parasites, the trend that emerges is the preference for triose phosphates. After Glc2P, the 
next substrates with highest activity are fructose bisphosphate (FBP) racemic (D/L) 
glyceraldehyde-3-phosphate (Gly3P) and D-Gly3P. Glycerol-1-phosphate (Glc1P) is also among 
the substrates with relatively higher activity, as is dihydroxyacetone phosphate (DHAP). 
Although FBP is an interesting outlier, the trend we observe is that the binding pocket for HAD2 
is appears tuned to accommodate triose phosphates. Unlike the P. vivax homolog, which has 
specific activity toward pyridoxal-5’-phosphate (PLP; Vitamin B6) that is comparable to Glc2P 
31, PfHAD2 had far less activity toward PLP, at roughly 20% the activity of Glc2P. This 
discrepancy highlights the difficulty in predicting substrate specificity of HAD proteins through 
homology alone. 
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Examining the phosphatase activity of our phosphomutant enzymes against the same 
panel of substrates, we identified some substrates that were differentially utilized between WT, 
S4AS9A, and S4DS9D enzymes (Fig. 5). For instance, the S4DS9D enzyme could more robustly 
dephosphorylate PLP and deoxyuridine triphosphate (dUTP), whereas the S4AS9A mutant was 
much less active against fructose 6-phosphate (F6P). Although this data is preliminary, and 
requires replication, it raises the possibility that phosphorylation of HAD2 alters its substrate 
specificity. Based on the crystal structure of PvHAD2, we would expect Ser4 and Ser9 to be 
relatively distal from the HAD2 active site, suggesting that serine phosphorylation does not 
result in direct contact with substrate, but rather may cause some form of conformational change 
that changes the binding pocket allosterically. It is also interesting to note that while we 
hypothesized the S4AS9A enzyme would mimic WT, this is not universally true, indicating that 
the hydroxyl group of the serine residue is important for HAD2 function, even before it becomes 
phosphorylated.  
Interestingly, many of the triose phosphates we observed in vitro, namely Gly3P and 
Glc1P, showed very little change upon HAD2 loss in the metabolomic data. One exception to 
this is DHAP which was elevated in E2-D2 strains, and decreased upon HAD2-GFP 
complementation. DHAP is rapidly interchanged with Gly3P by triose phosphate isomerase, so 
perhaps this is the source of the discrepancy37. Furthermore, this method of metabolic profiling 
measures the steady state pool levels of metabolites and is not suited to detect flux through a 
pathway. Thus, if these metabolites are quickly funneled to other fates, their buildup may not be 
detected.  
We also tested HAD2 activity toward nucleotide phosphates. Despite the broad effect of 
HAD2 mutation on nucleotide phosphates (Fig. 4), HAD2 did not have robust phosphatase 
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activity upon these, indicating that the nucleotide effect of HAD2 is indirect. Although they are 
omitted from Figure 5, guanosine monophosphate (GMP) and cytidine triphosphate (CTP), were 
also tested with WT HAD2, yielding activity of <0.015 µmol/min/mg. Finally, our most 
promising metabolomic candidates, OBP and SBP, are not readily accessible for purchase from 
any chemical vendors, so they could not be directly tested in our assays. To test the phosphatase 
activity of HAD2 against OBP and SBP, we instead developed a crude assay to synthesize these 
substrates in vitro, incubating aldolase with DHAP and ribose 5-phosphate (R5P) to generate 
OBP, or DHAP and erythrose 4-phosphate (E4P) to generate SBP. Shown in Figure 6, we then 
measured the phosphatase activity of HAD2 upon the incubated mixture. When compared to 
phosphate release of the reactants without aldolase, there was no significant increase in HAD2 
phosphatase activity when the full reaction was in place (Fig. 6). This suggests that HAD2 
activity against OBP and SBP is no higher than its activity against DHAP, E4P, and R5P. 
However, it should be noted that we were not able to control the concentration of OBP or SBP 
present, nor even confirm that these compounds were successfully generated. To conclusively 
test the hypothesis of HAD2 dephosphorylating SBP and OBP, confirmation of those 
compounds’ presence will be necessary. 
2.3.6 Genetic manipulation of HAD2  
Because of the inherent complexity of our metabolomic work due to the multitude of 
genetic differences between HAD2-null mutants and their parental strains, we sought a cleaner 
genetic approach to evaluating HAD2 function in parasites. By generating parasites whose only 
difference from parental strains was the presence or absence of HAD2, particularly in an 
inducible manner, we can be more confident that metabolic differences we observe are due to 
HAD2, either directly or indirectly, rather than polymorphisms elsewhere in the genome. 
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Furthermore, while we already have had success rescuing had2, pfk9 mutant parasites with a 
HAD2-GFP construct (i.e. the E2-A8 strain), we were concerned that the underlying pfk9 
mutations might mask or further complicate any metabolic changes observed by the addition of 
HAD2-GFP due to the key role PFK9 plays in regulation of all of carbon metabolism38. 
 Therefore, the first genetic method we used was to transfect an extra copy of pTEOE110: 
HAD2-GFP into a wild-type background, using the same transposase-mediated method as in the 
complementation parasites E2-A8. This resulted in successfully acquired parasites with 
exogenous HAD2-GFP expressed cytosolically (Fig. 7). These parasites have yet to be 
characterized metabolically. 
 There are several disadvantages to using the pTEOE/piggyBac system. First, as a 
transposase-mediated system, there is no control over the locus of insertion, meaning that in the 
absence of multiple transfections, the metabolic or phenotypic observations cannot be 
confidently attributed to the extra copy of HAD2 without the consideration that an endogenous 
gene’s disruption is the source of the phenotype. Secondly, depending on the relationship 
between endogenous HAD2 activity and its substrate availability, addition of more HAD2 may 
not have much effect if the system is already saturated with HAD2 activity. Finally, because this 
method of transfection is static rather than inducible, the long culturing period before attaining 
transgenic parasites allows compensatory mutations to arise before parasites are even acquired.  
We therefore decided to generate an inducible knockdown of HAD2 at the endogenous 
locus using the previously described anhydrotetracycline (aTc)-repressible system39,40. Using 
CRISPR/Cas9, we inserted a 3xHA tag and a 10x aptamer array to the C-terminus of the 
endogenous HAD2 gene, so that translation of HAD2 could be repressed in the absence of aTc 
and permitted in the presence of aTc (Fig. 8A). We successfully acquired transfectants of this 
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system, calling this strain “PF4”, and immunoblotting for HA demonstrates that removal of aTc 
results in modest reduction of HAD2 expression (Fig. 8B).  
To confirm whether this modest reduction of HAD2 was sufficient to phenocopy the 
HAD2R157X parasites originally obtained in FSM-resistance screens, we evaluated these parasites 
for their FSM resistance and their growth rate. As seen in Figure 8C and 8D, respectively, the 
PF4 parasites had minimal difference in growth and FSM resistance when comparing +aTc 
conditions to -aTc conditions (note that while it may appear in Fig. 8C that a difference in 
growth is emerging over time, carrying this out for longer did not reveal a true difference in 
growth; not shown). The FSM half-maximal effective concentration (EC50) did increase by 1.2-
fold, but this is significantly less than the 5-fold increase observed in HAD2R157X parasites from 
our original screen1.  
 
2.4 Discussion 
We have reported that, similar to the homologous enzyme PfHAD1, mutation to PfHAD2 
confers fosmidomycin resistance and dramatic changes to parasite metabolism. To better 
understand how parasites regulate metabolism and evolve FSM resistance, we sought to uncover 
the mechanism by which HAD2 mutation confers FSM resistance by elucidating its natural role 
in the cell and how its function might be regulated by the parasite and its environment. 
 While several hypotheses arose from metabolomic profiling of E2-D2, E2-D2S, and E2-
A8 parasites, perhaps most promising of which was the dephosphorylation of SBP and OBP, 
these hypotheses could not be validated by in vitro biochemical assays, and the metabolomic 
data is complicated by the complex genetic background of these parasites. By contrast, 
enzymatic data suggests that triose phosphates are among the most readily dephosphorylated by 
 55 
HAD2. The dephosphorylation of triose phosphates by HAD2 does align with our model for how 
its homolog, HAD1 functions. HAD1 mutants have elevated glycerol 1-phosphate (Glc1P) which 
may be easily oxidized to Gly3P, the direct precursor to DOXP, to allow elevated DOXP levels 
and FSM resistance. As shown in Figure 5, PfHAD2 also dephosphorylates Glc1P, like HAD1, 
so this may be the mechanism for HAD2 as well. Alternatively, or in addition, one of the highest 
naturally-occurring HAD2 substrates is Gly3P itself. The dephosphorylation of Gly3P would 
likely directly impair the synthesis of DOXP, explaining how loss of HAD2 promotes elevated 
levels of DOXP and subsequent FSM resistance. Additionally, FBP is another substrate upon 
which HAD2 has high activity, and loss of HAD2 results in elevated FBP. The fact that 
suppressor mutations in the E2-D2S parasites arose in PFK9, which produces FBP, indicates that 
this may be a true function of HAD2 as well. As HAD proteins are notorious for their substrate 
promiscuity, any or all of these might be true substrates of HAD2 within the parasite. 
 These models are complicated by our findings that the phosphatase activity of HAD2 is 
strongly inhibited by free phosphate. Because this activity is so strongly inhibited by cellularly 
relevant concentrations of phosphate, it may be that phosphatase activity is not the cellular role 
of HAD2. Perhaps another reaction, such as phosphotransferase activity, is less inhibited by free 
phosphate. Unfortunately, this is a difficult reaction to assay in vitro, as the correct phosphate-
donor and acceptor would need to be chosen to assay. Alternatively, some promiscuous 
phosphatases are known to catalyze sulfate transfer activity as well41. Metabolic profiling may be 
able to assist in teasing out these possible alternative reactions for HAD2, highlighting the 
usefulness of our HAD2-GFP-overexpressing parasites. 
This also highlights the need for an inducible knockdown system. Unfortunately, our 
inducible knockdown was unable to phenocopy HAD2R157X parasites obtained in FSM resistance 
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screens. We hypothesize that this is due to the incomplete knockdown, as there is still detectable 
HAD2 present in the parasites, and previous work by others has demonstrated the precedent for 
certain P. falciparum proteins being expressed in great excess, requiring robust knockdown to 
observe a phenotype42. We therefore propose that a more substantial inducible 
knockout/knockdown will be an invaluable tool moving forward in our understanding of HAD2, 
and suggest future work that implements a Di-Cre system for inducible knockout or a more 
complete knockdown with a TetR-DOZI system that introduces RNA aptamers both upstream 
and downstream of the coding sequence. With a robust knockdown, in addition to the HAD2-
GFP overexpressing parasites, metabolomic studies may be able to conclusively ascertain the 
metabolic role of HAD2 in parasites. 
 If these metabolic studies confirmed a role for HAD2 dephosphorylating triose 
phosphates or FBP, or identified other substrates, an open question would remain as to the 
biological purpose of this activity. Our observation that inorganic phosphate inhibits HAD2 
activity offers a possible answer. Wild-type parasites require ~5 mM inorganic phosphate to 
grow optimally, and are sensitive to decreases in the phosphate concentration, while HAD2R157X 
parasites are hypersensitized to this drop in phosphate (Fig 3C). Perhaps HAD2 serves as a 
regulator of the intracellular phosphate concentration, and utilizes triose phosphates and FBP as 
the source of phosphate release. This may explain why HAD2 would have such robust capacity 
for dephosphorylation despite existing in a prohibitively high concentration of phosphate. 
Intracellular phosphate homeostasis is critical for countless purposes, including the energy needs 
of the cell and biosynthesis of macromolecules43–47, which might explain why dysregulation of 
this system by loss of HAD2 leads to growth defects in parasites. 
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Finally, the effect that serine phosphorylation of HAD2 has on its function remains 
unclear. We showed by our phospho-mimetic mutants that phosphorylation of both Ser4 and 
Ser9 may confer a slight (~20%) increase in phosphatase activity, which is relatively subtle 
compared to other enzymes in which phosphorylation canonically confers a more dramatic shift 
in on/off status48,49. Additionally, phosphomutant enzymes appeared to have a slightly altered 
substrate specificity, notably increasing the activity of HAD2 toward PLP, to better align with 
the P. vivax HAD2. Perhaps phosphorylation of HAD2 is a response to availability of phosphate 
sources in the cell, allowing the enzyme to utilize readily available phosphometabolites to 
maintain phosphate homeostasis. Alternatively, or perhaps in conjunction, perhaps 
phosphorylation controls the localization of HAD2, another common function of enzyme 
phosphorylation50,51, to provide access to different substrates. Future studies investigating the 
role of phosphorylation on HAD2 may benefit from rescuing HAD2-knockdown parasites with 
our phospho-ablated or phospho-mimetic constructs to detect phosphorylation-dependent 
differences in localization and metabolomics in parasites. Protein crystallization and analysis of 
the three-dimensional structure of HAD2’s binding pocket, and how it might change upon 




2.5.1 Parasite strains and culture. 
All parasites used were of the 3D7 parental strain with the exception of PF4, which was 
in an NF54attB background. Unless otherwise indicated, parasites were maintained at 37°C in 5% 
O2–5% CO2–90% N2 in a 2% suspension of human erythrocytes in RPMI medium (Sigma-
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Aldrich) modified with 27 mM NaHCO3, 11 mM glucose, 5 mM HEPES, 0.01 mM thymidine, 
1 mM sodium pyruvate, 0.37 mM hypoxanthine, 10 µg/ml gentamicin, and 5 g/liter Albumax 
(Thermo Fisher Scientific). 
2.5.2 Plasmodium growth measurement 
Parasitemia in daily growth assays was measured via flow cytometry by incubating 10 µL 
of parasite culture with 190 µL of 0.4 µg/mL acridine orange (Invitrogen) in PBS for 1 minute. 
Stained parasites were analyzed on a BD FACS Canto flow cytometer gating on DNA and RNA-
bound dye signal using FITC and PerCP-Cy5.5 filters, respectively. 50,000 events were recorded 
for each sample. 
2.5.3 Generation of recombinant HAD2. 
The predicted coding sequence of HAD2 was amplified using the HAD2_LIC_F and 
HAD2_LIC_R primers (Table 1). A catalytic mutant (D26A) and phospho-mutants (S4AS9A 
and S4DS9D) were also generated. The had2D26A allele was created using the HAD2_D26A_F 
and HAD2_D26A_R site-directed mutagenesis primers (Table 1). The S4AS9A allele was 
generated with PMF003 and PMF007, and the S4DS9D allele was generated with PMF006 and 
PMF007.  
Ligation-independent cloning was used to clone HAD2 (WT and mutants) into vector 
BG186152, which introduces an N-terminal 6×His fusion into the expressed protein. 
BG1861:6×His-HAD2 was transformed into One Shot BL21(DE3)pLysS Escherichia coli cells 
(Thermo Fisher Scientific). Protein expression was induced for 2.5-3 h with 1 mM isopropyl-β-
D-thiogalactoside at mid-log phase (optical density at 600 nm [OD600] of 0.4 to 0.5). Cells were 
collected by centrifugation and stored at −20°C. 
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Cells were lysed in buffer containing 1 mg/ml lysozyme, 20 mM imidazole, 1 mM 
dithiothreitol, 1 mM MgCl2 10 mM Tris HCl (pH 7.5), 30 U benzonase (EMD Millipore), and 
cOmplete EDTA-free protease inhibitor tablets (Roche). 6×His-HAD2 was bound to nickel 
agarose beads (Gold Biotechnology), washed with a mixture containing 20 mM imidazole, 
20 mM Tris HCl (pH 7.5), and 150 mM NaCl, and eluted in a mixture containing 300 mM 
imidazole, 20 mM Tris HCl (pH 7.5), and 150 mM NaCl. This eluate was further purified by size 
exclusion gel chromatography using a HiLoad 16/600 Superdex 200-pg column (GE Healthcare) 
equilibrated in a mixture containing 25 mM Tris HCl (pH 7.5), 250 mM NaCl, and 1 mM MgCl2. 
The elution fractions containing HAD2 were pooled and concentrated, and glycerol was added to 
reach a concentration of 10% (wt/vol). Protein solutions were immediately flash frozen and 
stored at −80°C. 
2.5.4 HAD2 activity assays. 
The rate of para-nitrophenyl phosphate (pNPP; Sigma-Aldrich S0942) hydrolysis by 
HAD2 was determined by continuous measurement of absorbance at 405 nm. Assays were 
performed at 37°C in a 50-µl volume consisting of 50 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 
10 mM pNPP, and 1.2 µM enzyme. Hydrolysis of other phosphorylated substrates by HAD2 was 
measured using an EnzChek phosphate assay kit (Life Technologies). The reaction buffer was 
modified to contain 50 mM Tris-HCl (pH 8.0), 20 mM MgCl2, 0.2 mM 2-amino-6-mercapto-7-
methylpurine riboside (MESG), and 1 U/ml purine nucleoside phosphorylase (PNP). Reaction 
mixtures contained 5 mM substrate and 730 nM enzyme. The activity of catalytically inactive 
6×His-HAD2D26A was measured for all substrates, and the data were used to normalize the 
activity found for the WT HAD2 enzyme. Activity was normalized to that obtained from 
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catalytically inactive 6×His-HAD2D26A. All data represent means of results from ≥3 independent 
experiments performed with technical replicates. 
2.5.4 pTEOE110:HAD2 and pSN054:HAD2 plasmid construction and 
transfection 
The pTEOE110 construct contains the heat shock protein 110 gene (PF3D7_0708800) 5′ 
untranscribed region (UTR) and a C-terminal GFP tag18. Human dihydrofolate reductase 
(hDHFR) is present as a selectable marker. Inverted terminal repeats are included for genome 
integration by a cotransfected piggyBac transposase (pHTH, MRA-912 from MR4; ATCC, 
Manassas, VA). HAD2 was amplified with the HAD2_XhoI_F and HAD2_AvrII_R primers 
(Table 1) and cloned into AvrII and XhoI sites in the pTEOE110 plasmid. 
The HAD2 conditional knockdown strain, “PF4”, was generated by transfecting NF54attB 
parasites53 using previously described methods39,40. CRISPR/Cas9 was used to edit the 
endogenous HAD2 locus, adding a 3xHA tag to the C-terminus of the gene, followed by a 10x 
aptamer array, a blasticidin (BSD) resistance marker, and the TetR-DOZI fusion protein. Primers 
PMF140 and PMF141 were used to amplify the 5’ homologous region (HR) from parasite 
gDNA, and primers PMF142 and PMF143 were used to amplify the 3’ HR. Resultant parasites 
were maintained in the presence of anhydrotetracycline (aTc; Cayman Chemicals) in DMSO at 
500nM unless otherwise specified. 
Transfections were performed as previously described18. Briefly, 50 to 100 μg of plasmid 
DNA was precipitated and resuspended in Cytomix (25 mM HEPES [pH 7.6], 120 mM KCl, 
0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM K2HPO4). A ring-stage P. 
falciparum culture was washed with Cytomix and resuspended in the DNA/Cytomix solution. 
Cells were electroporated using a Bio-Rad Gene Pulser II electroporator at 950 µF and 0.31 kV. 
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Electroporated cells were washed with media and returned to normal culture conditions. 
Parasites expressing the construct were selected by continuous treatment with 5 nM WR92210 
for the pTEOE plasmid (Jacobus Pharmaceuticals) or with 2.5 µg/mL BSD (Fisher) for the 
pSN054 plasmid. Transfectants were cloned by limiting dilution, and the presence of the HAD2-
GFP construct was verified by PCR using gene- and GFP-specific primers (HAD2_R157X_F 
and GFP_R; Table 1). Maintenance of the endogenous HAD2 and PFK9 genotypes was verified 
by Sanger sequencing. 
2.5.5 Microscopy 
Fluorescent microscopy images were taken using a Zeiss Axio Observer D1 (Carl Zeiss 
Inc.) at the Washington University Molecular Microbiology Imaging Facility. Images were 
acquired with a Plan-Apochromat 100x (NA1.4) objective using the Zen 2.3 pro (blue edition) 
software. 
2.5.6 Quantification of FSM resistance 
Asynchronous P. falciparum cultures were diluted to 1% parasitemia and were treated 
with FSM (Life Technologies) in water at concentrations up to 500 μM. Growth inhibition 
assays were performed in opaque 96-well plates at 100 μL culture volume. After 3 days, parasite 
growth was quantified by measuring DNA content using Quant-iT PicoGreen dsDNA reagent 
(Thermofisher), as previously described54. Picogreen fluorescence was measured on a Perkin 
Elmer multimode Envision microplate reader. EC50 values were calculated by nonlinear 





Figure 1. PfHAD2 is a small molecule phosphatase.  
(A) HAD2 is an active phosphatase, and HAD2D26A is a catalytic mutant (cat. mut.) that can be 
used as a negative control for HAD2-specific activity. “no enz.” represents a no-enzyme control. 
Data shown represent the enzyme activities seen using the synthetic phosphatase substrate pNPP. 
Error bars represent standard errors of the means (SEM) (****, P ≤ 0.0001 [unpaired t test]; n.s., 
not significant). (B) Activity of HAD2, normalized to the activity of the catalytic mutant 
(HAD2D26A), for a variety of substrates (Glc2P, glycerol 2-phosphate; M6P, mannose 6-




Figure 2. HAD2 is inhibited by inorganic phosphate.  
(A) Lineweaver-Burke plot of HAD2 inhibition by free inorganic phosphate (Pi). The pattern of a 
fixed Vmax with variable x-intercept (Km) is consistent with competitive inhibition. (B) Inorganic 
phosphate IC50 of HAD2 enzymatic activity compared to HAD1. (C) Parasite sensitivity to low 
media phosphate. (D) Comparison of wild-type (WT), phospho-ablated (S4AS9A), and phospho-
mimetic (S4DS9D) HAD2 IC50 for inorganic phosphate. No statistically significant differences, 
using ordinary one-way ANOVA and Tukey’s test for multiple comparisons. All data represent 




Figure 3: Comparison of S4AS9A and S4DS9D.  
Wild-type, S4AS9A, and S4DS9D recombinant enzyme was tested for activity against glycerol-
2-phosphate (Glc2P) in the EnzChek phosphate release assay. Statistics were performed using an 
ordinary one-way ANOVA test with Tukey’s test for multiple comparisons. Data represent the 
means ± SEM of 3 technical replicates of the same enzyme preparations. 
 65 
 
Figure 4: Metabolic profiling of HAD2 mutant parasites. 
HAD2-null, PFK9 suppressor mutant, and HAD2-GFP-complemented parasites were fed 13C-
labeled glucose, and metabolites were extracted and analyzed by LC-MS at time points of 0, 1, 5, 
10, and 30 minutes. All colors are relative to a WT control. 
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Figure 5: Phosphatase activity of HAD2 on a wide substrate panel.  
Phosphatase activity on substrates at 1 mM concentration, was performed using the 50 µL 
EnzChek phosphate release assay. Data represent mean ± SEM of three replicate experiments. 
Abbreviations: Glc2P, glycerol 2-phosphate; FBP, fructose-1,6-bisphosphate; DL Gly3P, (D/L)-
glyceraldehyde 3-phosphate; D-Gly3P, (D)-glyceraldehyde 3-phosphate; F6P, fructose 6-
phosphate; Glc1P, glycerol 1-phosphate; AMP, adenosine monophosphate; 2dRib5P, 2-
deoxyribose 5-phosphate; DHAP, dihydroxyacetone phosphate; PPi, inorganic pyrophosphate; 


















































































monophosphate; Sedo7P, sedoheptulose 7-phosphate; ATP, adenosine triphosphate; Suc6P, 
sucrose 6-phosphate; dUTP, deoxyuridine triphosphate. 
 
 
Figure 6: Phosphatase activity of HAD2 upon SBP and OBP.  
Using a the EnzChek phosphate release assay, HAD2 was incubated with either DHAP and E4P 
or DHAP and R5P, either in the presence or absence of pre-incubation with aldolase to generate 
SBP or OBP, respectively. Glc2P was used as a positive control for HAD2 activity. Data 
represents two independent experiments, each performed in triplicate. Statistics were performed 




Figure 7: Successful generation of HAD2-GFP overexpressing parasites in 3D7.  
Bright field, GFP channel, and merged images of transgenic parasites that were transfected with 
HAD2-GFP under an HSP110 promoter using the piggyBac transposase.  
 
 
Figure 8: Partial knockdown of HAD2 in WT background.  
(A) Scheme of TetR-DOZI regulatable system (B) Western blot of HAD2 partial knockdown, 
with HSP70 loading control. (C) Growth of PF4 parasites upon aTc removal, measured by 
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acridine orange staining and flow cytometry. Data represent 3 replicates ± SEM. (D) 72-hr dose-
response of FSM on PF4 parasites ±aTc. +atc EC50 = 2.82 ± 0.06 µM; -aTc EC50 = 3.37 ± 0.06 
µM. Data represent means of 3 experiments ± SEM. 
 
2.7 Tables 
Table 1. Primers used in this study. 
Primer name Purpose Sequence (5’->3’) 
HAD2_R157X_F 
Genotyping had2R157X 







PFK9_F Amplifying PFK9 
CTCACCACCACCACCACCATATGGATACC
AAGAGTGGAGATAAAA 
PFK9_R Amplifying PFK9 
ATCCTATCTTACTCACTTAGTTCATTCTTT
TTCTCTGGTTTTC 
PFK9_seq_1 Sequencing PFK9 CACAGGTAATGAATTCCCAGC 
PFK9_seq_2 Sequencing PFK9 ATCATCGGCATTCTGACATAAC 
PFK9_seq_3 Sequencing PFK9 GATCTATGCGTTTTGAACAATTAG 
PFK9_seq_4 Sequencing PFK9 CCTGTTAAGCCACTTTCAATAAC 
PFK9_seq_5 Sequencing PFK9 CCCAGTTGATTCTCTATCCATTAA 
PFK9_seq_6 Sequencing PFK9 GGTCCATTTGATGCTTCGAAAC 
PFK9_seq_7 Sequencing PFK9 CGTTGTTATACTGTAAAGACTCCA 
PFK9_seq_8 Sequencing PFK9 CTAGTCCCATTTCTTTTGAAATAAGAA 
HAD2_LIC_F 
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Chapter 3: Metabolic signatures of the 





















The following work was incorporated into a larger collaborative study published in Molecular 
Systems Biology, authored by Simon A Cobbold, Madel V Tutor*, Philip M Frasse*, Emma 
McHugh, Markus Karnthaler, Darren J Creek, Audrey Odom John, Leann Tilley, Stuart A Ralph, 
and Malcolm J McConville (*authors contributed equally)1. The purposes of the study were to 
understand metabolic fates of different carbon sources in P. falciparum and to compile a full 
draft metabolome of the parasites. The work utilized HAD4 as a proof-of-principle that 
metabolic changes seen in cultured parasites could be validated by in vitro enzymatic assays. 
Another HAD protein, Lipin, was also investigated, demonstrating further utility of the 
metabolic labeling approach. While the manuscript examines several conditions and enzymes, 
this dissertation chapter will focus on the methods, results, and discussion of the sections specific 
to HAD proteins. These sections have been altered slightly to focus on HAD proteins and 
provide additional discussion of how this HAD data fits into the framework of this thesis. PMF 
conducted the recombinant protein purification and biochemical assays for HAD4, gene 
knockout was performed by SAC and MVT. Mass Spectrometry by SAC and DJC, mutant 










The malaria parasite, Plasmodium falciparum, proliferates rapidly in human erythrocytes 
by actively scavenging multiple carbon sources and essential nutrients from its host cell. 
However, a global overview of the metabolic capacity of intraerythrocytic stages is missing. 
Using multiplex 13C‐labelling coupled with untargeted mass spectrometry and unsupervised 
isotopologue grouping, we have generated a draft metabolome of P. falciparum and its host 
erythrocyte consisting of 911 and 577 metabolites, respectively, corresponding to 41% of 
metabolites and over 70% of the metabolic reaction predicted from the parasite genome. An 
additional 89 metabolites and 92 reactions were identified that were not predicted from genomic 
reconstructions, with the largest group being associated with metabolite damage‐repair systems. 
Validation of the draft metabolome revealed four previously uncharacterized enzymes which 
impact isoprenoid biosynthesis, lipid homeostasis and mitochondrial metabolism and are 
necessary for parasite development and proliferation, two of which are haloacid dehalogenase 
(HAD) proteins. This study defines the metabolic fate of multiple carbon sources 
in P. falciparum, and highlights the activity of metabolite repair pathways in these rapidly 
growing parasite stages, opening new avenues for drug discovery. The metabolic roles of two 








3.2.1 Introduction to metabolic labeling  
Considerable progress has been made in reducing the incidence of malaria over the last 
decade, although the decline in malaria cases has stalled in recent years and resistance to 
frontline antimalarials is on the rise2. Identifying new antimalarials with novel targets therefore 
remains a priority, and significant investment has been made in expanding the drug development 
pipeline with novel classes of antimalarials3,4. Metabolic enzymes and metabolite transporters are 
direct or indirect targets of most of the existing antimalarials and current lead compounds5,6. 
However, the total number of enzymes/transporters that have been rigorously validated as drug 
targets remains small. A detailed understanding of the metabolism of the different developmental 
stages of the malaria parasite, Plasmodium falciparum, and the host cells within which they live 
is therefore necessary for informing the development of new antimalarial therapies. 
Plasmodium falciparum progresses through a number of different developmental stages 
during its life cycle in the Anopheles mosquito and its human host. Infection in humans is 
initiated by infective sporozoites that develop asymptomatically in the liver, resulting in the 
release of thousands of merozoites that initiate repeated cycles of infection and asexual 
replication in erythrocytes [i.e., red blood cells (RBCs)] that cause the clinical symptoms 
associated with malaria. The P. falciparum intraerythrocytic developmental cycle (IDC) takes 
approximately 48 hr and involves the development of the metabolically active trophozoite and 
schizont stages, followed by cell division of individual parasites into 16–32 new merozoites. The 
massive expansion of parasite biomass during development is fueled by the uptake and 
catabolism of glucose, as well as a number of other essential nutrients (e.g. amino acids, purines 
and vitamins) that are either directly scavenged from the RBC or derived from breakdown of 
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RBC hemoglobin and other proteins7–10. Considerable progress has been made in delineating key 
salvage and metabolic pathways involved in P. falciparum asexual development, which has 
formed the basis for genome‐scale models of parasite metabolism11–14. Despite these advances, 
> 40% of the protein‐encoding genome remains unannotated and a significant fraction of 
annotated metabolic genes have yet to be assigned to specific metabolic pathways or reactions. 
In the phylum Apicomplexa, many genes have also been repurposed to fulfil non‐canonical 
functions, impeding genomic reconstructions and a systematic understanding of the total 
metabolic capacity of the pathogen15,16. Finally, enzyme promiscuity and side reactions can result 
in the production of unanticipated and novel metabolites that can have important roles in 
regulating cellular metabolism17–19, further complicating predictions of enzyme function based 
on gene homology. 
Defining the observable metabolic capacity of key developmental stages  
of P. falciparum and its host cell is required to verify the accuracy of genomic reconstructions 
and to identify unexpected metabolic pathways and gene functions. A number of approaches 
have been used to undertake a global analysis of the metabolic capacity of other organisms. For 
example, a system‐wide reverse genetics approach was used to identify the metabolic function or 
indirect metabolic impact of each gene within E. coli20. The emergence of genome‐wide 
disruption libraries in P. falciparum and P. berghei makes this approach theoretically 
possible21,22. However, these studies have highlighted the essentiality of many metabolic 
enzymes in Plasmodium spp., limiting the effectiveness of this approach. Even viable but slow‐
growing mutants generated through such approaches are likely to be difficult to compare directly 
to parental parasites at a metabolic level. The converse approach – acquiring untargeted mass 
spectrometry data and verifying the “observed” metabolome – has not yet been fully exploited 
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because of the lack of well‐established pipelines for data filtering and metabolite identification. 
Current liquid chromatography–mass spectrometry platforms allow detection of > 10,000 mass‐
to‐charge (m/z) features, yet a significant majority (> 90%) of these features correspond to 
background noise or degeneracy23–25. The absence of autonomous methods for controlling the 
false discovery rate has hampered the compilation of an accurate metabolome for most 
organisms to date. 
Here we use stable‐isotope resolved metabolomics to prioritize m/z features 
corresponding to metabolites actively synthesized by P. falciparum or the host RBC26,27. 
Previous work has demonstrated the ability of this approach to define the extent of active 13C‐
glucose metabolism in RBCs28, and here we expand this approach to ten biologically 
relevant 13C‐substrates in P. falciparum‐infected RBCs. Filtering for actively‐labelled 
metabolites enabled > 95% of m/z features to be removed, and the remaining m/z features were 
then identified and the active metabolome defined. This approach led to the identification of 577 
metabolites in uninfected human RBCs and 911 metabolites in P. falciparum‐infected RBCs 
corresponding to 41% coverage across the predicted metabolome of P. falciparum (the 
summation of all expected metabolites from all known pathways inferred from a genomic 
reconstruction irrespective of enzyme gaps). The pattern of stable isotope labelling for each 
metabolite allowed us to further infer metabolic reactions corresponding to 70.5% coverage 
across predicted reactions in P. falciparum, with the mismatch between metabolite and reaction 
coverage largely due to a subset of metabolites participating in many reactions. Defining the 
“observed” metabolome without constraining the results to the expected composition inferred 
from genomic reconstructions revealed 89 metabolites and 92 reactions not predicted from 
genomic reconstructions. These studies have highlighted unanticipated complexity 
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in P. falciparum metabolism, including the presence of active metabolite damage and repair 
systems in rapidly dividing parasite stages. 
3.2.2 The HAD proteins examined with this approach 
We wanted to explore the role of two uncharacterized haloacid dehalogenase (HAD) 
phosphatases, given the important role this protein family plays in regulating metabolic flux and 
metabolite repair. We targeted PF3D7_1118400 (annotated as HAD4) and PF3D7_0303200 
(annotated as a member of the HAD superfamily, hereon referred to as Lipin) for inducible 
disruption. These enzymes were chosen to validate the metabolic labeling approach with a 
parallel in vitro biochemical approach, as well as demonstrate the utility of this method of 
isotope-tracing metabolomics. It should be noted that Lipin contains a HAD-like Superfamily 
domain (IPR036412) and therefore is not included in the phylogenetic tree shown in Chapter 1, 




Endogenous loci of both HAD proteins, HAD4 and Lipin, were targeted via Cas9‐
mediated double‐stranded break towards the center of each gene and the 3’‐half replaced with a 
recodonized sequence flanked by two loxP sites29. The 3’‐end was also HA‐tagged and a glmS 
ribozyme introduced in the 3’‐UTR. Transfection of this construct into a 3D7 parasite line 
expressing an integrated copy of the dimerizable cre‐recombinase then enabled inducible 
excision of the gene upon rapamycin addition, or transcript degradation when glucosamine was 
added. Transfections were performed with linearized rescue DNA template and integration 
confirmed by PCR (Fig. S1). HA‐tagged proteins of the expected size were detected and were 
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efficiently depleted following the addition of 100 nM rapamycin and 2.5 mM glucosamine 
(Fig 1A). A transgenic line with lactate dehydrogenase 1 (LDH1) under inducible disruption was 
used as a positive control. Disruption of Lipin significantly impaired parasite growth, whereas 
loss of HAD4 had no effect (Fig 1B). Loss of LDH1 led to specific metabolic changes, with 
increased abundance of pyruvate (the enzyme’s substrate) and reduced abundance of lactate 
(Fig 1C), demonstrating the validity of the approach for inferring enzyme function. 
3.3.1 Lipin is a lipid phosphatase important for optimal parasite growth 
Loss of Lipin was associated with elevated levels of ceramides and lyso‐phosphatidic 
acid (LPA) lipid species in iRBC (Fig 1D and Table 1). Sphingosine 1‐P and sphinganine 1‐P 
were also elevated, suggesting that this enzyme dephosphorylates diverse lipid substrates in vivo. 
This phenotype is consistent with the function of Lipin domain‐containing proteins in other 
eukaryotes, in regulating intracellular pools of phosphatidic acid and diacylgycerols, and flux of 
these lipids into other pathways of bulk lipid synthesis (phospholipid, triacylglycerol). 
Interestingly, infection with wild‐type P. falciparum leads to a depletion of phosphatidic acid 
and accumulation of diacylglycerol in the iRBC30. 
3.3.2 HAD4 is a dispensable nucleotide phosphatase 
HAD4 disruption led to an accumulation of several nucleotides and glycolytic 
intermediates which feed into lipid metabolism (Fig 1E, Table 2). In order to gain further 
insights into the potential function of HAD4, we recombinantly expressed and purified HAD4 
for analysis of in vitro activity (Fig 2). Phosphatase activity was confirmed (Fig 1F) and 
inhibited by free phosphate with an IC50 of 2.1 ± 0.21 mM (Fig 1G). HAD4 appeared to 
dephosphorylate a wide range of nucleotide substrates with a preference for nucleotide 
monophosphates (Fig 1H). HAD4 may therefore function as a nucleotide monophosphate 
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phosphatase, consistent with accumulation of monophosphates following depletion, including the 
elevation of orotidine‐P and reduced levels of the dephosphorylated orotidine following HAD4 
depletion (Fig 1E). The preference of HAD4 towards the monophosphates versus diphosphates 
(up to sixfold) is similar to the HAD nucleotide monophosphatase YrfG present in E. coli32. This 
preference is likely an underestimate as diphosphate nucleotide substrates will produce 
monophosphate nucleotides in the assay leading to further hydrolysis and higher activity 
measurements. 
 Interestingly, BLASTp searches for E. coli genes most homologous to HAD4 reveal that 
the nearest E. coli homolog is not YrfG, but rather YigB, which is predominantly a flavin 
mononucleotide (FMN) phosphatase32. To assess whether HAD4 also catalyzes 
dephosphorylation of FMN, we implemented a BIOMOL green assay to detect inorganic 
phosphate release by HAD4, as our original assay was incompatible with the intrinsic absorption 
of FMN. As compared to deoxyguanosine monophosphate (dGMP), which was the strongest 
substrate in our larger assay, FMN was far less-robustly dephosphorylated (Figure 3). Although 
FMN was not detected in metabolomics, the related metabolite, flavin adenine dinucleotide 




We performed a preliminary characterization on two putative haloacid dehalogenases. 
Lipin was shown to dephosphorylate a subset of lipid species and to be necessary for normal 
parasite growth. The P. berghei ortholog is also predicted to be essential21 but no data are 
available at other lifecycle stages. It will be of interest to determine the precise lipid substrate 
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specificity of this phosphatase and determine whether the enzyme is necessary for bulk lipid 
regulation or is necessary for specialized lipid signalling30,31. In contrast, HAD4 appears to 
dephosphorylate a range of nucleotides, with a preference for nucleotide monophosphates. 
Despite the lack of a growth defect in asexual RBC stages and the dispensability of this protein 
in P. berghei liver stage development33, HAD4 may contribute to optimal metabolic flux and 
nucleotide homeostasis by repressing monophosphate accumulation. In particular, loss of HAD4 
led to an accumulation of orotidine phosphate and a reciprocal decrease in the non‐canonical 
orotidine (Fig 1E), suggesting HAD4 may regulate pyrimidine biosynthetic flux via 
dephosphorylation of a key intermediate. Furthermore, the dysregulation of downstream 
glycolytic intermediates, despite low or absent phosphatase activity upon those substrates in 
vitro, suggests that HAD4 exerts glycolytic effects through the regulatory capacity of 
nucleotides34,35.  
As described in Chapter 2, related HAD proteins (HAD1, HAD2, and PGP) have all been 
linked to parasite sensitivity to the isoprenoid biosynthesis inhibitor fosmidomycin (FSM)19,36,37. 
Although FSM resistance was not tested in Lipin- or HAD4-knockout parasites, we hypothesize 
that the glycolytic effects of HAD4 could also confer resistance to FSM, as was seen with HAD1 
and HAD2.  
Interestingly, homology to documented HAD proteins from E. coli was not predictive of 
the substrate profile of HAD4, as its activity more closely resembled YrfG than the more 
homologous YigB. This discrepancy speaks to the nature of HAD proteins. It is well-
documented that HAD proteins can be both specific and promiscuous in their substrate 
profiles32,38, mediated by the Cap domain that closes upon substrates in the binding pocket39. 
Perhaps the tendency of these enzymes to be promiscuous, as well as their divergent 
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evolutionary origins40, may explain why it is difficult to predict function from polypeptide 
sequence homology alone. This supports the notion that biochemical and/or metabolic studies 
like this one will be necessary for future characterization of HAD proteins, as homology alone is 
insufficient and can lead to erroneous functional assignment. 
 
3.5 Methods 
3.5.1 Recombinant Protein Expression 
PfHAD4 (PlasmoDB ID 3D7_1118400) was amplified from P. falciparum genomic DNA using 
the following primers: 
5’‐CTCACCACCACCACCACCATATGAAAGATGAACAAATATCATGTTATTATC −3’ 
5’‐ ATCCTATCTTACTCACTTATGCAAGTATACTATCTAGATCTCG −3’ 
The PCR product was cloned by ligation‐independent cloning into vector BG186141, which 
introduces an N‐terminal 6X‐His tag. The catalytic mutant HAD4D29A was generated by PCR 
amplification with the above primers in addition to the following primers: 
5’‐ AATTGATAACGTTCGCCCTTGACCATACGATATG −3’ 
5’‐ ATCGTATGGTCAAGGGCGAACGTTATCAATTTTA −3’ 
These primers were used to introduce an A→C point mutation in the coding sequence. The 
HAD4D29A construct was cloned by ligation‐independent cloning into a modified BG1861 vector 
that also includes a KFS motif in front of the 6xHis tag to increase protein expression42. 
Constructs were verified by Sanger sequencing. 
Constructs were transformed into BL21 (DE3) pLysS Escherichia coli (Life 
Technologies). Cells were grown at 37˚C and induced with 1 mM isopropyl‐β‐D‐thiogalactoside 
(IPTG). Cells were harvested by centrifugation and resuspended in lysis buffer containing 10 
 89 
mM Tris–HCL (pH 7.5), 20 mM imidazole, 1 mM MgCl2, 200 mM NaCl, 1 mg/ml lysozyme, 1 
mM dithiothreitol (DTT) and cOmplete Mini EDTA‐free Protease Inhibitor tablets (Roche), and 
sonicated. Soluble protein was bound to nickel agarose beads (Gold Biotechnology), eluted in 
20 mM Tris–HCl pH 7.5, 150 mM NaCl and 300 mM imidazole, and further purified by size 
exclusion chromatography using a HiLoad 16/600 Superdex 200 pg column (GE Healthcare) 
equilibrated with 25 mM Tris–HCl (pH 7.5), 250 mM NaCl and 1 mM MgCl2 buffer. Fractions 
containing HAD4 were pooled, concentrated with a centrifugal filter, flash‐frozen and stored at 
−80°C. 
3.5.2 HAD4 enzymatic assays 
All assays were performed in clear 96‐well half‐area plates using a FLUOstar Omega 
microplate reader (BMG Labtech) at 37°C. Reaction rates were determined using GraphPad 
Prism software. All reaction rates represent the mean and standard error of at least three 
experiments, each with technical replicates. Substrates were purchased from Sigma‐Aldrich, 
except for GTP, dGTP, dATP, dCTP, dTTP, dUTP (Roche), dTMP (BioBasic Canada), DOXP 
(Echelon Biosciences) and fructose 1‐phosphate (Santa Cruz Biotechnology). 
Other substrates tested that had activity < 0.1 µmol/min/mg were as follows: cytosine 
triphosphate; adenosine triphosphate; uridine diphosphate; deoxyuridine triphosphate; 
deoxycytosine triphosphate; deoxythymidine triphosphate; inosine triphosphate; deoxyadenosine 
triphosphate; D/L‐glyceraldehyde‐3‐phosphate; sorbitol‐6‐phosphate; sodium pyrophosphate; 
deoxyxylulose‐5‐phosphate; galactose‐1‐phosphate, sucrose‐6‐phosphate; 2‐deoxy‐ribose‐5‐
phosphate; glucose‐6‐phosphate; glycerol‐2‐phosphate; mannose‐6‐phosphate; thiamine 
monophosphate; fructose‐6‐phosphate; thiamine pyrophosphate; sedoheptulose‐7‐phosphate; 
racemic glycerol‐1‐phosphate; 2‐phosphoglyceric acid; 2,3‐diphosphoglycerate; myo‐inositol‐2‐
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phosphate; mannose‐1‐phosphate; trehalose‐6‐phosphate; glucose‐1‐phosphate; phosphoenol 
pyruvate; and dihydroxyacetone phosphate. 
General phosphatase activity and phosphate inhibition were measured using the 
substrate para‐nitrophenyl phosphate (pNPP) (New England Biolabs). Reactions were performed 
in 50 μL volumes with 1 mM pNPP, 50 mM Tris–HCl (pH 7.5), 5 mM MgCl2 and inorganic 
phosphate (0 mM–42 mM). Reactions contained 1 µg purified recombinant enzyme. Para‐
nitrophenyl production was quantified by absorbance at 405 nm. 
Enzyme activity against phosphorylated substrates was measured using the EnzChek 
Phosphate Assay Kit (Invitrogen) according to supplier instructions. Each 50µl assay contained 
200 ng recombinant purified enzyme and 1 mM substrate. The reaction was quantified by 
absorbance at 360nm, and reactions were linear with respect to time and enzyme concentration. 
Enzyme activity against flavin mononucleotide (FMN) was measured using the BIOMOL Green 
kit (Enzo Life Sciences) to account for the overlap in absorbance between FMN and the 
EnzChek kit. Each 50 µl assay contained 200 ng recombinant purified enzyme, 25 mM Tris–HCl 
(pH 7.5), 250 mM NaCl, 1 mM MgCl2 and 1 mM substrate. A time course was taken to obtain 
kinetic data, and the reaction was quantified by absorbance at 620 nm.  
Substrate abbreviations are as follows: dGMP, deoxyguanosine monophosphate; dIMP, 
deoxyinosine monophosphate; dCMP, deoxycytosine monophosphate; GMP, guanosine 
monophosphate; IMP, inosine monophosphate; XMP, xanthosine monophosphate; AMP, 
adenosine monophosphate; 8oxodGMP, 8‐oxo‐deoxyguanosine monophosphate; dAMP, 
deoxyadenosine monophosphate; GDP, guanosine diphosphate; UMP, uridine monophosphate; 
CMP, cytosine monophosphate; dTMP, deoxythymidine monophosphate; dGDP, 
deoxyguanosine diphosphate; GTP, guanosine triphosphate; dADP, deoxyadenosine 
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diphosphate; ADP, adenosine diphosphate; TTP, thymidine triphosphate; dGTP, deoxyguanosine 
triphosphate; PLP, pyridoxal‐5‐phosphate; R5P, ribose‐5‐phosphate; FBP, fructose‐1,6‐
bisphosphate; E4P, erythrose‐4‐phosphate; and 3PGA, 3‐phosphoglyceric acid. 
3.5.3 Cultivation and stable‐isotope labelling 
Plasmodium falciparum‐infected RBCs were cultivated in RPMI 1640 GlutaMAX 
supplemented with 500 µM hypoxanthine, 22 µg/ml gentamicin, 0.2% (w/v) D‐glucose, 25 mM 
HEPES and albumax II (0.5% w/v). Cultures were routinely synchronized with 5% sorbitol (w/v) 
to maintain a 12‐hour developmental range. Transfectant parasite cultures were maintained with 
5% human serum and 0.25% (w/v) albumax II. Uninfected RBCs from the same donor were 
maintained under identical conditions for 48 h prior to experimentation. Trophozoite‐
stage P. falciparum‐infected RBCs were magnetically enriched to > 95% parasitemia (Colebrook 
Bioscience) and cell density determined using a Neubauer Haemocytometer. Following a one‐
hour recovery in fresh RPMI 1640 at 37°C, 1 × 108 cells were centrifuged and the media replaced 
with 5 ml of RPMI containing unlabeled substrates or 11 mM 13C6‐glucose, 2 mM 13C5 glutamine, 
1.1 mM 13C6 arginine, 1 mM 13C3 serine, 1 mM 13C5 proline, 5 mM 13C2 acetate, 
23 mM 13C1 bicarbonate, 1 mM 13C6 lysine, 10 mM 13C3 glycerol or 13C‐amino acid mix at 
1 mg/ml (and a 12C‐amino acid mix 1mg/ml used as a control). iRBC and matched uRBC 
samples were incubated for 5 h under standard culturing conditions. 
3.5.4 Metabolite extraction 
An aliquot of culture (1 × 108 cells/sample) was transferred to a microcentrifuge tube and 
centrifuged at 14,000 g for 30 s. The medium was aspirated, and the cell pellet was resuspended 
in ice‐cold PBS (1 ml) to quench cell metabolism and transferred equally into two 
microcentrifuge tubes. Following centrifugation (14,000 g, 30 s), the PBS was aspirated and 
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200 µl of 80% acetonitrile (containing 1 µM 13C5 15N1 aspartate or 5 µM 13C5 valine as the internal 
standard) was added and rapidly mixed for polar LC‐MS analysis. Samples were centrifuged to 
remove precipitated protein (14,000 g, 5 min) and the supernatant transferred to a glass mass 
spectrometry vial (containing an insert) and stored at −80°C until LC‐MS analysis. For GC‐MS 
and LC‐MS lipid analysis, the quenched cell pellet was suspended in 100 µl chloroform and 
vortex‐mixed, prior to addition of 400 µl of methanol:H2O (3:1 v/v) with further vigorous 
mixing. Samples were centrifuged for 5 min at 14,000 g and the supernatant transferred to a fresh 
microcentrifuge tube. H2O (200 µl) was added to generate a biphasic mixture which was vortex‐
mixed and then centrifuged for 1 min at 14,000 g, and the top aqueous layer was collected for 
derivatization and GC‐MS analysis. The lower organic phase was collected for lipid analysis. 
For GC‐MS analysis, samples were dried by vacuum centrifugation, then resuspended in 90% 
methanol (100 µl) and transferred to a glass mass spectrometry insert. Samples were dried by 
vacuum centrifugation, washed with 100 µl methanol and dried. Samples were resuspended in 
20 µl of methoxyamine (20 mg/ml) prepared in pyridine, sealed and incubated overnight with 
shaking at ambient temperature. The next day, 20 µl of BSTFA was added to each sample and 
incubated for 1 h prior to GC‐MS analysis. 
Lipid analysis was carried out on the remaining lower organic phase. The organic layer 
was transferred to a fresh microfuge tube and dried down under nitrogen flow. Dried samples 
were stored at −80°C until ready for lipid LC‐MS analysis. 
3.5.5 LC‐MS acquisition 
Polar metabolite detection was performed on an Agilent 6550 Q‐TOF mass spectrometer 
operating in negative mode. Metabolites were separated on a SeQuant ZIC‐pHILIC column 
(5 µM, 150 × 4.6 mm, Millipore) using a binary gradient with a 1200 series HPLC system across 
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a 45‐min method using 20 mM ammonium carbonate (pH 9) and acetonitrile as outlined in 
Cobbold et al, (2016)43. Two independent replicates of the metabolite profiling following AMR1 
and Lipin depletion were performed using the same ZIC‐pHILIC chromatography on a Thermo 
Q‐Exactive operating in both positive and negative mode (rapid switching) as described 
previously44. Lipid extracts were analyzed on an Agilent 6550 Q‐TOF using the reverse phase 
chromatography outlined by Bird et al (2011)45. 
GC‐MS analysis was performed using methods previously described46. Metabolites were 
separated using a BD5 capillary column (J&W Scientific, 30 m × 250 µM × 0.25 µM) on a 
Hewlett Packard 6890 system (5973 EI‐quadrupole MS detector). The oven temperature gradient 
was 70 °C (1 min); 70°C to 295°C at 12.5°C/min, 295°C to 320°C at 25°C/min; 320°C for 
2 min. MS data were acquired using scan mode with a m/z range of 50–550, threshold 150 and 
scan rate of 2.91 scans/second. GC retention time and mass spectra were compared with 
authentic standards analyzed in the same batch for metabolite identification. 
3.5.6 Draft metabolome compilation 
Raw Agilent.d files were converted to mzXML with MSconvert and analyzed using the 
X13CMS R package26. XCMS centWave peak detection was performed with a 10 ppm mass 
tolerance, following obiwarp retention time correction. The getIsoLabelReport function was 
performed with P < 0.01 (Welch’s t‐test), to identify features that significantly labelled under 
each 13C‐labelling condition in both iRBC and uRBC cell types (isotope mass 
tolerance = 15 ppm). The getIsoDiffReport function then compared the significantly labelled 
features between iRBC and uRBC using P < 0.01 (Welch’s t‐test). IsoDiffReport m/z features 
were removed if > 1,200 m/z, and the putative M0 species queried to the METLIN database with 
a 10 ppm mass tolerance, excluding all toxicants and adducts, except M‐H, from the search. 
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Only m/z features with a putative METLIN match were retained for further analysis. m/z features 
were further curated to remove mis‐annotated in‐source fragments and isotopologues, and 
where 13C‐enrichment was < 1%. m/z features with a retention time of < 250 s were removed 
from the polar metabolite analysis (assuming these lipid‐like species were also detected in the 
lipid C18 LC‐MS analysis). This processing was performed for all 13C‐labelling conditions 
across both C18 lipid and pHILIC polar LC‐MS data and a single metabolite list complied. 
Metabolite identification was performed either with retention time matching to authentic 
standards (approximately 150 in‐house metabolite standards or the HMDB compound library), or 
MS/MS matching. Polar MS/MS data were collected with an auto preferred MS/MS method at a 
collision energy of 10V, 20V and 40V at a threshold of 10,000 on an Agilent 6545 Q‐TOF using 
the same chromatography outlined above. MS/MS spectra were searched against the METLIN 
PCDL database via the Agilent Qualitative software package and manually curated. MS/MS 
spectra without a match were reacquired in positive and negative mode and manually searched 
against the online METLIN database. Lipid MS/MS data were collected as above and converted 
to (ABFconverter) and analyzed with the MSDial software package47. 
Polar GC‐MS data were analyzed using the DeXsi software package48 and metabolite 
identifications confirmed using an in‐house metabolite standards library and merged with the 
LC‐MS datasets. 
A first iteration of the observable metabolome of P. falciparum was compiled, and 
unique KEGG IDs (acquired from MetaboAnalyst 3.049) were used to compare to the predicted 
metabolome of P. falciparum reported by Huthmacher et al (2010)50. Under the conditions 
tested, we could not confidently assign stereoisomers or precise structures (e.g. D‐glucose) and 
assigned KEGG IDs to be consistent with the level of evidence present in the literature and with 
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the format used by Huthmacher et al (2010)50. uRBC and iRBC datasets were then re‐extracted 
for expected m/z of metabolites predicted from Huthmacher et al (2010)50, to assess the rate of 
false negatives but also because certain classes of metabolites were not expected to label under 
any of the conditions tested (e.g. vitamins and some cofactors). Putative matches were then 
verified using authentic standards and MS/MS matching. This iteration of the observable 
metabolome of iRBC and uRBC cell types was then grouped according to the level of 
identification: (i) match to authentic standard and MS/MS match, (ii) match to authentic standard 
or MS/MS match, (iii) 13C‐labelling data consistent with known metabolic pathway and (iv) exact 
mass match (≤ 10 ppm). To capture additional metabolites that were unlabeled across all 13C‐
substrates, all m/z features from unlabeled uRBC and iRBC extracts were compared with the 
expected exact mass of all metabolites in the predicted P. falciparum and RBC metabolomes. 
Putative hits were confirmed via pure standards or MS/MS matching where possible. 
3.5.7 Pathway reconstruction 
Metabolite enrichment analysis was performed with Metaboanalyst 3.0, and pathway 
reconstruction was performed for each stable‐isotope condition. Observed metabolites that were 
labelled under a given condition were compared to the theoretical reactions for both iRBC and 
uRBC50. A matched reaction was defined as having a labelled metabolite corresponding to either 
an expected product or substrate. Unpredicted reactions were reported when an identified 
metabolite was labelled under a given 13C‐substrate but did not match to a predicted reaction. A 
putative reaction was proposed based on the nearest proximity to an identified metabolite with 
consistency in the labelling pattern. 
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3.5.8 Generation of transgenic parasites for inducible protein disruption 
For each gene of interest, a protospacer adjacent motif (PAM) was selected at the center 
or towards the start of the gene which ranked the highest via CHOP‐CHOP v251. Guide oligos 
were synthesized for cloning into the BtgZI site of pUF‐Cas9g using the In‐Fusion cloning kit 
(Takara). The gene was modified using a rescue template containing a 5’‐homology arm 
immediately upstream of the PAM site, an artificial intron containing a loxP site, a recodonized 
version of the down‐stream gene sequence, a 3xHA tag, which was synthesized by GeneArt. The 
rescue template was cloned into the pGlmS plasmid using the BglII and SpeI52. The 3’‐homology 
arm was generated via PCR of P. falciparum genomic DNA and cloned into the pGlmS plasmid 
with EcoRI and KasI. Following verification of the correct DNA sequence, both pUF‐Cas9g and 
pGlmS plasmids were purified with a midi‐prep kit (Macherey‐Nagel). pGlmS plasmid was 
linearized overnight using BglI, BglII and PvuI. 75–150 µg of pUF‐Cas9g and linearized pGlmS 
were transformed into 3D7 ring‐stage parasites with dimerizable Cre‐recombinase integrated into 
its genome29. Cultures were maintained on WR99210 and blasticidin and complete integration 
was confirmed on recovered parasites via PCR. 
Inducible disruption of each targeted protein was performed cultivating transfected 
parasites under standard conditions in the presence or absence of 100 nM rapamycin and 2.5 mM 
glucosamine. Initial tests were performed to determine length of treatment required to deplete the 






Figure 1. Inducible disruption of haloacid dehalogenase 4 and a putative Lipin.  
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(A) Anti‐HA Western blots for each protein targeted for disruption with a detectable band 
corresponding to the expected product size. 100 nM rapamycin and 2.5 mM glucosamine were 
added to induce protein depletion for either one cycle (LDH1) or three cycles (Lipin and HAD4). 
Anti‐PfBiP was used as the loading control. (B) Growth of DiCre‐3D7 transgenic lines following 
LDH1, HAD4 and Lipin depletion with 100 nM rapamycin and 2.5 mM glucosamine was 
assessed relative to uninduced parasite cultures. The untransfected DiCre‐3D7 parasite line was 
used as a negative control. Data are presented as the mean ± standard error of the mean (SEM) 
from three independent replicates. (C) Untargeted LC‐MS analysis of LDH1 depletion (one 
cycle of rapamycin and glucosamine treatment) indicated minimal but selective metabolic 
changes. m/z feature intensities are plotted as the log2 ratio of treated/untreated and the 
Benjamini–Hochberg‐corrected P values across six biological replicates plotted as –log10(P). 
Below, LDH1 substrate and product (pyruvate and lactate, respectively) abundance plotted as the 
ratio of treated/untreated from biological replicates (mean ± SEM) and the parental DiCre line 
presented as the negative control. (D) Loss of Lipin (PF3D7_0303200) leads to accumulation of 
various lipid species (three cycles of rapamycin and glucosamine treatment). Data are presented 
as the mean log2 fold change Lipin‐depleted (treated) enriched trophozoite‐stage iRBCs to 
untreated controls from three to six biological replicates (± SD). The schematic depicts the 
proposed lipid phosphatase activity of Lipin. (E) Loss of HAD4 leads to increases in intracellular 
levels of several nucleotides and intermediates in lower glycolysis. Data are represented as the 
mean log2 fold change of enriched trophozoite‐stage iRBCs treated for three cycles compared to 
untreated controls from three/four biological replicates. Three nucleotide–nucleoside pairs are 
depicted in the top inset panels, and HAD4 disruption leads to accumulation of the nucleotide 
monophosphate and depletion of the nucleoside. The schematic depicts lower glycolysis and 
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triose‐phosphate interconversion, with the corresponding metabolite levels following HAD4 
disruption depicted in the lower right inset. (F) Phosphatase activity against the generic substrate 
pNPP of wild‐type HAD4, catalytically inactive HAD4D29A and a no‐enzyme (No enz.) control, 
presented as the mean ± SEM (three biological replicates). (G) Inhibition of HAD4 phosphatase 
activity by inorganic phosphate. Phosphatase activity against the generic substrate pNPP as the 
mean ± SEM from three independent experiments. The inorganic phosphate IC50 of HAD4 is 
2.1 ± 0.21 mM. (H) Substrate specificity of HAD4. Substrates are divided into nucleotide 
phosphates (black) and other metabolites such as sugar phosphates and vitamins (white). 
Presented is the enzyme activity from three independent experiments mean ± SEM. Substrate 
concentrations were 1 mM, and abbreviations are listed in methods. 
 
 
Figure 2. Coomassie‐stained SDS–PAGE gel of purified HAD4.  







Figure 3. FMN phosphatase activity of HAD4.  
Phosphate release by HAD4 incubated with the given substrate was measured by BIOMOL 
Green detection reagent over time. Shown are the mean and SEM of three independent 
experiments, each with technical replicates. Statistics were performed with unpaired t-test. 







Figure S1. PCR confirmation of integration.  
'Int' indicates primers specific for the integrated locus and 'NI' indicates primers specific for the 
endogenous (nonintegrated)locus. DiCre represents the untransfected parental line stably 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2: Mass Spectrometry data for treated/untreated parasites of HAD4 KO 
m/z
# 
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 Chapter 4: Enzymatic and structural 
characterization of HAD5, an essential 
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4.1 Abstract 
The malaria parasite Plasmodium falciparum is responsible for over 200 million 
infections and 400,000 deaths per year. At multiple stages during its complex life cycle, P. 
falciparum expresses several essential proteins tethered to its surface by 
glycosylphosphatidylinositol (GPI) anchors, which are critical for biological processes such as 
parasite egress and reinvasion of host red blood cells. Targeting this pathway therapeutically has 
the potential to broadly impact parasite development across several life stages. Here, we 
characterize an upstream component of GPI anchor biosynthesis, the putative 
phosphomannomutase (EC 5.4.2.8) of the parasites, HAD5 (PF3D7_1017400). We confirm the 
phosphomannomutase and phosphoglucomutase activity of purified recombinant HAD5. By 
regulating expression of HAD5 in transgenic parasites, we demonstrate that HAD5 is required 
for malaria parasite egress and erythrocyte reinvasion. Finally, we determine the three-
dimensional crystal structure of HAD5 and identify a substrate analog that specifically inhibits 
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HAD5, compared to orthologous human phosphomannomutases. These findings demonstrate 
that the GPI anchor biosynthesis pathway is exceptionally sensitive to inhibition, and that HAD5 
has potential as a multi-stage antimalarial target. 
 
4.2 Introduction 
Malaria remains an enormous global health burden for much of the world, resulting in 
over 200 million infections and 400,000 deaths every year, the majority of which are in children 
under the age of five1. One of the primary barriers to effective malaria treatment and control is 
the emergence of resistance to all approved antimalarial chemotherapeutics2,3, prompting an 
urgent call for the development of new therapies and the identification of novel drug targets. 
Malaria is caused by apicomplexan parasites of the genus Plasmodium, primarily the species 
Plasmodium falciparum. P. falciparum has a complex life cycle, in which parasites develop in a 
mosquito host, are deposited into a human during a mosquito blood meal, and migrate to the liver 
where they infect hepatocytes. Parasites are released from the liver into the bloodstream and 
begin an asexual cycle of replication within red blood cells, occasionally branching off into 
sexual stage gametocytes that can be taken up by mosquitoes to start the cycle anew4. 
This complex, multi-host life cycle has stymied efforts to develop therapeutics and 
vaccines to eradicate this disease, as it has been difficult to identify effective vaccine and 
therapeutic targets that span multiple life stages. In recent years, the push for new therapeutics 
and vaccines has focused on a strategy of developing transmission-blocking vaccines and 
therapies, which impair the development or viability of gametocytes or target the mosquito 
vector itself, thus preventing vector-borne transmission5–7. Our goal is therefore to identify novel 
targets for antimalarial therapeutics that are not only essential for intraerythrocytic growth of the 
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parasite, but are also essential for sexual- and/or mosquito-stage parasites, indicating their 
potential in transmission blocking strategies. 
Malaria parasites are highly metabolically active8,9, and several known antimalarials 
target unique and essential metabolic processes in the parasites10–14. Metabolic enzymes have 
great potential for chemical inhibition, as substrate analogs can be rationally designed and 
developed as potential inhibitors, making these enzymes well-suited as “druggable” targets15. We 
therefore sought a metabolic enzyme that is expressed and essential during multiple life stages of 
Plasmodium falciparum. These constraints narrowed our search to the upstream steps of glycosyl 
phosphatidylinositol (GPI) anchor synthesis. 
GPI anchors are an essential component of all life stages of Plasmodium falciparum. In 
intraerythrocytic parasites, these glycolipid anchors tether several essential proteins to the 
parasite plasma membrane prior to red blood cell egress and reinvasion16. Most abundant 
amongst these GPI-anchored proteins (GPI-APs) is merozoite surface protein 1 (MSP1)16–18. 
Proper MSP1 localization and processing is necessary for parasites to egress from the 
erythrocyte, and mature MSP1 anchored to the surface of free merozoites facilitates the binding 
and invasion of new red blood cells. In the absence of the GPI-anchoring C-terminus of MSP1, 
parasites are defective in their ability to egress19, and antibodies developed against MSP1 prevent 
merozoite reinvasion20. Several other GPI-APs are also involved in parasite egress and invasion, 
including other merozoite surface proteins (MSPs) and rhoptry-associated membrane antigen 
(RAMA)16,18,21. GPI anchored proteins are also expressed in other life stages of P. falciparum. 
Gamete- and ookinete-stage GPI anchored proteins include Pfs25 and Pfs230, which are 
considered as possible vaccine candidates22–25, while circumsporozoite protein (CSP), the critical 
antigen of the RTS,S and R21 vaccines, is an essential GPI-anchored protein of the sporozoite 
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stages26–30. Thus, it is clear that successful targeting of GPI anchor biosynthesis would not only 
effectively treat symptomatic blood-stage infection, but may also block transmission of the 
parasites at multiple stages. 
One enzyme of the GPI anchor biosynthesis pathway that has yet to be characterized in P. 
falciparum is the putative phosphomannomutase, HAD5 (PMM; PF3D7_1017400). 
Phosphomannomutases (PMMs) are responsible for the conversion of mannose 6-phosphate 
(M6P) to mannose 1-phosphate (M1P), the precursor to GDP-mannose. GDP-mannose is then 
converted to dolichol-p-mannose, which is the building block for incorporating mannose into 
glycolipids. In asexual P. falciparum, the dominant mannosylated glycolipids are GPI anchors31, 
as N-glycans in these parasites only contain N-acetyl glucosamine32–34, so targeting of mannose 
metabolism is predicted to specifically inhibit GPI anchor synthesis. HAD5 is also predicted to 
be essential35, and transcriptomic studies show its expression during the blood stage36,37 and 
sexual stages38, making it a potential multi-stage antimalarial drug target. In this study, we 
characterize the putative phosphomannomutase of P. falciparum, HAD5, demonstrating its 




4.3.1 HAD5 is a phosphomannomutase 
HAD5 (PF3D7_1017400) has been annotated as a putative phosphomannomutase 
through homology to other known phosphomannomutases. Phosphomannomutases are 
responsible for interconverting M6P and M1P to generate M1P for downstream glycolipid 
production, most notably GPI anchors in P. falciparum (Fig. 1A)39–41. To determine the 
 143 
biochemical function of HAD5, we purified recombinant HAD5 (Fig. 1B) and examined its 
hexose phosphate mutase activities (Fig. 1C, S1). We found that HAD5 was active in the 
phosphomannomutase assay (0.56 ± 0.48 µmol/min/mg), with even more robust activity (7.67 ± 
0.06 µmol/min/mg) upon addition of the known co-factor glucose-1,6-bisphosphate (G-1,6-P)41, 
which is comparable to the specific activity of other phosphomannomutases42,43. Furthermore, as 
has been seen for other phosphomannomutases43,44, HAD5 exhibits some promiscuity in its 
substrate preference, as it also displays phosphoglucomutase activity at 0.31 ± 0.03 
µmol/min/mg. Comparing the catalytic efficiencies of HAD5 toward phosphomannose and 
phosphoglucose suggests that phosphomannomutase activity is the dominant enzymatic function 
of HAD5, with a roughly 4-fold higher catalytic efficiency (kcat/Km) compared to its 
phosphoglucomutase activity (Table 1). 
4.3.2 HAD5 is essential for intraerythrocytic parasite growth 
To assess the essentiality of HAD5 in intraerythrocytic parasite stages, we used a 
previously described conditional knockdown system in cultured asexual P. falciparum45,46 (Fig. 
2A). We placed a Tet repressor-binding aptamer array at the 3’- and 5’-end of the endogenous 
HAD5 locus by CRISPR/Cas9-mediated integration. In parasite integrants, the presence of 
anhydrotetracycline (aTc) promotes HAD5 translation, while washing out aTc leads to inhibition 
of translation, and we term this conditional knockdown strain “HAD5KD”. Immunoblotting 
confirms substantial reduction in cellular abundance of HAD5 in the absence of aTc (Fig. 2B). In 
HAD5KD parasites, 0 nM aTc conditions led to an absence of growth, whereas addition of aTc 
promoted growth in a dose-dependent manner (Fig. 2C), indicating that HAD5 is essential for 
asexual growth of P. falciparum. 
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Because phosphosugar mutases often utilize more than one substrate, we examined 
whether the phosphomannomutase activity of HAD5 was responsible for its essential function in 
asexual parasites. Attempts to chemically rescue parasite growth with hexose phosphates such as 
M6P and M1P were unsuccessful (Fig. S2A), as was expected due to the impermeability of the 
erythrocyte and parasite membranes to such highly charged compounds. However, we found that 
simple chemical supplementation of the media with D-mannose was sufficient to rescue growth 
when HAD5 expression is reduced. This indicates that the primary mechanism of death in these 
parasites is due to defects in mannose metabolism (Fig. 2D, S2B). Notably, while artificially 
elevated concentrations of D-mannose completely rescued parasite growth, a physiologically 
relevant concentration of 50 µM [equivalent to that of human serum47] did not provide a 
statistically significant rescue of parasite growth. 
4.3.3 HAD5 is required for parasite egress and invasion 
GPI anchors, which contain mannose16,18,31, are required for egress of the malaria parasite 
from the infected host cell, as well as reinvasion of merozoites46,48–55. Because of its essential 
role in mannose metabolism, we hypothesized that HAD5 may be required for efficient egress 
and invasion. To evaluate this possibility, we washed out aTc at the beginning of the life cycle in 
synchronized parasites. Parasites grown in -aTc conditions over the course of one life cycle 
developed morphologically normally through the majority of life cycle stages, including the 
development of multi-nucleated schizonts. Whereas +aTc conditions allowed parasites to 
continue into the next life cycle and form newly reinvaded “ring”-stage parasites, -aTc parasites 
were arrested in late schizogony (Fig. 2E), which suggests a defect in parasite egress when 
HAD5 expression is knocked down. Notably, when HAD5 expression is reduced, parasites retain 
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normal mature schizont architecture by transmission electron microscopy, indicating that neither 
gross developmental defects nor structural aberrations prevent parasites from egressing (Fig. S3). 
To examine whether HAD5 is required for invasion, as well as egress, we examined the 
reinvasion capacity of HAD5KD parasites. Segmented schizont-enriched cultures of HAD5KD 
±aTc were mechanically lysed and the freed merozoites were allowed to reinvade fresh RBCs. 
Under these conditions, knockdown parasites were unable to reinvade new host cells (Fig. S4). 
Thus, the knockdown of HAD5 confers defects to parasite biology that prevent both egress and 
reinvasion of the parasites. 
4.3.4 HAD5 knockdown disrupts GPI anchor synthesis 
Mannose metabolism is linked to parasite egress through biosynthesis of GPI anchors56. 
In P. falciparum, GPI anchors are synthesized through addition of one glucosamine (GlcN) and 
three to four mannose residues to a phosphatidylinositol backbone. These mannose residues are 
derived from the product of phosphomannomutase, M1P, which is converted to GDP-mannose 
and subsequently to dolichol-phosphate mannose, the direct mannose donor to GPI anchors (Fig. 
3A)57. Several GPI-APs contribute to egress and invasion of parasites16,19,21. We therefore 
hypothesized that reduced HAD5 expression leads to loss of phosphomannomutase activity and 
causes parasite death by disruption of GPI anchor biosynthesis. To directly evaluate the effect of 
HAD5 knockdown on GPI anchor biosynthesis, we labeled mid- to late-trophozoite parasites 
with [3H]-GlcN and extracted GPI precursors as previously described18,56,58,59. HAD5KD parasites 
grown in +aTc conditions had the expected repertoire of GPI anchor precursors (Fig. 3B, 3C). A 
variety of precursors are observed, with earlier, less polar species (with fewer mannose groups) 
migrating further than more polar, highly-mannosylated species. When HAD5 expression is 
reduced, there is a relative accumulation of the earlier precursors, as well as a reduced 
 146 
production of fully mature, highly mannosylated precursors (Fig. 3B), indicating a defect in GPI 
anchor biosynthesis. In particular, there was a significant reduction of the highly polar band 9 
and significant buildup of less polar band 4 when HAD5 expression was reduced (Fig. 3C). 
Intriguingly, despite the substantial knockdown of HAD5 and the complete loss of growth in 
these parasites, the abundance of many mannosylated precursors is unchanged and highly 
mannosylated GPI precursors are still observed, suggesting that this biosynthetic pathway is not 
completely ablated. 
To confirm the role of HAD5 in GPI biosynthesis, we deployed two established chemical 
tools, mannosamine (ManN) and GlcN, which impair growth of P. falciparum through inhibition 
of GPI anchor biosynthesis60,61. We expected that if HAD5 knockdown disrupts GPI anchor 
biosynthesis, parasites should be hypersensitized to ManN and GlcN treatment. Indeed, when 
expression of HAD5 is reduced with an intermediate concentration of aTc (3 nM) that still 
permits modest asexual growth, knockdown parasites yielded a marked shift in half-maximal 
effective concentration (EC50) (Fig. 3D, 3E). These results further implicate HAD5 in the 
production of GPI anchors in P. falciparum. 
4.3.5 HAD5-dependent GPI anchor synthesis enables proper anchoring of 
MSP1 
Reduced GPI anchor biosynthesis in malaria parasites is expected to impact the 
localization and function of a number of essential GPI-anchored parasite proteins. While several 
GPI-anchored proteins have been characterized in P. falciparum intraerythrocytic stages, the 
most abundant is MSP116,17. MSP1 must be targeted and anchored through GPIs and 
proteolytically processed in order for schizont-stage parasites to egress from the erythrocyte, and 
the MSP1 complex is also critical for binding and reinvading new red blood cells19,62. For this 
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reason, we investigated whether HAD5-dependent GPI anchor synthesis is required for 
localization and anchoring of MSP1. We expected that, when the pathway is intact, MSP1 is 
successfully anchored to the parasite plasma membrane. In contrast, when HAD5 expression is 
knocked down, GPI anchors will fail to fully incorporate mannose and GPI-anchored proteins, 
including MSP1, will remain untethered to the membrane (Fig. 3A). To evaluate this effect, we 
used immunofluorescence to detect the localization of MSP1. When schizonts grown in ±aTc 
conditions were mechanically lysed and the resultant merozoites were imaged, there was a 
modest but significant decrease in MSP1 signal surrounding the daughter merozoites when 
HAD5 expression is reduced (Fig. 4A, 4B), indicating that MSP1 membrane attachment is 
diminished, causing it to diffuse away from the cell.  
To independently confirm this finding, we partitioned lysate from early schizont-stage 
parasites into membranous and soluble fractions63. Whole lysate and fractions were assessed by 
immunoblotting for MSP1, and the relative proportion of MSP1 in the membrane fraction 
compared to lysate was calculated. In +aTc conditions, a large proportion of MSP1 separates 
with the detergent-enriched phase, with some full-length MSP1 in the soluble phase. Upon 
HAD5 knockdown, there was a subtle reduction in the proportion of cellular MSP1 bound to the 
membrane (Fig. S5). This difference did not reach significance; however, substantial biological 
variability in MSP1 expression is present within merozoite populations, as indicated in Figure 
4B, and post-hoc power analysis of this data indicates that we were underpowered to observe a 
significant difference (Power = 0.290)64. Together with our analysis of GPI anchor biosynthesis 
in these parasites (Fig. 3), these data confirm some functional preservation of GPI biosynthesis 
when HAD5 expression is reduced. 
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4.3.6 Disruption of mannose metabolism by HAD5 knockdown does not affect 
fosmidomycin sensitivity in parasites 
HAD5 and other phosphomannomutases are part of the haloacid dehalogenase (HAD) 
superfamily of proteins (Interpro: IPR023214), a ubiquitous family of enzymes that primarily 
conduct phosphatase and phosphotransferase reactions65. HAD5 is a member of subfamily IIB 
(IPR006379) of the HAD superfamily and has substantial sequence homology to other P. 
falciparum HAD proteins in this subfamily (HAD1 and HAD2) and the related subfamily IIA 
(IPR006357) protein, phosphoglycolate phosphatase (PGP)66. One notable commonality between 
these subfamily II P. falciparum HAD proteins is their effect on the parasite’s sensitivity to the 
antimalarial fosmidomycin (FSM), which is a well-validated inhibitor of the apicoplast 
methylerythritol phosphate pathway of isoprenoid biosynthesis10. Mutations in either HAD167 or 
HAD268 render parasites resistant to FSM, and PGP-knockout parasites are hypersensitive to 
FSM69. To examine whether HAD5 also plays a role in FSM susceptibility, we assessed the FSM 
dose-response of parasites grown in saturating or intermediate aTc conditions. Unlike its close 
homologs, HAD5 knockdown had no effect on the FSM EC50 of parasites (Fig. S6). 
4.3.7 HAD5 is distinct from human PMMs and can be specifically inhibited 
Previous studies have investigated egress and invasion as a promising target for 
antimalarial drug discovery, suggesting that HAD5 may likewise be of interest for antimalarial 
drug discovery46,48–51; however, phosphomannomutases are found widely throughout nature, 
including two genes in the human genome, HsPMM1 and HsPMM270,71. We therefore evaluated 
the potential for selective inhibition of P. falciparum HAD5 over human PMM1 and PMM2 
(Fig. S7A). Previous work has successfully demonstrated the use of substituted ketoheptoses and 
other phosphosugar analogues as inhibitors of microbial phosphomannomutases72,73, which we 
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sought to replicate with HAD5. Using a panel of 11 phosphosugar analogues (Fig. S8A), we 
screened each compound for its ability to inhibit recombinant HAD5, PMM1, and PMM2. The 
majority of the compounds had negligible inhibition against all three enzymes (Fig. S8). 
Compound D9, however, inhibits purified recombinant HAD5 with a half-maximal inhibitory 
concentration of 79 ± 2.6 µM, several-fold more potently than the inhibition of either PMM1 or 
PMM2 (Fig. 5A). Moreover, we find dramatic time-dependent effects on the ability of D9 to 
inhibit HAD5, as pre-incubating HAD5 with D9 prior to assaying activity substantially increased 
D9 potency, such that a 60-minute pre-incubation yielded HAD5 activity of only 4.5% of a 
vehicle-treated control (Fig. 5B). This effect was not seen for HsPMM1, demonstrating that the 
potential to specifically inhibit HAD5 may be even greater under ideal binding conditions. As 
expected given its poor drug-like characteristics (and likely inadequate cellular permeability), 
compound D9 did not impair the growth of asexual P. falciparum at concentrations up to 100 µM 
(Fig. S9A). The selective inhibition of HAD5 by D9 is an important proof-of-concept that 
distinct structural features of HAD5 may be harnessed for parasite-specific inhibitor 
development.  
 To uncover the structural basis for HAD5-specific inhibition, we solved the crystal 
structure of HAD5 to 3.5 Å resolution. Like other known phosphomannomutases and members 
of the HAD superfamily65,74, HAD5 comprises two domains with an overall fold similar to that 
of HsPMM1 (Fig. 5C, Table S1). There were no large structural differences between the human 
and parasite enzymes, so we next evaluated the substrate-binding pocket by computationally 
docking D9 onto the HAD5 crystal structure (Fig. S9B). Although the overall binding pockets 
were similar and the amino acid sequence within the pocket are highly conserved, subtle 
differences in side-chain positioning may account for the parasite specificity of D9. Further 
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analysis of the binding pocket is restricted by the current resolution of 3.5Å. Furthermore, 
comparing D9 to the inactive compounds D7 and D11, the singular difference is the presence of 
a hydroxyaminomethyl group on carbon 6 of compound D9, whereas an aminomethyl group or 
hydroxymethyl group are present on D7 and D11, respectively (Figure S8A), a difference that 
may explain the disparity in potency and specificity. 
 
4.4 Discussion 
We report here the lethal knockdown and biochemical characterization of the 
phosphomannomutase in P. falciparum, HAD5. Loss of HAD5 leads to growth arrest in 
asexually replicating parasites, marked by defects in egress and reinvasion. This growth defect 
can be rescued by media supplementation with D-mannose, indicating that disruption of 
mannose metabolism is the primary mechanism of death in HAD5KD parasites; however, a 
physiologically relevant concentration of 50 µM D-mannose is unable to significantly rescue 
growth, bolstering the case for this pathway as a therapeutic target. We further report the specific 
inhibition of HAD5 enzymatic activity compared to orthologous human phosphomannomutases 
by the hexose-phosphate analogue, compound D9, highlighting the potential for specific 
therapeutics to be developed to HAD5. 
 Unexpectedly, despite the dramatic decrease in HAD5 protein levels and the compelling 
loss of growth upon HAD5 knockdown, GPI anchor synthesis and MSP1 anchoring to merozoite 
surfaces are only modestly impacted. Residual HAD5 activity may be present after knockdown 
and sufficient for generating detectable GPI precursors and subsequent tethering of some GPI-
APs, including MSP1. Alternatively, P. falciparum expresses two annotated 
phosphoglucomutases (PGMs) (PF3D7_1012500 and PF3D7_0413500)75 that could potentially 
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catalyze phosphomannomutase activity as well, indicating some functional redundancy to 
HAD5. Residual HAD5 or functional redundancy by PGMs could also explain our observation 
that D-mannose rescues HAD5 knockdown. Intracellular mannose is likely converted to M6P by 
hexokinase, and thus some phosphomannomutase activity would still be required for successful 
rescue of the GPI-anchor pathway. In either case, while residual phosphomannomutase activity 
present in HAD5KD may not eliminate GPI synthesis entirely, it is insufficient to sustain parasite 
growth. This speaks to an exquisite sensitivity of malaria parasite cells to disruption in this 
pathway, whereby minor perturbations in GPI anchor synthesis nonetheless completely interrupt 
parasite growth, highlighting the promise of this pathway as a therapeutic target.  
 In addition, we find that HAD5KD parasites have a complete cell cycle arrest, although 
others have found that untethering MSP1 from the membrane by removing its GPI-anchoring C-
terminus still allows for minimal parasite growth19. We expect that this discrepancy is due to the 
role of HAD5 in function of all GPI-anchored parasite proteins, not solely MSP1. These other 
GPI-APs include related MSPs, RAMA, and 6-cysteine proteins, many of which are refractory to 
deletion and likely essential16,21,35,76. With the incomplete loss of GPI synthesis, it may be that 
each one of these GPI-APs, including MSP1, are only relatively de-anchored, but the modest 
reduction in this post-translational modification across multiple cellular proteins works in 
concert to cause parasite growth arrest.  
 We therefore propose that HAD5, as an upstream member of the GPI biosynthesis, has 
great potential as an antimalarial target. We expect that HAD5 inhibition will have broad 
downstream effects on parasite biology across several life cycle stages. That compound D9 has 
markedly improved potency against malaria HAD5 compared to orthologous human enzymes 
provides key proof-of-concept for ongoing development of specific HAD5-directed antimalarial 
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therapeutics. While compound D9 has limited antimalarial efficacy, this is likely due to its 
charged phosphonate, expected to have poor cellular penetration. This liability may be improved 
through a variety of medicinal chemistry strategies, including the addition of pro-drug moieties 
to mask this charge, a strategy that has been highly effective for other phosphonate antimalarials 
in development 77–79. Finally, the crystal structure of HAD5 is likely to be valuable to ongoing 
efforts to develop more potent and specific HAD5 inhibitors as antimalarials. 
 This study also adds to the growing literature on HAD-like proteins in P. falciparum. 
Three related HAD proteins each independently modulate parasite sensitivity to the isoprenoid 
biosynthesis inhibitor FSM, which prompts the question of whether this effect would be similarly 
seen with other HAD proteins67–69. Alternatively, the non-mevalonate isoprenoid biosynthesis 
pathway may be particularly sensitive to cellular metabolic perturbations. We find that HAD5 
serves as an interesting counterexample. HAD5 knockdown yields no changes to FSM 
sensitivity, providing evidence of a HAD protein and a metabolic perturbation that does not 
impact the sensitivity of parasites to inhibition of isoprenoid metabolism. 
 Finally, we note that HAD5 and the GPI anchor biosynthesis pathway are expressed 
throughout the parasite’s life cycle. Several GPI-anchored proteins are expressed in gamete- and 
oocyst-stage parasites80,81, and CSP, the target of the RTS,S malaria vaccine and the more recent 
R21 vaccine candidate26–29, is a GPI-anchored protein expressed on the surface of sporozoites 
that facilitates sporozoite development30 and targets sporozoites to the liver82. Furthermore, 
sexual-stage parasites harbor additional fates of mannose 1-phosphate, including C-
mannosylation83,84 and O-fucosylation85,86, suggesting that HAD5 will play a critical role in 
parasite biology across several life stages. Hence, HAD5 serves an essential role in parasite 
metabolism and shows promise as a specific therapeutic target. The inhibition of HAD5 not only 
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4.5.1 Parasite Strains and Culturing 
Unless otherwise indicated, parasites were maintained at 37°C in 5% O2, 5% CO2, 90% 
N2 in a 2% suspension of human red blood cells in RPMI medium (Gibco) modified with the 
addition of 30 mM NaHCO3, 11 mM glucose, 5 mM HEPES, 1 mM sodium pyruvate, 110 µM 
hypoxanthine, 10 µg/mL gentamicin, (Sigma) and 2.5 g/L AlbuMAX I (Gibco). Deidentified 
RBCs were obtained from the Barnes-Jewish Hospital blood bank (St. Louis, MO), St. Louis 
Children’s Hospital blood bank (St. Louis, MO), and American Red Cross Blood Services (St. 
Louis, MO). 
The HAD5 conditional knockdown strain, “HAD5KD”, was generated by transfecting 
NF54attB parasites87 using previously described methods45,46. Resultant parasites were maintained 
in the presence of anhydrotetracycline (aTc; Cayman Chemicals) in DMSO at 500 nM unless 
otherwise specified. Parasites were synchronized with a combination of 5% sorbitol (Fisher 
Bioreagents) and 1.5 µM Compound 1 (MedChemExpress)88,89 
4.5.2 Plasmodium growth measurement 
Parasitemia in daily growth assays was measured via flow cytometry by incubating 10 µL 
of parasite culture with 190 µL of 0.4 µg/mL acridine orange (Invitrogen) in PBS for 1 minute. 
Stained parasites were analyzed on a BD FACS Canto flow cytometer gating on DNA and RNA-
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bound dye signal using FITC and PerCP-Cy5.5 filters, respectively. 50,000 events were recorded 
for each sample. 
4.5.3 Merozoite reinvasion 
Merozoite reinvasion was assessed as previously described90. Parasites were 
synchronized, grown in ±aTc, and treated with 10 µM epoxysuccinyl-L-leucylamido(4-
guanidino)butane (E64) (Sigma) for 8 hours to stall them in late schizont stages. E64 was washed 
out, and cultures were passed through a 1.2 µm filter to lyse the schizonts. Lysates were 
incubated with fresh red blood cells for 1 hour to allow reinvasion before cultures were washed 
again to remove debris. Parasitemia was assessed 24 hours post-reinvasion by acridine orange 
staining and flow cytometry. Reinvasion efficiency was assessed by normalizing resultant 
parasitemia to the measured parasitemia prior to lysis. 
4.5.4 Light and Fluorescent Microscopy 
Parasite development was monitored by thin smear of synchronized parasites that were 
dyed with modified Giemsa Stain (Sigma). For fluorescent microscopy, E64-treated schizont 
stage parasites were mechanically lysed by passing them through a 1.2 µm filter90. Lysates were 
added to poly-lysine-coated glass slides, fixed in 4% paraformaldehyde, 0.0075%glutaraldehyde 
in PBS, and permeabilized in 0.1% TritonX-100. Immunofluorescence was performed using 
mouse anti-MSP1 monoclonal antibody (Novus Biologicals) and goat-anti-mouse Alexafluor 
488 secondary antibody (Life Technologies). Samples were then preserved with ProLong Gold 
antifade reagent with DAPI (Life Technologies). 
All immunofluorescence and bright field images were taken using a Zeiss AxioObserver 
D1 inverted microscope (Carl Zeiss Inc.), equipped with a Axiocam 503 color camera, at the 
Washington University Molecular Microbiology Imaging facility. Images were acquired with a 
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Plan-Apochromat 100x (NA 1.4) objective using the ZEN 2.3 pro (blue edition) software. 
Fluorescent signal was quantified using the ImageStudioLite software from LI-COR. 
4.5.5 Transmission Electron Microscopy 
For ultrastructural analyses, highly synchronized infected RBCs were fixed in 2% 
paraformaldehyde/2.5% glutaraldehyde (Polysciences Inc., Warrington, PA) in 100 mM sodium 
cacodylate buffer, pH 7.2 for 1 hr at room temperature. Samples were washed in sodium 
cacodylate buffer and postfixed in 1% osmium tetroxide (Polysciences Inc.) for 1 hr at room 
temperature. Samples were then rinsed in dH20, dehydrated in a graded series of ethanol, and 
embedded in Eponate 12 resin (Ted Pella Inc., Redding, CA). Sections of 95 nm were cut with a 
Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with 
uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission electron 
microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8 megapixel digital camera 
and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn, 
MA). 
4.5.6 Cloning 
The coding sequence of HAD5 was cloned from cDNA of 3D7 parasites using primers 
P1 and P2 (Table S2) and cloned into the BG1861 vector91, which introduces an N-terminal 
6xHis-tag, by ligation independent cloning (LIC). This coding sequence was subsequently cut-
and-pasted into a pET28a vector with NdeI and BamHI-HF (NEB), followed by ligation with 
NEB Quick Ligase using manufacturer’s protocols. The coding sequence did not match 
published reference sequence of PF3D7_1017400, as an adenosine-to-guanosine mutation 
yielded an Asn-to-Ser substitution at residue 100. To revert this sequence to the reference 
sequence, primer P3 (Table S2) was used in the QuikChange Multisite-directed mutagenesis kit 
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(Agilent), and the resulting plasmid was transformed into XL10 Gold ultracompetent 
Escherichia coli cells. The HAD5D11A allele was generated from the WT plasmid, again using 
the QuikChange multisite-directed mutagenesis kit and primer P4 (Table S2). Homo sapiens 
PMM1 and PMM2 coding sequences were identified from UniProt, codon-optimized for E. coli, 
and synthesized by Integrated DNA Technologies (Table S3). These gene blocks were amplified 
and extended using primers P5+P6 (PMM1) and P7+P6 (PMM2) and PrimeSTAR GXL DNA 
polymerase (Takara)(Table S2). These sequences were then cloned into the pET28a plasmid by 
Gibson assembly at NdeI and BamHI-HF cut sites, and plasmids were transformed into XL10 
Gold ultracompetent E. coli cells. 
E. coli mannose-1-phosphate guanylyl transferase (ManC) was cloned for use in 
phosphomannomutase assays. The coding sequence of EcManC was identified from UniProt and 
a gene block of the sequence was ordered from Integrated DNA Technologies (Table S3). This 
sequence was cloned by LIC into a BG1861 vector that had been modified with a starting KFS 
sequence downstream of the 6xHis-tag to enhance protein expression92, and the resulting plasmid 
was transformed into Stellar competent cells (Takara). 
4.5.7 Recombinant Protein Expression & Purification 
To generate recombinant protein for enzyme assays and crystallography, the pET28a 
plasmids were transformed into BL21 Gold (DE3) competent E. coli cells (Agilent). Cells were 
grown to optical density at 600nm (OD600) of 0.6-0.8 in Terrific Broth medium (24 g/L yeast 
extract, 20 g/L tryptone, 4 mL/L glycerol, 17 mM KH2PO4, 72 mM K2HPO4) shaking at 37˚C, 
and then induced for approximately 18 hours with 1mM isopropyl-beta-D-thiogalactoside 
(IPTG) at 16˚C. Cells were collected by centrifugation and resuspended in lysis buffer containing 
25 mM Tris HCl (pH 7.5), 250 mM NaCl, 1 mM MgCl2, 10% glycerol, 20 mM imidazole, and 
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100 µM phenylmethylsulfonyl fluoride (PMSF) and lysed by sonication. Lysate was centrifuged 
at 18,000xg for 1 hr and the supernatant containing soluble protein was bound to nickel agarose 
beads (Gold Biotechnology), washed with buffer containing 25mM Tris HCl (pH 7.5), 250 mM 
NaCl, 1 mM MgCl2, 10% glycerol, 20 mM imidazole, and eluted with 10 mL of buffer 
containing 25mM Tris HCl (pH 7.5), 250mM NaCl, 1mM MgCl2, 10% glycerol, and 320mM 
imidazole. Eluate was dialyzed overnight at 4˚C in the presence of 30 units of thrombin protease 
(Sigma) into buffer containing 25 mM Tris HCl (pH 7.5), 250mM NaCl, 1 mM MgCl2, 10% 
glycerol. The dialyzed, thrombin-cleaved mixture was then run over nickel agarose beads and 
benzamidine-sepharose beads (GE Healthsciences) to remove the cleaved His-tag and thrombin. 
The flow through protein was collected and further purified by size-exclusion chromatography 
using a HiLoad 16/60 Superdex-200 column (GE Healthsciences), equilibrated in dialysis buffer. 
Elution fractions containing the protein of interest were identified by UV absorbance and SDS-
PAGE, pooled, and concentrated to 6 mg/mL. Protein solutions were flash frozen in liquid 
nitrogen and stored at -80˚C (Figure 1B, S7A). 
EcManC for enzyme activity assays was expressed by cloning the BG1861:ManC vector 
into BL21(DE3) pLysS E. coli cells (Life Technologies). Cells were grown in LB broth to an 
OD600 of 0.7-0.8 and induced with 1mM IPTG for 2hr at 37˚C. Cells were harvested and protein 
was purified as described for other proteins above. However, as this construct lacked the 
thrombin-cleavable site from the pET28a vector, the elution from nickel beads was directly run 
over the size exclusion column, then pooled and concentrated (Figure S7B). 
4.5.8 HAD5 activity assays 
Phosphomannomutase activity of HAD5 was measured using a linked enzyme scheme 
(Fig. S1A), modified from the EnzChek phosphate release kit (ThermoFisher). 200 µM of 2-
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amino-6-mercapto-7-methyl-purine riboside (MESG) and 1x EnzChek reaction buffer (50 mM 
Tris HCl, 1 mM MgCl2, pH 7.5, containing 100 µM sodium azide) were incubated with 1 U/mL 
Purine Nucleoside Phosphorylase (PNP), 1 U/mL pyrophosphatase, 125 µM GTP, 52 µg/mL 
recombinant purified E. coli ManC, and 1mM mannose-6-phosphate. 12.5 µM glucose-1,6-
bisphosphate was also added to demonstrate its activating properties on HAD5. All reagents 
were obtained from Sigma-Aldrich. The reaction was started by adding 50 ng recombinant 
HAD5 (WT or D11A), which is within the linear range of the assay (Figure S1B). Reactions took 
place in 40 µL, and the production of nucleotide by PNP was measured at 360nM. 
Phosphoglucomutase assays (Fig. S1C) were developed by incubating 1mM glucose-1-
phosphate, 0.75 mM NADP+, 2.5 U/mL glucose-6-phosphate dehydrogenase, and 10 µM 
glucose-1,6-bisphosphate in 50 µL reactions containing 25 mM NaCl, 25 mM Tris HCl pH 7.5, 
and 1 mM MgCl2. All reagents were obtained from Sigma-Aldrich. Again, 50 ng of HAD5 was 
added to start the reaction (Fig. S1D), and the production of reduced NADPH was measured by 
absorbance at 340 nm. 
All reactions took place at room temperature in clear CoStar 96-well half-area plates and 
absorbances were measured by a Perkin Elmer multimode Envision plate reader. For Michaelis-
Menten kinetics of each assay, two-fold serial dilutions of substrate concentrations (either M6P 
or G1P, respectively) were made and all other components of the assays were kept constant.  
4.5.9 Inhibition assays of recombinant HAD5 
Synthesis of compounds D1-D11 (Fig. S8A) have been described previously72,73, with the 
exception of compound D9, whose synthesis is described, and characterization data included, in 
the attached supporting information. To assess inhibition of HAD5, compounds D1-D11 were 
suspended in water and added to the phosphoglucomutase assay of HAD5 activity (the 
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phosphomannomutase assay was not used, as cross inhibition was seen with downstream 
components of that assay, but not with the phosphoglucomutase assay; Fig S8D). 5 µL of water 
volume in the assay was replaced with 5 µL serial dilutions of analogs, with final concentrations 
ranging from 0 µM – 1 mM. The rate of product formation in each condition was used to 
determine the half maximal inhibitory concentration (IC50) for each inhibitor. In addition to 
HAD5, these assays were performed with recombinantly purified human PMM1 and PMM2. For 
these inhibition assays, 200 ng of HAD5 (139 nM), PMM1 (133 nM), or PMM2 (65 nM) was 
used to start the reaction. 
Time-dependent inhibition was assessed by pre-incubating HAD5 or PMM1 in 416 µM 
D9 for time points up to 60 minutes, before adding the enzyme+inhibitor mixture to the full 
reaction mixture, achieving a final [D9] of 50 µM.  
4.5.10 Parasite growth inhibition assays 
Dose-response inhibition experiments were performed on asynchronous parasites. Three 
experimental replicates were performed, with technical duplicates, for each experiment. 
GlcN and ManN inhibition experiments were performed by adding 2-fold dilutions of each 
compound in water, from 0 mM to 2 mM, to a 100 µL culture of parasites. 1 µM of chloroquine 
was used as a positive control. Inhibition of cultured parasites by compound D9 was assessed 
using 100 µM D9 or equivalent volume of water. Parasite growth in these experiments was 
assessed by acridine-orange staining and flow cytometry measurement of parasitemia 72 hours 
after treatment. 
Dose-response of fosmidomycin (FSM) was assessed using concentrations up to 50 µM 
FSM in water, and growth was measured after 72 hour treatment on a PerkinElmer multimode 
Envision plate reader by Quant-iT PicoGreen dsDNA reagent (Thermofisher) staining. 
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4.5.11 Western blotting 
To verify tagging and knockdown of protein, cultures of HAD5KD were grown for 24 
hours in ±aTc conditions, then RBCs were lysed with cold PBS + 0.1% saponin. Samples were 
centrifuged to pellet parasites and remove excess hemoglobin, then parasites were lysed in RIPA 
(50 mM Tris, pH 7.4; 150 mM NaCl; 0.1% SDS; 1% Triton X-100; 0.5% DOC) plus HALT-
Protease Inhibitor Cocktail, EDTA-free (Thermo Fisher). Lysates were centrifuged at high speed 
to pellet and remove hemozoin. Cleared lysates were then diluted in SDS sample buffer (10% 
SDS, 0.5 M DTT, 2.5 mg/mL bromophenol blue, 30% 1 M Tris pH 6.8, 50% glycerol) and 
boiled for 5 min. Lysates were separated by SDS-PAGE, then transferred to 0.45 μm 
nitrocellulose membrane (Thermo Scientific). Membranes were blocked in PBS + 3% bovine 
serum albumin, then probed with primary antibodies: mouse anti-FLAG (M2, Sigma), rabbit 
anti-HSP70 (Agrisera). Membranes were washed in PBS + 0.5% Tween 20, then probed with 
secondary antibodies goat anti rabbit IRDye 800CW 1:20,000 (LI-COR) and donkey anti-mouse 
IRDye 680LT 1:20,000 (LI-COR). Membranes were then washed in PBS + 0.1% Tween 20 and 
imaged on a LI-COR Odyssey platform. 
4.5.12 Autoradiography and GPI anchor quantification 
GPI anchor autoradiography was performed as previously described18,56,58. Briefly, 33-39 
hr old parasites that had been grown in ±aTc conditions were washed and resuspended in 
glucose-free media (RPMI R1383 + 20 mM D-fructose, 25 mM HEPES, 21 mM NaHCO3, 0.37 
mM hypoxanthine, 11 mM glutathione, 5 g/L Albumax I, and 10 µg/mL gentamicin). 150 µCi of 
40 Ci/mmol [3H]GlcN (American Radiochemicals) was added to each 10 mL culture and 
incubated for 3 hours. Parasites were saponin lysed and glycolipids were extracted with 
chloroform:methanol:water (10:10:3), nitrogen evaporation, and n-butanol partitioning59. 
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Resultant glycolipids were run on TLC Silica gel 60 F254 plates (Millipore Sigma) using 
chloroform:methanol:water (10:10:3) as a solvent. TLC plates were exposed to autoradiography 
films (MidSci), which were developed after 1 week of exposure. Films were imaged on a BIO-
RAD ChemiDoc MP imaging system, and signal was quantified by the ImageLab software from 
Bio-Rad. 
4.5.13 TritonX-114 Membrane Partitioning 
Membrane partitioning was adapted from Doering et al.63. Briefly, at approximately 40-
44 hours post invasion, synchronized parasite cultures were magnetically purified (Miltenyi 
Biotec), and elution was centrifuged and resuspended in 1 mL ice-cold Tris-buffered saline 
(TBS) + 1x HALT protease inhibitor (PI) cocktail, EDTA-free (Thermo Fisher). 200 µL 
precondensed Triton X-114 was added to lyse parasites, and lysates were incubated on ice for 15 
min. Lysates were centrifuged to remove debris. Then followed a series of 5 extractions with 
cold TBS+PI and precondensed TritonX-114, followed by warming to 37˚C and centrifugation to 
separate phases. The lysate, detergent-enriched phase, and the soluble phase were analyzed by 
SDS-PAGE and Western blotted as described above using mouse anti-plasmepsin V 1:2093 and 
rabbit anti-HAD1 1:1067, or rabbit anti-MSP1 1:1000 MSP194. Detergent samples were diluted 5-
fold in TBS prior to SDS-PAGE to avoid TritonX-114 interference with the gel. 
4.5.14 Protein Crystallography and Ligand Docking 
Crystals of P. falciparum HAD5 were grown at 4˚C using vapor diffusion in hanging 
drops comprised of 2 µL protein (6 mg/mL) and 2 µL crystallization buffer (0.1M bis -tris-
propane pH 6.5, 0.1 M calcium acetate, 16% (w/v) PEG 8000, and 2% (v/v) benzamidine 
hydrochloride). Prior to data collection, crystals were flash frozen in mother liquor supplemented 
with 25% glycerol. All diffraction images were collected at 100K at beamline 19-ID of the 
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Structural Biology Center at Argonne National Laboratory Advanced Photon Source. HKL3000 
was used to index, integrate, and scale the data sets95. Prior to phasing, a homology model 
of PfHAD5 was created using SWISS-MODEL96 based on human alpha phosphomannomutase 1 
(PDB: 6CFR97, sequence identity 51%). Molecular replacement was performed using PHASER98 
and the homology model of PfHAD5 as a search model. COOT and PHENIX were used for 
iterative rounds of model building and refinement99,100. Data collection and refinement statistics 
are summarized in Table S1. Atomic coordinates and structure factors of PfHAD5 have been 
deposited in the RCSB Protein Data Bank (PDB: 7MYV). 
The PfHAD5 structure was prepared for docking using AutoDock Tools 1.5.7101. The 
three-dimensional structure of compound D9 was prepared using Avogadro102, and was prepared 
for docking using AutoDock Tools 1.5.7. Docking was performed with AutoDock Vina using 















Figure 1. HAD5 is a bifunctional phosphomannomutase/phosphoglucomutase.  
(A) Schematic of phosphomannomutase's role in metabolism. Phosphomannomutases like 
HAD5 interconvert mannose 6-phosphate and mannose 1-phosphate, providing the latter for 
downstream glycolipid production and synthesis of GPI anchors in P. falciparum. (B) SDS-
PAGE gel of recombinant wild-type (WT) HAD5 and a catalytically inactive mutant (D11A). 
(C) Displayed are the mean ± standard error of the mean (SEM) of HAD5 activity across three 
independent trials, with D11A activity subtracted as background. Abbreviations: G-1,6-P, 
glucose-1,6-bisphosphate; PMM, phosphomannomutase assay; PGM, phosphoglucomutase 
assay. p-values were determined using an ordinary two-way ANOVA (Tukey's test for multiple 




Figure 2. HAD5 is essential for intraerythrocytic parasite growth.  
(A) Schematic of the regulatable knockdown system introduced at the native locus of 
PfHAD545,46. (B) Western blot of transgenic HAD5KD parasite lysate ±aTc, using α-HA to detect 
HAD5 and α-HSP70 as a loading control. Removal of aTc results in successful knockdown of 
HAD5. Approximate expected protein masses: PfHSP70, 74 kDa; PfHAD5-3xHA, 32 kDa. (C) 
Fold-change in parasitemia over time of HAD5KD parasites grown in varying concentrations 
of aTc. Data represent mean ± SEM of three independent experiments with technical duplicates. 
Significance was determined by one-way ANOVA with Fisher's LSD; *p=0.03; ***p<0.001. (D) 
Fold change in parasitemia of HAD5KD parasites grown in varying aTc concentrations with D-
mannose rescue. Significance was determined by ordinary two-way ANOVA with Tukey's 
correction for multiple comparisons. ****p<0.0001, ns = not significant. Data represent mean ± 
SEM of three independent experiments with technical duplicates. (E) Bright-field images of 
Giemsa-stained thin-smear synchronized parasites over time. HPI = hours post-invasion. 
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Figure 3. Knockdown of HAD5 disrupts GPI anchor biosynthesis.  
(A) Model of the predicted effect that knocking down HAD5 will have on GPI anchor precursor 
synthesis and subsequent anchoring of GPI-APs. Abbreviations: Ins, inositol; GlcN, 
glucosamine; M, mannose; E, ethanolamine; M6P, mannose 6-phosphate; M1P, mannose 1-
phosphate.  (B) Representative autoradiography film of GPI-anchor-precursors from [3H]GlcN-
labeled parasites. Bands toward the top migrated farthest on a silica TLC plate, indicating they 
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are less polar and less mannosylated. (C) The radiographic signal was quantified and is 
represented as proportions of total signal. Band numbers indicate the corresponding band from 
A. Shown are the mean and SEM of three independent experiments, analyzed by ordinary two-
way ANOVA with Fisher's LSD test. *p=0.038, **p=0.008.  (D,E) Dose response curve of 
parasite growth in the presence of glucosamine (GlcN; D) or mannosamine (ManN; E). Data 




Figure 4. Knockdown of HAD5 diminishes membrane anchoring of the egress and invasion 
protein MSP1.  
(A) Representative immunofluorescent images of mechanically freed merozoites that were 
grown in ±aTc conditions and schizont enriched by E64 treatment. (B) Quantification of MSP1 
signal from A. Data points represent three independent experiments, each with >25 observed 
merozoites, removing those under a threshold of 10,000 RFU. Bar graphs represent the mean + 





Figure 5. HAD5 is sufficiently distinct from human PMMs to be specifically inhibited.  
(A) Dose response curve of compound D9 against recombinant PfHAD5, HsPMM1, and 
HsPMM2. Data represents the mean ± SEM of three independent experiments, each with 
technical replicates. (B) Activity of PfHAD5 or HsPMM1 was assayed after preincubating 
enzymes for the given time with 416 µM of D9 prior to adding the preincubation to the reaction 
mix (final [D9] = 50µM). As a control (ctrl), enzymes were incubated with an equal volume of 
water for 60 minutes. Statistics were performed with an ordinary Two-way ANOVA, using 
Dunnett's test for multiple comparisons. **p=0.0046 ****p < 0.0001, ns = not significant. (C) 
3.5 Å resolution crystal structure of PfHAD5 (orange) aligned to HsPMM1 (cyan; PDB 2FUC) 







Figure S1. Enzymatic activity assays.  
(A) Schematic of the phosphomannomutase (PMM) activity assay, in which HAD5 converts 
mannose 6-phosphate (M6P) to mannose 1-phosphate (M1P). A series of linked-enzyme steps 
translates that activity into a spectrophotometric signal at 360 nm. (B) Graph depicting 
enzymatic activity in the PMM assay with varying HAD5 concentration, demonstrating that our 
chosen value of 50 ng / 40 µL reaction is within the linear range of the assay with respect to 
enzyme concentration. (C) Schematic of the phosphoglucomutase (PGM) activity assay, in 
which HAD5 converts glucose 1-phosphate (G1P) to glucose 6-phosphate (G6P), which is then 
used by glucose 6-phosphate dehydrogenase (G6PDH) to generate NADPH, which can be 
measured at 340 nm. (D) Graph depicting enzymatic activity in the PGM assay with varying 
HAD5 concentration, demonstrating that our chosen value of 50 ng / 50 µL reaction is within the 






Figure S2. Chemical rescue of parasite growth.  
(A) HAD5KD parasite growth was measured in the presence of varying anhydrotetracycline 
(aTc) concentrations with chemical rescue by four different chemicals: mannose 1-phosphate 
(M1P), mannose 6-phosphate (M6P), glucose 1-phosphate (G1P), and glucose 6-phosphate 
(G6P) at 20 µM concentration. Data depicts the mean ± standard error of the mean (SEM) of 
duplicate experiments and represents fold change in parasitemia over time. Statistics were 
performed on the Day 6 parasitemia, using a two-way ANOVA with Dunnett's multiple 
comparisons test, with individual variances computed for each comparison. In all cases, chemical 
rescues were compared to the vehicle control within a given aTc concentration, with no 
significant rescue of growth observed (ns = not significant). (B) Shown are the complete data of 
the fold change in parasitemia over time when HAD5KD parasites are grown in varying aTc and 
D-mannose concentrations. Data represent mean ± SEM of three independent experiments with 






Figure S3. Ultrastructures of HAD5KD schizonts by transmission electron micrograph.  
Transmission electron microscopy of highly synchronized schizont parasites showing successful 
















Figure S4. HAD5 KD Parasites are deficient in reinvasion.  
Schizont-stage parasites 40-44 hours post invasion, grown in ±aTc conditions, were E64-arrested 
as late schizonts for 8 hours, mechanically lysed, and allowed to reinvade over fresh red blood 
cells. 24 hours later, parasitemia was assessed by flow cytometry and normalized to pre-lysis 
schizontemia, demonstrating a deficiency in reinvasion by parasites grown in –aTc conditions. 














Figure S5. TritonX-114 partition of MSP1.  
(A) Representative Western blot of whole lysate (L), membranous fraction (m), and soluble 
fraction (s) of 40-44hr parasites grown in ±aTc, and blotted for MSP1. Full Length (FL) and 19 
kDa fragments of MSP1 are indicated. Plasmepsin 5 (PM5) and HAD1 were used as membrane 
and soluble controls, respectively. Molecular Weight ladder sizes are indicated in kDa on the 
left. (B) Quantification of A. Full Length and MSP119 were summed in each lane, and the 
relative signal in membranous lanes were compared to that of whole lysate. Data represent mean 










Figure S6. Knockdown of HAD5 has no effect on FSM sensitivity.  
72-hour dose-response curves of asynchronous parasites treated with fosmidomycin in either 
intermediate or saturating aTc concentrations. % Growth was relative to a vehicle control. The 
EC50 ± SEM (in µM) for each condition were: 3 nM, 0.57 ± 0.02; 50 nM, 0.62 ± 0.04. Not 














Figure S7. Purified recombinant proteins.  
Coomassie-stained SDS-PAGE gels of final purified forms of recombinant HsPMM1, HsPMM2 





Figure S8. Structures and evaluation of compounds D1-D11.  
(A) Structures of the 11 compounds tested for inhibition against PfHAD5, HsPMM1, 
and HsPMM2. (B) Activity of recombinant PfHAD5, HsPMM1, and HsPMM2 when treated 
with 125 µM of the indicated compounds as a percentage of treatment with a vehicle control. 
Data represent the mean ± SEM of 3 independent experiments with technical replicates. Statistics 
were performed with a two-way ANOVA using Tukey's test for multiple comparisons. 
****p<0.0001. All other comparisons between enzymes for a given compound were not 
significant. (C) Diagram of the amended assay to assess compound inhibition of downstream 
components of the assay. Assays were commenced with the addition of substrate (G6P). (D) 
Quantification of assay shown in C. Assay activity is depicted relative to treatment with a vehicle 
control. Data represent the mean ± SEM of 3 independent experiments with technical replicates. 
Statistics were performed with an ordinary one-way ANOVA using Dunnett's test for multiple 


















Figure S9. Compound D9 does not inhibit parasites in culture.  
(A) Displayed is the percent growth after 72 hours of parasites (starting parasitemia ~1.2%) 
when treated with 100 µM compound D9, compared to vehicle control. The experiment was 
performed on wild type parasites of two different strains (3D7 and NF54), as well as HAD5KD 
parasites ±aTc. Three independent experiments, each with technical replicates, were performed. 
Statistics were performed with an ordinary one-way ANOVA using Tukey's test for multiple 
comparisons, ns = not significant. (B) Shown is the D9 compound (green), computationally 
docked to PfHAD5 crystal structure (orange), highlighting its location in the binding pocket, 
compared to subtle differences in the binding pocket of HsPMM1 (cyan). Mg2+ ions are 




Synthesis of phosphonate analogue of 6NHOH-G1CP (D9) 
Scheme 1. Synthesis of phosphonate analogue of 6NHOH-G1CP (D9) 
 
 
The synthesis of α-D-glucose-1-phosphonate D9 analogue commenced with the selective 
debenzylation-acetolysis (104) of the benzyl C-6 substituent of diethyl-C-(1-Deoxy 2,3,5,6-tetra-
O-benzyl-α-D-gluctopyranosyl) methanephosphonate (1) using a solution of freshly fused ZnCl2 
(5.2 equiv) in 1:5 HOAc–Ac2O in 98% yield. (Scheme 1). We observed that it was important to 
keep the temperature at 0 °C during the course of the reaction (30 min). The precursor 
phosphonate of 1 was synthesized according to our previously reported in three steps starting 
from 2,3,4,6-tetra-O-benzyl-D-glucopyranose 105.  Conventional de-O-acetylation of 2 with 
potassium carbonate in methanol gave the alcohol 3 in high yield. Although deacetylation of the 
acetyl protecting group at C-6 in 2 was first attempted using a mixture 1:3:7 TEA-H2O-MeOH, 
but only poor yields of alcohol 2 was obtained mainly due to low solubility of 2. Synthetic 
alcohol 3 was converted to the corresponding aldehyde 4 by using the Dess-Martin periodinane 
(DMP) in 98% yield (106). First we examined reaction with using 1 equivalent of DMP, but the 
yield was low, then we increased amounts of DMP to 1.5 and 2 equivalents. Our optimal result 
was obtained when we used 1.5 equivalents of DMP. Without further purification, condensation 
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of aldehyde 4 with hydroxylamine hydrochloride in pyridine afforded the desired oxime 5 in 
94% yield 106. Further reduction of 5 with sodium cyanoborohydride (NaBH3CN) under acidic 
condition provided the hydroxylamine 6 in 78% yield 106. Deprotection of both benzyl ether and 
ethyl ester groups was readily accomplished with an excess of iodotrimethylsilane (TMSI) 105,107. 
For preparation of target phosphonate D9, different quantities of TMSI were examined.  With 10 
equivalents of TMSI compound 6, was converted to the final product D9 in 95% yield. It should 




pyran-2-yl)methyl acetate (2).  
 
 
 A solution of ZnCl2 (708 mg, 5.2 eq, 5.2 mmol) in Ac2O/AcOH (5:1, 12 mL) was cooled to 0 °C 
then a solution of 1 (674 mg, 1mmol) in Ac2O/AcOH (5:1, 12 mL) was added dropwise. The 
solution was stirred for overnight at room temperature under N2. After evaporation, the residue 
was suspended in water (20 mL) and extracted with DCM (40 mL x 2). The combined organic 
extracts were dried (MgSO4), filtered and concentrated. Purification by flash chromatography 
(Hexanes-EtOAc, 1:1) afforded compound 2 (660 mg, 98%) as a colorless liquid; Rf 0.50 
(Hexanes-EtOAc, 1:3). 1H NMR (500 MHz, CDCl3), δH (ppm) 1.35 (6H, td, 3JHH = 7.1 Hz, 4JHP 
= 2.4 Hz, 2OCH2CH3), 2.06 (3H, s, CH3CO), 2.20-2.26 (2H, m, CH2-P), 3.57 (1H, t, 3JHH = 9.1 
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Hz, H-4), 3.72-3.75 (2H, m, H-2, H-3), 3.80 (1H, dt, 3JHH = 9.7 Hz, 3JHH = 2.8 Hz, H-5), 4.10-
4.16 (4H, m, 2OCH2CH3), 4.24 (1H, dd, 2JHH = 12.0 Hz, 3JHH = 2.1 Hz, H-6a or H-6b), 4.45 (1H, 
dd, 2JHH = 12.0 Hz, 3JHH = 3.6 Hz, H-6a or H-6b), 4.35-4.56 (1H, m, H-1), 4.58 (1H, d, 2JHH = 
10.9 Hz, CH2 of Bn), 4.68 (1H, d, 2JHH = 11.5 Hz, CH2 of Bn), 4.71 (1H, d, 2JHH = 11.5 Hz, CH2 
of Bn), 4.81 (1H, d, 2JHH = 11.5 Hz, CH2 of Bn), 4.87 (1H, d, 2JHH = 10.9 Hz, CH2 of Bn), 4.94 
(1H, d, 2JHH = 10.9 Hz, CH2 of Bn), 7-28-7.36 (15H, m, 3Ph). 13C NMR (125 MHz, CDCl3), δC 
(ppm) 16.69 (d, 3JCP = 3.7 Hz, 2OCH2CH3), 16.73 (d, 3JCP = 3.7 Hz, 2OCH2CH3), 21.08 
(CH3CO), 22.87 (d, 1JCP = 144.0 Hz, CH2-P), 61.81 (d, 2JCP = 6.4 Hz, OCH2CH3), 62.03 (d, 2JCP 
= 6.1 Hz, OCH2CH3), 63.31 (CH2-6), 69.88 (d, 2JCP = 5.1 Hz, C-1), 70.49 (C-5), 73.34, 75.14, 
75.58 (3CH2 of Bn), 77.40 (C-4), 79.31 (d, 3JCP = 12.7 Hz, C-2), 77.40 (C-3), 127.98, 128.14, 
128.29, 128.67, 128.71, 137.95, 137.99, 138.53 (3Ph), 170.92 (C=O).31P NMR (121 MHz, 
CDCl3), δP (ppm) 28.88. HRMS (ESI, Positive Mode) calcd for C34H43NaO9P [M + Na] + 
649.2537, found 649.2534. 
 
((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-((diethoxyphosphoryl)methyl)tetrahydro-2H-
pyran-2-yl)methyl acetate (3).  
 
To a solution of 2 (626 mg, 1 mmol) in MeOH (30 mL), K2CO3 (500mg, 3.6 mmol) was added at 
room temperature. The resulting solution was then stirred overnight. After evaporation, the 
residue was suspended in water (30 mL) and extracted with DCM (40 mL x 2). The combined 
organic extracts were dried (MgSO4), filtered and concentrated to provide the crude product (543 
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mg, 93%) as a colorless liquid which was used in subsequent reactions without further 
purification (Rf 0.22 (Hexanes-EtOAc, 1:3). 1H NMR (500 MHz, CDCl3), δH (ppm) 1.35 (6H, t, 
3JHH = 7.1 Hz, 2OCH2CH3), 1.78 (1H, brs, OH), 2.04-2.12 (1H, m, CH2-P), 2.32-2.41 (1H, m, 
CH2-P), 3.40 (1H, t, 3JHH = 8.1 Hz, H-4), 3.60-3.67 (1H, m, H-2), 3.73-3.81 (3H, m, H-3, H-6a, 
H-6b), 3.85 (1H, td, 3JHH = 8.3 Hz, 3JHH = 2.6 Hz, H-5), 4.12-4.17 (4H, m, 2OCH2CH3), 4.43-
4.45 (1H, m, H-1), 4.61-4.83 (6H, m, 3CH2 of Bn), 7-29-7.40 (15H, m, 3Ph). 13C NMR (125 
MHz, CDCl3), δC (ppm) 16.62 (d, 3JCP = 5.8 Hz, 2OCH2CH3), 24.38 (d, 1JCP = 144.1 Hz, CH2-P), 
61.97 (d, 2JCP = 5.9 Hz, OCH2CH3), 62.00 (CH2-6), 62.25 (d, 2JCP = 6.4 Hz, OCH2CH3), 68.66 
(d, 2JCP = 5.6 Hz, C-1), 73.42 (CH2 of Bn), 73.89 (C-5), 74.76, 75.14 (2CH2 of Bn), 77.42 (C-4), 
78.88 (d, 3JCP = 13.7 Hz, C-2), 80.79 (C-3), 127.95, 128.02, 128.09, 128.17, 128.19, 128.64, 
128.67, 128.70, 137.98, 138.11, 138.47 (3Ph).31P NMR (121 MHz, CDCl3), δP (ppm) 29.79. 
HRMS (ESI, Positive Mode) calcd for C32H41NaO8P [M + Na] + 607.2431, found 607.2420. 
 
Diethyl(((2S,3R,4S,5S,6S)-3,4,5-tris(benzyloxy)-6-formyltetrahydro-2H-pyran-2-yl) methyl) 




To a solution of 3 (584 mg, 1 mmol) in anhydrous CH2Cl2 (30 mL), Dess-Martin periodinane 
(636 mg, 1.5 mmol, 1.5 equiv) was added at room temperature. The resulting solution was then 
stirred at same temperature for 4h under nitrogen. The solution was diluted CH2Cl2 (30 mL), and 
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then saturated NaHCO3(aq) and saturated Na2S2O3(aq) were added to the reaction sequentially. 
The resulting mixture was stirred for another 30 min at room temperature. The organic layer was 
separated, and the aqueous layer was extracted with EtOAc. The combined organic extracts were 
dried (MgSO4), filtered and concentrated to provide the crude product (547 mg, 94%) as a 
colorless liquid which was used in subsequent reactions without further purification (Rf 0.30 
(Hexanes-EtOAc, 1:3). 1H NMR (500 MHz, CDCl3), δH (ppm) 1.28-1.35 (6H, m, 2OCH2CH3), 
2.11-2.19 (1H, m, CH2-P), 2.31-2.39 (1H, m, CH2-P), 3.52 (1H, dd, 3JHH = 5.3 Hz, 4JHP = 3.3 Hz, 
H-2), 3.76 (1H, t, 3JHH = 5.3 Hz, H-3), 3.81 (1H, t, 3JHH = 4.8 Hz, H-4), 4.09-4.18 (4H, m, 
2OCH2CH3),  4.28 (1H, d, 3JHH = 4.7 Hz, H-5), 4.46  (1H, d , 2JHH = 11.6 Hz, CH2 of Bn), 4.53-
4.57 (3H, m, H-1 and CH2 of Bn ), 4.62-4.70 (3H, m, CH2 of Bn ), 7-20-7.36 (15H, m, 3Ph), 9.83 
(1H, s, CHO). 31P NMR (121 MHz, CDCl3), δP (ppm) 28.67.  
 
Diethyl (((2S,3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-((E)-(hydroxyimino)methyl)tetrahydro-
2H-pyran-2-yl) methyl)phosphonate (5).  
 
 
 To a solution of 4 (582 mg, 1 mmol) in anhydrous pyridine (15 mL), hydroxylamine 
hydrochloride (104 mg, 1.5 mmol, 1.5 equiv) was added at room temperature. The resulting 
solution was then stirred at same temperature for 5h and then pyridine was removed at 50 °C 
under high vacuum. Water (30 mL) was added to the residue and the mixture was extracted with 
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CH2Cl2 (30 mL x 2).  The combined organic extracts were dried (MgSO4), filtered and 
concentrated. Purification by flash column chromatography (Hexanes-EtOAc, 1:2) afforded 
compound 5 as a mixture of E/Z isomers (561 mg, 94%) as a colorless liquid; Rf 0.41 (Hexanes-
EtOAc, 1:3). 1H NMR (500 MHz, CDCl3), δH (ppm) 1.29-1.37 (6H, m, 2OCH2CH3), 2.07-2.50 
(2H, m, CH2-P), 3.43-3.80 (3H, m, H-2, H-3, H-4), 4.06-4.19 (4H, m, 2OCH2CH3), 4.23-4.36 
(1H, m, H-5), 3.48-4.55 (1H, m, H-1), 4.57-4.95 (6H, m, 3CH2 of Bn), 7-15-7.37 (16H, m, 3Ph, 
CH=N), 9.38 (1H, brs, OH). 13C NMR (125 MHz, CDCl3), δC (ppm) 16.52 (d, 3JCP = 6.5 Hz, 
OCH2CH3), 16.60 (d, 3JCP = 6.4 Hz, OCH2CH3), 22.36 (d, 1JCP = 143.2 Hz, CH2-P), 62.05 (d, 
2JCP = 6.4 Hz, OCH2CH3), 62.20 (d, 2JCP = 5.7 Hz, OCH2CH3), 70.10 (d, 2JCP = 5.4 Hz, C-1), 
71.31 (C-5), 73.39, 75.24, 75.43 (3CH2 of Bn), 78.81 (d, 3JCP = 12.9 Hz, C-2), 80.13, 80.71 (C-3, 
C-4), 127.74, 127.82, 128.05, 128.12, 128.21, 128.51, 128.63, 128.70, 137.91, 138.01, 138.71 
(3Ph), 148.14 (CH=N).31P NMR (121 MHz, CDCl3), δP (ppm) 28.96 (minor isomer), 30.46 








 To a solution of 5 (597 mg, 1 mmol) and NaBH3CN (125 mg, 2 mmol, 2 equiv) in MeOH (30 
mL), a solution of HCl (6N in MeOH) was added dropwise at 0 °C until pH 1-3. The resulting 
solution was then stirred at room temperature for 10h. The reaction was quenched by the addition 
of saturated NaHCO3 (aq) and the mixture was extracted with EtOAc (40 mL x 2).  The 
combined organic extracts were dried (MgSO4), filtered and concentrated. Purification by flash 
column chromatography (CH2Cl2-MeOH, 40:1) afforded compound 5 (467 mg, 78%) as a 
colorless liquid; Rf 0.50 (CH2Cl2-MeOH, 40:1). 1H NMR (500 MHz, CDCl3), δH (ppm) 1.35 
(6H, td, 3JHH = 7.1 Hz, 4JHP = 1.7 Hz, 2OCH2CH3), 2.13-2.21 (1H, m, CH2-P), 2.33-2.42 (1H, m, 
CH2-P), 2.82 (1H, dd, 2JHH = 13.6 Hz, 3JHH = 9.5 Hz, H-6a or H-6b), 3.27 (1H, t, 3JHH = 9.3 Hz, 
H-4), 3.40 (1H, dd, 2JHH = 13.6 Hz, 3JHH = 1.7 Hz, H-6a or H-6b), 3.70-3.79 (2H, m, H-2, H-3), 
4.00 (1H, dd, 3JHH = 9.5 Hz, 3JHH = 1.7 Hz, H-5), 4.09-4.22 (4H, m, 2OCH2CH3), 4.35-4.41 (1H, 
m, H-1), 4.62 (1H, d, 2JHH = 11.0 Hz, CH2 of Bn), 4.64 (1H, d, 2JHH = 11.7 Hz, CH2 of Bn), 4.76 
(1H, d, 2JHH = 11.7 Hz, CH2 of Bn), 4.83 (1H, d, 2JHH = 10.9 Hz, CH2 of Bn), 4.87 (1H, d, 2JHH = 
11.0 Hz, CH2 of Bn), 4.92 (1H, d, 2JHH = 10.9 Hz, CH2 of Bn), 7-29-7.36 (15H, m, 3Ph). 13C 
NMR (125 MHz, CDCl3), δC (ppm) 16.61 (d, 3JCP = 4.8 Hz, 2OCH2CH3), 16.64 (d, 3JCP = 4.6 
Hz, 2OCH2CH3), 24.16 (d, 1JCP = 145.7 Hz, CH2-P), 55.59 (CH2-6), 61.96 (d, 2JCP = 6.3 Hz, 
OCH2CH3), 62.68 (d, 2JCP = 6.5 Hz, OCH2CH3),68.97 (C-5), 68.93 (d, 2JCP = 5.6 Hz, C-1), 
73.70, 75.20, 75.71 (3CH2 of Bn), 79.63 (d, 3JCP = 13.4 Hz, C-2), 80.80 (C-4), 82.13 (C-3) 
172.89, 128.00, 128.04, 128.07, 128.09, 128.17, 128.60, 128.71, 138.00, 138.07, 138.58 
(3Ph).31P NMR (121 MHz, CDCl3), δP (ppm) 28.83. HRMS (ESI, Positive Mode) calcd for 




methyl)phosphonic acid (D9).  
 
 
To a solution of 6 (180 mg, 0.3 mmol) in anhydrous CH2Cl2 (3 mL), iodotrimethylsilane (427 μL, 
3.0 mmol, 10 equiv) was added dropwise at 0 °C under nitrogen. The resulting solution was then 
stirred at room temperature for 3h. The reaction was quenched by the addition of methanol. The 
mixture was concentrated, dissolved in H2O (10 mL) and washed with diethyl ether (20mL x 5). 
The aqueous layer was lyophilized to afford the target D9 as a colorless foam (78 mg, 95%). 1H 
NMR (500 MHz, D2O), δH (ppm) 2.01-2.06 (1H, m, CH2-P), 2.21-2.27 (1H, m, CH2-P), 3.31 
(1H, t, 3JHH = 9.5 Hz, H-4), 3.57 (1H, dd, 2JHH = 13.6 Hz, 3JHH = 10.0 Hz, H-6a or H-6b), 3.57-
3.62 (2H, m, H-3, H-6a or H-6b), 3.70-3.75 (1H, m, H-2), 3.92 (1H, dd, 3JHH = 9.8 Hz, 3JHH = 2.3 
Hz, H-5), 4.39-4.41 (1H, m, H-1). 13C NMR (125 MHz, D2O), δC (ppm) 23.29 (d, 1JCP = 136.9 
Hz, CH2-P), 52.50 (CH2-6), 66.28 (C-5), 70.55 (d, 3JCP = 12.9 Hz, C-2), 71.73 (C-4), 72.26 (d, 
2JCP = 5.8 Hz, C-1), 72.60 (C-3). 31P NMR (121 MHz, D2O), δP (ppm) 24.50. HRMS (ESI, 




Figure S10. 1H NMR of compound 2 
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Figure S11. 31P NMR of compound 2 
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Figure S12. 13C NMR of compound 2 
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Figure S13. 1H NMR of compound 3 
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Figure S14. 31P NMR of compound 3 
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Figure S15. 13C NMR of compound 3 
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Figure S16. 1H NMR of compound 4 
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Figure S17. 31P NMR of compound 4 
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Figure S18. 1H NMR of compound 5 
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Figure S19. 31P NMR of compound 5 
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Figure S20. 13C NMR  of compound 5 
 197 
 
Figure S21. 1H NMR of compound 6 
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Figure S22. 31P NMR of compound 6 
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Figure S23. 13C NMR of compound 6 
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Figure S24. 1H NMR of compound D9 
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Figure S25. 31P NMR of compound D9 
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Table 1. Phosphomannomutase and phosphoglucomutase activity of HAD5.  
Displayed are the mean ± SEM of three independent trials for the kinetic parameters of HAD5 
converting M6P to M1P (PMM) or G1P to G6P (PGM). 
 
 
Enzyme Assay kcat (s-1) Km (µM) kcat/Km (M-1s-1) 
PMM 
1.7 x 10-4 
± 1.9 x 10-5 
32 ± 3.6 5.4 
PGM 
7.8 x 10-6 
± 1.2 x 10-6 










Table S1. Summary of crystallographic statistics. 
Crystal PfHAD5 
Space group P6522 
Cell dimensions a=b=161.3. Å, c=109.7 Å 
Data Collection  
Wavelength 0.979 Å 
Resolution range  
(highest shell) 
40.3-3.50 Å (3.56-3.520 Å) 




<I/ > (highest shell) 18.5 (2.7) 
Rsym (highest shell) 33.4% (143%) 
Refinement  
Rcrys / Rfree 25.4% / 31.0% 
No. of protein atoms 3,941 
No. of ligand atoms 2 
R.m.s. deviation, bond lengths 0.003 Å 
R.m.s. deviation, bond angles 0.74° 
Avg. B-factor: protein, ligand 92.7, 59.1 Å2 












For cloning HAD5 sequence from P. 
falciparum cDNA into BG1861 vector 
P2 ATCCTATCTTACTCACTTACAAG
AAATTCTCTCTTAAAATTTTAAC 
For cloning HAD5 sequence from P. 












Forward primer for cloning HsPMM1 gblock 
into pET28a vector. 
P6 CGGAGCTCGAATTCGGATCCTAT
CTTACTC 
Reverse primer for cloning HsPMM1 and Hs 
PMM2 gblocks into pET28a vector. 
P7 CGGAGCTCGAATTCGGATCCTAT
CTTACTCACTTA 
Forward primer for cloning HsPMM2 gblock 






Table S3: gBlock sequences used in cloning 
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The human malaria parasite Plasmodium falciparum has a complex metabolism, with 
unique pathways and regulatory mechanisms that can be exploited for antimalarial therapeutic 
design. To further understand the metabolic networks in these parasites, we sought to 
characterize a subset of the known metabolic regulators, haloacid dehalogenase (HAD) proteins. 
We described the substrate specificity of the enzyme HAD2, explored the function of serine 
phosphorylation in regulating its activity, and characterized its sensitivity to inorganic phosphate. 
We thus developed a model explaining how loss of HAD2 confers resistance to fosmidomycin 
and hypersensitivity to low phosphate media. We also described two related HAD proteins, 
HAD4 and Lipin, demonstrating their dispensability and showing the effects they have on 
metabolism. HAD4 is a nucleotide phosphatase in vitro, and its in vivo metabolic effects are also 
linked to downstream glycolysis, possibly through the regulatory effect that nucleotides exert on 
glycolytic enzymes. Lipin is a phospholipid phosphatase, loss of which causes growth defects 
and dysregulated phospholipid metabolism. Finally, we described HAD5, an indispensable, 
druggable phosphomannomutase of malaria parasites. We demonstrated the essentiality of 
HAD5, and the effect that its knockdown has on parasite egress. We also demonstrated the 
druggability of HAD5 and showed that it can be specifically inhibited compared to human 
phosphomannomutases. Finally, we solved the crystal structure of HAD5, which may aid in 




5.2 Diverse functions of HAD proteins in malaria parasites 
HAD enzymes catalyze a diverse assortment of biochemical reactions in cells, primarily 
involving phosphate transfer, which includes phosphatase, phosphotransferase, and 
phosphosugar mutase reactions1. Herein, we characterized the different reactions and substrate 
specificities of four HAD proteins, demonstrating the breadth of roles that HAD proteins play in 
parasite metabolism. 
5.2.1 The hypothetical role of HAD2 in parasite metabolism 
 Truncating R157X mutations in PfHAD2 have been found to confer resistance to 
fosmidomycin (FSM) at the expense of diminished growth2. We not only found that HAD2 is a 
small molecule phosphatase, but further characterized its substrate specificity. Recombinant 
HAD2 most actively dephosphorylates fructose phosphates and triose phosphates in vitro. The 
dephosphorylation of triose phosphates may help to explain why metabolomic data also shows 
elevated deoxyxylulose 5-phosphate (DOXP) in these parasites, as DOXP is a downstream 
product of triose phosphates. This DOXP elevation if the proximal cause of FSM resistance2. 
We further concluded that fructose 1,6-bisphosphate (FBP) may also be a natural 
substrate of HAD2, explaining the buildup of this metabolite in HAD2R157X parasites as well. 
This also helps explain why these parasites acquired hypomorphic suppressor mutations in 
phosphofructokinase (PFK9), and could suggest that a buildup of FBP might be toxic to the 
parasites. FBP toxicity has been observed when delivered intraperitoneally or intravenously in 
rodents3,4, but we do not have a model for how this might be toxic toward the highly 
glycolytically active parasites, and it merits further investigation. The mechanism of rodent 
toxicity of FBP remains unclear, but could be linked to Ca2+ balance or changes in pentose 
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phosphate pathway functionality4,5, so these may be worth testing in parasites that have elevated 
FBP as well. 
As its natural function in parasites, it remains unclear why it would be advantageous for 
HAD2 to dephosphorylate these triose phosphates or fructose phosphates. Based on our in vitro 
demonstration that HAD2 is potently inhibited by inorganic phosphate (Pi), and the observation 
that HAD2R157X parasites are hypersensitized to diminished growth in low phosphate, we 
concluded that HAD2 may be involved in regulating phosphate homeostasis in the parasites. In 
this model, the triose phosphates and fructose phosphates are simply the sources of phosphate for 
HAD2 to maintain intracellular phosphate levels. 
Finally, we investigated the possible functions of phosphorylating Ser4 and Ser9 of 
HAD2. We produced preliminary evidence that phosphorylation of these residues may lead to 
increased overall HAD2 activity, and possibly to changes in substrate specificity. We reason that 
the kinase(s) responsible for HAD2 phosphorylation may be sensitive to phosphate levels or to 
concentrations of certain phosphometabolites, which has been seen in other systems6. Thus, the 
regulation of HAD2 activity could serve as a feedback mechanism to maintain a balance of free 
phosphate and the phosphometabolites used as phosphate sources. 
Future investigations of HAD2 should focus on clean genetic mutants, including a more 
substantial knockdown or knockout, as well as HAD2-overexpressing parasites. This will 
provide unambiguous genetic differences that can be used for metabolic validation of our model. 
It will also be informative to investigate our FBP toxicity hypothesis, as well as the regulation of 
phosphate homeostasis in parasites. We are particularly interested to know the direct cause of 
defective growth when HAD2 is lost. We hypothesize that reactions requiring free phosphate 
may be dysregulated in these parasites, and propose investigating the important glycolytic 
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enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which uses Pi to produce 1,3-
bisphosphoglycerate7. Another enzyme that could potentially be affected by dysregulated Pi is 
purine nucleoside phosphorylase (PNP), a validated target of quinine and mefloquine8 that is 
involved in the purine salvage pathway and is required for robust parasite growth9. Based on our 
model of phosphate dysregulation, we hypothesize that HAD2R157X parasites will be 
hypersensitized to Pi-dependent enzyme inhibitors like quinine, mefloquine, other PNP 
inhibitors10,11, or GAPDH inhibitors12–14.  
5.2.2 Lessons from HAD5 and the GPI-anchor pathway for antimalarial 
development 
Glycosyl phosphatidylinositol (GPI) anchors have long been of interest in protozoan 
parasites, particularly in trypanosomes, which are densely covered by GPI-anchored proteins 
(GPI-APs)15,16. Even in Plasmodium falciparum, in silico prediction of antimalarial drug targets 
has identified phosphomannose isomerase (PMI), which is directly upstream of 
phosphomannomutase in GPI biosynthesis, as a potentially promising antimalarial target17. The 
allure of inhibiting GPI-anchors in parasites stems from their universal expression, and likely 
essentiality, throughout all stages of the parasite’s life cycle, as well as evidence that protein-free 
GPI anchors contribute to toxicity during infection18. Despite this, few studies19 have 
intentionally sought to design or repurpose existing drugs like those that target PMI in other 
organisms20–22 as antimalarials, nor has PMI in P. falciparum been published on at all.  
With our characterization of HAD5, a phosphomannomutase in parasites that is essential 
for development, we bolster the case for targeting the GPI-anchor biosynthesis pathway in 
malaria parasites. At present, our HAD5 inhibitor D9 is not effective in cultured parasites, likely 
due to limited cell permeability, but we propose that simple strategies could be implemented to 
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optimize potency and increase permeability of D9. In parallel, repurposing known inhibitors of 
PMI and PMM23 from other systems could also be tested for use in intraerythrocytic parasites as 
well as sexual-, mosquito-, and liver-stage parasites. With our crystal structure of HAD5 in hand, 
more rational design and optimization of these compounds can also be implemented. Although 
our 3.5Å resolution crystal structure may not be perfected for rational drug design yet, as side 
chain orientations are not fully resolved, this structure does lay the foundation for future 
structure determination, and our experience demonstrates the ease with which HAD5 can be 
purified and crystallized. 
In addition to developing drugs to target intraerythrocytic parasites, we also hope to 
develop a genetic strategy for validating mosquito-stage essentiality of P. falciparum genes like 
HAD5. Using our HAD5KD parasites, we plan to induce gametocytogenesis and feed 
gametocytes to mosquitos, which will then feed on either +aTc or -aTc nectar. At present, it 
remains unclear if ingested aTc will be able to penetrate the mosquito midgut epithelium to 
access developing parasites, so we hope to validate this as a method to inducibly test gene 
essentiality throughout multiple life stages. If successful, this method of inducible knockdown 
within mosquitos could then be applied to many other potential drug targets believed to be 
essential in mosquito-stage parasites, a strategy that is currently lacking in the field of malaria 
parasite genetic editing24. 
Finally, the story of inhibiting HAD5 adds to an age-old debate of target-based 
approaches versus whole-cell phenotypic screening in antimalarial discovery25,26. The potential 
disadvantages of starting with a target first, as we did with HAD5, are: there may not be any 
known compounds to inhibit the target of interest, those that do exist may not have good drug-
like qualities, and there may be a disconnect between in vitro potency and in vivo efficacy or 
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essentiality. However, in the modern era of parasite genetics, with CRISPR/Cas9 and inducible 
knockdown or knockout systems, our ability to effectively predict in vivo efficacy and gene 
essentiality has been greatly improved. While we did encounter issues with drug-like qualities of 
our D9 compound, great strides have also been made in medicinal chemistry to improve 
permeability27–29, making this strategy more feasible. Lastly, the critique that target-based 
approaches risk the absence of existing inhibitors remains valid. However, we argue that this risk 
can be minimized by focusing on metabolic targets. As we observed with HAD5 in collaboration 
with Dr. David Jakeman, inhibitors to metabolic enzymes can easily be conceived and 
synthesized using the enzyme’s natural substrate as a backbone. This has successfully been used 
for other phosphomannomutases30,31, and we demonstrated its effectiveness with HAD5. 
Therefore, with modern advances in genetic editing of parasites and optimization of drug-like 
characteristics, we argue that target-based approaches remain a valid strategy to compete with 
high-throughput phenotypic screening, and the GPI-anchor biosynthesis pathway is a promising 
candidate for antimalarial drug development. 
5.2.3 Other HAD proteins of interest 
We have demonstrated that PF3D7_0303200 is a phospholipid phosphatase, termed 
Lipin, and have shown that it is necessary for robust growth of the parasites32. Future studies 
using in vitro biochemical assays to validate the substrate specificity of PfLipin may be 
interesting, as well as uncovering how Lipin activity is regulated, as it is expected to have many 
phosphorylation sites33–38. In other systems, Lipins are dephosphorylated by the Dullard/Nem1 
protein phosphatase, which activates Lipin39,40. Notably, Dullard proteins contain a Nuclear LIM 
Interactor-interacting factor (NLI-IF) domain41, which is also present in at least three P. 
falciparum HAD genes: NIF2 (PF3D7_0515900), NIF3 (PF3D7_1355700), and NIF4 
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(PF3D7_0726900)42. Of particular interest to us is NIF4, because both PfLipin and PfNIF4 have 
been found to be mutated in a resistance screen for the compound MMV665917 (Appendix A). 
Determining the target of this antimalarial compound, as well as elucidating how Lipin and NIF4 
might be involved in resistance, is worth investigating further. 
We also use both in vitro biochemical assays and cultured parasite metabolic labeling to 
demonstrate that HAD4, which clusters closely with previously described P. falciparum HAD 
members42, is a nucleotide phosphatase. Although loss of HAD4 did not affect parasite viability 
or growth, the disruption of nucleotide metabolism may be exploitable with inhibitors of 
nucleotide salvage and synthesis pathways. We also find that downstream glycolytic 
intermediates are elevated in HAD4 knockouts. Based on trends we have seen with HAD1, 
HAD2, and phosphoglycolate phosphatase (PGP)2,43,44, we hypothesize that this may also lead to 
elevated MEP pathway intermediates, and thus resistance to FSM. Lastly, further investigation of 
how HAD4 is indirectly linked to glycolysis may be useful in our greater understanding of 
parasite metabolic networks. 
The HAD superfamily is a vast and varied assortment of proteins, and the list of P. 
falciparum HAD proteins is representative of this42. For that reason, future endeavors to study 
HAD proteins must prioritize those with higher likelihood of importance, interest, and expected 
function. Because the subfamily II members have thus far been among the most well 
characterized, we recommend continuing to investigate those and their nearest homologs. One 
particularly intriguing enzyme has been termed HAD3 (PF3D7_1226100), the last of the 
subfamily II HAD proteins in the genome. HAD3 is predicted to be both essential45 and widely 
expressed across many parasite life stages46,47. Although we have experienced that homology 
cannot predict substrate specificity, we note that homologous proteins to HAD3 are involved in 
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flavin metabolism48,49, which would be worth exploring with HAD3 as well. Our attempts to 
purify soluble, recombinant HAD3 are described in Appendix B, as are recommendations for 
how to move forward with optimizing its purification and using genetic tools to test its function. 
 
5.3 Reexamining the link between HAD proteins and the 
MEP pathway  
We have previously hypothesized that the emergence of HAD proteins as mediators of 
FSM resistance in parasites2,43,44 may be evidence for one of two possible scenarios: 1) HAD 
proteins, or at least subfamily II HAD proteins, are somehow inherently linked to MEP pathway 
metabolism or 2) the MEP pathway is finely metabolically tuned, and is sensitive to slight 
perturbations in parasite metabolism. Our observations that HAD5 knockdown yields no changes 
to FSM sensitivity in parasites serve as a counterexample to both of these hypotheses. While 
large-scale metabolomics was not performed with HAD5KD parasites, we did demonstrate 
HAD5’s function as a metabolic enzyme, and therefore conclude that perturbation of at least one 
branch of metabolism – mannose and GPI metabolism – has no effect on FSM sensitivity. 
Resistance to FSM was not investigated in Lipin and HAD4 knockout parasites, but these 
would be interesting additions to the dataset. As a lipid phosphatase, we expect that Lipin may be 
too far removed from the MEP pathway to confer changes to FSM resistance, similar to HAD5. 
Conversely, HAD4 knockout led to changes in glycolytic intermediates, particularly triose 
phosphates like glycerol-3-phosphate and glyceraldehyde 3-phosphate (Gly3P)32. While we 
believe this is only an indirect effect of HAD4’s activity upon regulatory nucleotides, the 
increased triose concentrations, especially Gly3P, could easily feed into the MEP pathway and 
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confer FSM resistance. Interestingly, HAD4 was never found to be mutated in screens for FSM 
resistance, despite its amenability to knockout. This could suggest that HAD4 mutation might 
not, in fact, alter FSM sensitivity, or it could simply be the result of an unsaturated screen. 
In light of our HAD5 findings and further investigation of HAD2, we amend our model 
of HAD proteins and FSM resistance. It seems the critical changes to metabolism required to 
alter FSM sensitivity may involve the triose phosphates. Rather than being uniquely sensitive to 
all metabolic perturbations, we hypothesize that the MEP pathway in parasites is particularly 
sensitive to disruptions in triose phosphate metabolism, as these are the precursors that feed into 
the pathway50. In this model, HAD enzymes are therefore linked to FSM resistance only insofar 
as they perturb triose phosphate levels, an effect that may be enriched in subfamily II HAD 
proteins. In the case of HAD1 and HAD2, these two highly homologous enzymes likely act 
directly upon triose phosphates, and are thus the most closely linked to FSM resistance. 
However, because of its sensitivity to inorganic phosphate inhibition and its possible role in 
intracellular phosphate homeostasis, the loss of HAD2 has less effect on triose phosphate levels 
than HAD1, explaining why it emerged less frequently than HAD1 in FSM resistance screens. 
As for phosphoglycolate phosphatase (PGP), knockout of this enzyme leads to lower levels of 
dihydoxyacetone phosphate (DHAP)44, which enters the apicoplast to feed into the MEP 
pathway50, and thus causes FSM hypersensitivity. 
 Because HAD enzymes are typically believed to be promiscuous in substrate 
utilization51, and are an enormous superfamily of primarily phosphatase enzymes, it is reasonable 
that several HAD enzymes have been implicated in triose phosphate metabolism and 
subsequently MEP metabolism. While not all HAD enzymes alter triose phosphate metabolism, 
we hypothesize that disrupted triose phosphate levels – by HAD enzymes or by other means – 
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will reliably yield altered FSM sensitivity in organisms that harbor the MEP pathway. It may be 
interesting to test this hypothesis in other organisms and with other enzymes, such as with E. 
coli, whose HAD enzymes and other phosphatases have been more extensively characterized49,52. 
 
5.4 Final Thoughts 
The urgent need for new antimalarial therapeutics and vaccines is clear, and a deeper 
understanding of parasite biology will lead to the discovery of new potential drug targets. Given 
the many prior successes of targeting metabolic pathways with antimalarials53,54, further 
elucidating key metabolic enzymes in parasites is a promising avenue of drug target discovery. 
As established regulators of metabolism, HAD proteins represent an untapped resource for our 
understanding of parasite metabolism. Because of their wide variety in function, from P-type 
ATPases to sugar phosphatases to phosphomannomutases 42,49,51,55, as well as the incongruence 
between sequence homology and substrate specificity, it is difficult to predict the function of 
novel HAD proteins a priori. However, at the very least, the type of enzymatic activity (e.g., 
phosphatase vs. phosphomutase) appears predictable, and the mechanism of catalysis, with Mg2+ 
ions coordinated by catalytic aspartate residues, is generally conserved1,51. Therefore, HAD 
proteins represent a reservoir of metabolic regulators with relatively predictable function and 
ease of investigation. Some, such as HAD5, are essential and possible drug targets themselves, 
while dispensable HAD proteins like HAD2 or HAD4 may still play important and exploitable 
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Appendix A: Searching for the target of 





















This work was conducted by Dana Hodge and myself, under the guidance of Dr. Audrey 
Odom John and in collaboration with Dr. Chris Huston and his lab. DH performed the resistance 
screening and quantified parasite resistance, and I entered the project to help analyze whole 
genome sequencing and validate hits through Sanger sequencing and recombinant enzyme 
assays. Because I was not involved in the resistance screening and quantification, the methods 
from that part of the project are omitted here. The presented data, as well as commentary on 
other genes of interest, was handed off to Dr. Huston’s lab to pursue further with a targeted 
approach in Cryptosporidium. 
 
A.1 INTRODUCTION 
One valuable toolbox at researchers’ disposal for the development of new antimalarial 
therapeutics is the Malaria Box, a selection of ~400 compounds known to exhibit antimalarial 
activity that were collected by the Medicines for Malaria Venture (MMV)1. To further optimize 
these compounds, many researchers have sought to uncover these compounds’ targets so that 
future medical chemists can optimize the target specificity and potency. One frequently 
implemented strategy to identify these targets is through drug resistance screens. In this method, 
parasites are cultured in low concentrations of the compound, gradually increasing the 
concentration in a stepwise fashion over long periods of time—several weeks in the case of 
Plasmodium falciparum. This process pressures parasites to evolve resistance, and the resultant 
growing parasites’ whole genomes are sequenced to identify any single nucleotide 
polymorphisms (SNPs) or other genetic aberrations that could feasibly be causing the resistance 
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phenotype. This was the method our lab implemented to evolve resistance to fosmidomycin, 
uncovering resistant parasites with hypomorphic SNPs in HAD1 and HAD22,3.  
Malaria Box compounds often not only exhibit antimalarial activity, but are also active 
against other parasites. The Malaria Box compound MMV665917 has shown promise as an anti-
cryptosporidial agent, with in vitro and in vivo efficacy against the apicomplexan parasites 
Cryptosporidium parvum and Cryptosporidium hominis4–7. To further optimize this compound, 
which is a derivative of piperazine, Dr. Christopher Huston’s lab at the University of Vermont 
was interested in determining the Cryptosporidium target of MMV665917. However, culturing 
methods of Cryptosporidium spp. are in their nascent stages8–10, and time-intensive techniques 
like a long resistance screen was not a practical method of identifying the target of MMV665917 
in those parasites. Therefore, Dr. Huston’s lab reached out to us to evolve resistance to the 
compound in P. falciparum. We reasoned that, because both Plasmodium and Cryptosporidum 
share an apicomplexan parasite lineage, identifying the target in the former would strongly 
suggest the target in the latter. With that in mind, Dana Hodge and I set about trying to identify 
the P. falciparum target of MMV665917. 
 
A.2 RESULTS 
A.2.1 Evolving resistance to MMV665917 in P. falciparum 
Wild-type P. falciparum parasites (“MR4E”, 3D7 background) exhibit a roughly 4.9 µM 
half-maximal effective concentration (EC50) to MMV665917. To evolve resistance, parasites 
were grown in three different concentrations higher than the EC50 : 10 µM (2x EC50), 20 µM (4x 
EC50) and 50 µM (10x EC50). However, these concentrations appeared to be too high, and no 
parasites were capable of definitive growth. 
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 We next set up a step-wise selection of parasites, working up to 5 µM, which ultimately 
led to successful continuous growth of parasites in 5 µM MMV665917. The EC50’s were only 
modestly increased however, and clean curves were difficult to obtain due to the insolubility of 
MMC665917 at high concentrations. To demonstrate resistance through another method, we 
chose a single concentration of the compound, 25 µM, and compared growth of parasites as a 
percentage of maximum (vehicle control) growth. Six parasite strains were obtained that 
demonstrated resistance compared to the MR4 control (Figure 1). Each of the resistant strains 
were cloned to obtain clonal populations.  
A.2.2 Sequencing of MMV665917-resistant clones 
Two clones from each resistant strain were subjected to whole genome sequencing 
(WGS). Across all clones, 2693 SNPs were identified from the WGS, which were sorted and 
prioritized based on the following criteria on the basis of likelihood to be real and likelihood to 
be causative: presence in both clones, not in known highly-variable genes such as var genes, and 
not found in our previous screens. Several genes were eliminated from these criteria, and the 
genes that remained were: TFIIH complex member XPB (PF3D7_1037600), the HAD 
superfamily member Lipin (PF3D7_0303200), the HAD superfamily member NLI-interacting 
phosphatase (PF3D7_1012700), HAD5 (PF3D7_1017400), aldo-keto reductase 
(PF3D7_1409100), serine/threonine protein kinase (PF3D7_0214600), structural maintenance of 
chromosomes protein 1 (PF3D7_1130700), histone deacetylase 2 (PF3D7_1008000), PRP2 
(PF3D7_1231600), deoxyribodipyrimidine photo-lyase (PF3D7_0513600), and pyruvate kinase 
(PF3D7_0626800) (Table 2). Some of these were further ruled out because although the specific 
SNPs had not been observed before, other SNPs within those genes had been seen in other 
screens. 
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Due to our interest in HAD proteins, we were especially interested in the three HAD 
proteins that emerged from these screens, particularly HAD5, as we had already begun 
independently investigating HAD5 when we received these WGS results. However, subsequent 
Sanger sequencing of the HAD5 locus revealed that this was not a real SNP, and the connection 
to HAD5 was lost. Nonetheless, the other two HAD proteins remained of interest. Furthermore, 
while the mutation in pyruvate kinase (PK) was only found in the clones of one resistant strain, it 
was in strain R5.9, which had the highest resistance. Taken together with the high likelihood of it 
being an impactful mutation (Ile408Asn), Sanger sequencing confirmation that this SNP was 
real, and the pivotal role that PK plays in central carbon metabolism, we were interested in 
further pursuing PK as an important gene to investigate.  
A.2.3 MMV665917 does not target RBC glycolysis 
We first aimed to investigate the possibility that MMV665917 might be targeting (either 
primarily or via off-target effects) a host enzyme within the RBC. In particular, if pyruvate 
kinase is the parasite target of the compound, then it could feasibly also inhibit the host pyruvate 
kinase as well. To evaluate whether RBC pyruvate kinase is inhibited by MMC665917, we 
quantified methemoglobin (MetHb) in MMV665917-treated, uninfected RBCs (uRBCs). MetHb 
is hemoglobin in which the heme-bound iron is in its oxidized (Fe3+) form, rather than reduced 
(Fe2+). Under normal conditions, when the cell can maintain proper redox metabolism, MetHb is 
quickly reduced to the Fe2+ form, which permits the binding of oxygen and therefore proper 
functioning. This reductive capacity is in part fueled by glutathione metabolism and NADH as an 
electron transporter11,12. Previous work from our lab demonstrated that inhibiting downstream 
components of RBC glycolysis results in a loss of reductive capacity, and an increase in relative 
MetHb levels13. Our previous work demonstrated this effect when subjecting RBCs to the 
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compound POMHEX, an inhibitor of RBC enolase, which is directly upstream of pyruvate 
kinase in glycolysis. We reasoned that a similar effect would be observed if RBC pyruvate 
kinase was inhibited, and tested the ability for MMV665917 to induce a buildup of MetHb in 
uRBCs. We found that MMV665917 treatment does not result in increased MetHb signal, even 
at concentrations much higher than that of POMHEX (Figure 2). This demonstrates that redox 
metabolism of the RBC is not disrupted by MMV665917, and suggests that RBC glycolytic 
enzymes like pyruvate kinase are not targeted by the drug. 
A.2.4 Testing parasite Pyruvate Kinase as the target of MMV665917 
To test the hypothesis that MMV665917 inhibits PfPK directly, we expressed and 
purified recombinant wild-type PfPK from E. coli, as well as the I408N mutant (Figure 3). Using 
a KinaseGlo kit that detects the production of ATP when PK is incubated with ADP and 
phosphoenolpyruvate (PEP), we found that the I408N mutation did not have any observable 
effect on PK catalysis of the ADP+PEP to ATP+pyruvate reaction (Figure 4). Moreover, using 
concentrations up to 1200 µM, there was little detectable inhibition of either WT or I408N PK 
activity by MMV665917 (Figure 4). While statistically significant differences are observed 
between DMSO treatment and several of the treated conditions, the effect was not dose-
dependent, and we hypothesize that more experimental replicates would erase those differences. 
These data demonstrate that PfPK is not the direct target of MMV665917, but raise the 
possibility that the I408N mutation somehow helps PfPK compensate for other mutations in the 
genome, similar to the suppressor mutations that emerge in PFK9 after HAD2 is mutated. 
Notably, Ile408 is located near the interfaces between monomers within the homotetrameric 
structure of PfPK (Figure 5), suggesting that the mutation might affect oligomerization states. 
However, size exclusion chromatography of both the WT and I408N mutant reveal that both 
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proteins eluted after roughly the same volume, 66-70 mL, which corresponds to the expected size 
of the tetramer in both cases (Figure 3). 
  
A.3 Discussion 
The cellular target of MMV665917 in P. falciparum, and in Cryptosporidium spp., 
remains unresolved. While we demonstrate here that pyruvate kinase activity is not inhibited by 
MMV665917, it is unclear what might have driven the I408N mutation to arise. This point 
mutation, and indeed any mutations to PfPK, have not been observed in any other resistance 
screens, suggesting that some form of selective pressure drove it to arise in the R5.9 parasites. 
This mutation does not appear to affect PK activity, nor does it alter oligomerization state of the 
enzyme.  
 There do remain some unexplored metrics of PK function that could be assayed to 
identify the function of the I408N mutation. PfPK is unlike many PKs from other species, as it is 
not activated by fructose 1,6-bisphosphate nor fructose 2,6-bisphosphate. However, PfPK is 
activated by glucose 6-phosphate (G6P) and inactivated by pyridoxal-5’-phosphate (PLP), ATP, 
oxalate, and citrate, so perhaps the I408N mutation sensitizes or ablates regulation by those 
means14,15. Notably, this residue is directly adjacent to the identified “effector site” of PfPK 
where G6P potentially binds (Fig. 5)15, suggesting that PfPKI408N may lose its allosteric 
regulation. Furthermore, some glycolytic enzymes are known to serve multiple “moonlighting” 
functions apart from their glycolytic activity. This is particularly notable in glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), which has been implicated in membrane fusion, 
endocytosis, iron transport, and RNA binding16–20. As for pyruvate kinase, are documented cases 
of its ability to moonlight as a protein kinase of histones21 and as a mediator of plant 
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mitochondria-chloroplast colocalization22. Perhaps PfPK shares some of these moonlighting 
roles (the P. falciparum mitochondrion and apicoplast are also closely associated23), or harbors 
another as-yet undescribed function, and the I408N mutation affects a non-glycolytic role of the 
enzyme. More rigorous phenotypic characterization of these parasites, as well as further 
assessment of allosteric regulation with in vitro assays, will help illuminate the function of the 
I408N mutation.  
 Apart from pyruvate kinase, several other genes of interest arose from our WGS that have 
yet to be fully examined. Of particularly interest to us are the two HAD proteins, Lipin and NLI-
interacting protein. We have previously seen that knockout of Lipin causes dramatic growth 
defects in parasites and accumulation of various lipid species like ceramides and phosphatidic 
acid24. Furthermore, NLI-interacting protein shares homology to the mammalian Dullard protein, 
a known phosphatase of Lipin that activates Lipin activity by dephosphorylating it. That two 
genes within the same pathway (one being a possible activator of the other) would be mutated in 
this screen at random is unlikely, and indicates that the function of Lipin as a lipid phosphatase is 
linked to the mechanism of MMV665917 inhibition.  
While it remains unclear if or how pyruvate kinase mutation is also linked to Lipin/NLI-
interacting protein, a tempting parallel can be drawn between this mutation pattern and that of 
HAD2 and PFK9: a HAD protein is mutated to confer resistance to a given inhibitor, causing a 
growth defect. Subsequently, mutation to a glycolytic enzyme compensates for that growth 
defect. In this case, we know that loss of Lipin diminishes growth, so if the Lipin mutation 




A.4.1 Cloning of Recombinant Enzyme Plasmids 
The pET15-MHL plasmid containing wild-type PfPK was obtained from Addgene 
(Catalog # 25278), which was deposited by Wernimont et al. after its use in the solving of the 
PfPyrK crystal structure (PDB: 3KHD). To prepare for robust protein expression, this PyrK 
sequence was cloned out of the pET15-MHL vector using primers PMF115 and PMF117, and 
subsequently with PMF116+PMF117, which add a ligation-independent cloning (LIC) extension 
onto each end (Table 1). This sequence was then inserted into our pKFS plasmid, a derivative of 
BG186125 that has a KFS sequence at the N-terminus to promote expression26. 
 To clone the I408N mutant, a TAT sequence encoding Ile was replaced with an ATT 
sequence that encodes Asn in the PMF116/PMF117 amplicon. This was achieved by amplifying 
the sequence in two segments, with primers PMF116+PMF119 and PMF117+PMF118 (Table 1), 
representing the N-terminal half and the C-terminal half of the sequence, respectively. PMF118 
and PMF119 primers are long enough to anneal with high fidelity to most of the sequence, but 
introduce the mutated codon in the middle. These two amplicons were then amplified together 
with PMF116+PMF117 to obtain a final mutated coding sequence, which was LIC-cloned into 
the pKFS vector as well.  
A.4.2 Purification of Recombinant Enzymes 
pKFS plasmids containing either WT or I408N variants of PfPK were transformed into 
chemically competent BL21(DE3) pLysS E. coli cells (ThermoFisher). These cells were grown 
in 4 L of LB media at 37˚C, shaking, until mid-log phase, then induced with 1mM IPTG at 37˚C 
for 2 hours. Cells were spun down, resuspended in Lysis Buffer (10 mM Tris HCl (pH 7.5), 
200mM NaCl, 1 mM MgCl2, 4 µL/L benzonase, 20 mM imidazole, 1 mM DTT, 1 mg/mL 
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lysozyme, and cOmplete EDTA-free protease inhibitor cocktail), and sonicated. Lysates were 
spun down, and soluble supernatants were purified by affinity to nickel agarose beads (Gold 
Biotechnology). Nickel-eluted protein was loaded onto a HiLoad 16/60 Superdex 200 column 
(GE HealthSciences), run with protein dilution buffer (25 mM Tris pH 7.5, 250 mM NaCl, 1 mM 
MgCl2), and fractions containing protein were pooled, concentrated, and flash-frozen for storage. 
A.4.3 Pyruvate Kinase enzyme assays 
  Pyruvate kinase activity was assayed using the KinaseGlo Luminescent Kinase Assay 
(Promega), following manufacturers protocols. Briefly, 100µl assays were performed, containing 
50 µL KinaseGlo Reagent, 4 µL of serial dilutions of MMV665917, 5 µL of 10 ng/µL pyruvate 
kinase, and 500 µM each of ADP and PEP, with protein dilution buffer filling the balance to 
100µL. Assay was allowed to proceed for at least 5 minutes, measuring the production of 
luminescence, and was performed in duplicate. 
A.4.4 Detection of MetHemoglobin 
 To assess whether MMV665917 was inhibiting the RBC glycolytic enzymes, such as 
RBC pyruvate kinase, we spectrophotometrically measured the production of MetHb in RBCs 
treated with the drug, as has been described previously13. 25 µl of serial drug dilutions was added 
to 75 µL of 3% hematocrit human blood in RPMI media, both with MMV665917 diluted in 
DMSO, as well as POMHEX diluted in DMSO, which is an inhibitor of RBC enolase13. This 
was allowed to incubate 72 hours, after which the production of MetHb was detected by 







Figure 1. Relative growth inhibition in MMV-resistant parasites.  
Parasite strains that emerged from stepwise resistance screens up to 5 µM were assessed for % 
maximal growth when grown at 25 µM MMV665917. Dashed line represents % growth 








Figure 2. MetHemoglobin production in RBCs treated with MMV665917.  
Ratio of MetHemoglobin (Abs630) to Oxyhemoglobin (Abs575) when uRBCs are treated with 
MMV665917. POMHEX is an inhibitor of RBC enolase, and serves as a positive control of 
MetHemoglobin formation. Depicted are the means ± SEM of three independent experiments 
with technical replicates. 
 
 





















Figure 3. Size Exclusion Chromatography gels of recombinant PK.  
(A) Wild-type and (B) I408N PfPK were expressed and purified from E. coli, nickel purified, and 
fractionated after size exclusion chromatography. Shown are Coomassie-stained gels of the size 












Figure 4. Activity of PK.  
(A)  Diagram of the pyruvate kinase assay, which generates ATP, to be used with a luciferin-based 
KinaseGlo kit. (B) Activity of wild-type and I408N PK in the pyruvate kinase assay when 
MMV665917 is added in increasing dosage. Data represent mean ± SEM of two replicates. 
Statistics were performed by 2-way ANOVA with Dunnett’s test for multiple comparisons. For a 



















































**p<0.01,***p<0.001. Columns without significance indicated are not significant. Statistics 





Figure 5. PfPK structure (PDB: 6KSH).  
Highlighted in green is Ile408, demonstrating its position near the interfaces between chains of the 
homotetramer and location within “Effector Site”-containing C-domain (pink). Structure and C-





Table 1. Primers used for cloning 
NAME SEQUENCE 
PMF115 5’ CATCCTTCAAGTACAAGAATTCGGCGGCCGGCGCAAGTAT 3’ 
PMF116 5’ CTCACCACCACCACCACCATTCATCCTTCAAGTAC 3’ 
PMF117 5’ ATCCTATCTTACTCACTCACTCAATTTGTACCACC 3’ 
PMF118 5’ TGCCGTAGAAACCGCAGAGTCAAATCAGGCGAGCC 3’ 
PMF119 5’ AGGGCAATGATCAGGCTCGCCTGATTTGACTCTGC 3’ 
 
 
Table 2. SNP list of specific genes of interest. 
Single Nucleotide Polymorphisms, and their expected amino acid changes, are given for specific 
genes of interest out of the 2693 identified SNPs across all strains. Numbers indicate the number 
of WGS reads at that locus that found the given SNP. 
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Between our findings with HAD1, HAD2, HAD4, HAD5, and Lipin1–3 as well as 
Dumont et al.’s published work on phosphoglycolate phosphatase4, there is a growing 
appreciation for the regulatory role that HAD proteins serve in parasite metabolism and drug 
resistance. The HAD proteins that have been described thus far generally cluster together, and 
one phylogenetically related gene that remains unstudied is HAD3 (PF3D7_1226100) (Chapter 
1, Figure 1).  
In addition to its phylogenetic similarity to other HADs of interest, HAD3 is intriguing 
because published transcriptomics demonstrate its expression in asexually replicating parasites, 
as well as even higher expression in gametocytes, oocysts and sporozoites5,6. As these stages of 
the parasite are important for transmission of malaria, deeper understanding of their metabolic 
regulation could be invaluable. Furthermore, transposon mutagenesis screens show that HAD3 is 
non-mutable, suggesting its essentiality in blood-stage parasites7. However, the Plasmodium 
berghei ortholog of HAD3 (PBANKA_1441000) is dispensable in a similar screen for 
essentiality, the PlasmoGem screen8. This data also claimed the HAD5 ortholog to be 
dispensable, which is not true of P. falciparum, highlighting the differences between P. 
falciparum and P. berghei and leaving open the question of HAD3 essentiality. 
Many of the HAD proteins from Escherichia coli have been described and characterized9, 
and that data serves to generate hypotheses of functions to orthologous proteins in other 
organisms. The E. coli gene most closely related to HAD3 is the 5-amino-6-(5-phospho-D-
ribitylamino)uracil phosphatase, YbjI. This enzyme in E. coli catalyzes an essential step in 
riboflavin biosynthesis10, as well as dephosphorylation of flavin mononucleotide (FMN)9. Thus, 
we hypothesize that HAD3, too, may be involved in flavin metabolism in P. falciparum 
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parasites. It should be noted however, that PfHAD4 also demonstrated highest homology to a 
FMN phosphatase, YigB, though its activity more closely mimicked that of YrfG, as shown in 
Chapter 3. Thus, homology alone is not a strong predictor of the substrate specificity of HAD 
proteins, and direct biochemical and metabolic investigation is necessary.  
In P. falciparum, riboflavin is taken up from the host cells and media and is essential for 
or utilized by >30 different parasite enzymes, including dihydroorotate dehydrogenase 
(DHODH) and the shikimate pathway enzyme, chorismate synthase, both of which are under 
investigation as drug targets11–15. If HAD3 is involved in regulating flavin metabolism in 
parasites, it may represent a critical point of metabolic control that could be exploited in 
conjunction with therapeutics that target these flavin-dependent pathways.  
Historically in our lab, several others have attempted to purify HAD3, to no avail. 
However, because I set my sights on HAD proteins as a whole, I believed that I could spend 
more time and effort optimizing its purification. Therefore, to investigate the function of HAD3, 
I attempted to express and purify recombinant HAD3 to assay its enzymatic activity. 
 
B.2 RESULTS 
B.2.1 Expression and purification of HAD3 from P. falciparum 
Earlier work from our lab had cloned the coding sequence of PfHAD3 from the genome 
into the BG1861 vector. Although this was successful, IPTG-induction of this strain exhibited 
minimal increased protein expression (Figure 1A). We reasoned that the gene sequence was 
simply not optimal for protein synthesis in E. coli, so we obtained a recodonized form of the 
gene, optimized for expression in E. coli. This was cloned into our pKFS expression vector. 
Expression of the codon-optimized PfHAD3 continued to be only modestly induced (Figure 1B) 
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but we decided to continue with it in the hopes of obtaining enough protein with large volumes 
of culture.  
 After lysis and separation of these cells, however, it became clear that the majority of 
PfHAD3 was insoluble, as it mostly appears to be present in the insoluble pellet rather than the 
soluble supernatant. A small portion of nickel-bound protein appears after the soluble fraction is 
bound, washed, and eluted from nickel beads, but the low signal suggests that a huge volume of 
culture would be necessary to eventually get enough HAD3 for enzyme assays (Figure 2), and it 
appears lower than expected so likely is not even HAD3.   
 Other strategies to help obtain more soluble HAD3 were attempted, including the use of 
ArcticExpress competent cells, which induce at 4˚C to allow slower synthesis and less potential 
for aggregation, as well as the addition of a maltose-binding-protein tag to confer solubility. In 
both cases, the resultant protein continued to be primarily or exclusively found in the insoluble 
fraction (not shown).  
B.2.2 Expression of orthologous HAD3 enzymes 
Because of our lack of success purifying recombinant Plasmodium falciparum HAD3 
from E. coli, we reasoned that perhaps an orthologue from a related Plasmodium species may be 
more amenable to recombinant expression and purification. Using the protein solubility predictor 
ProsoII16, we found that the Plasmodium orthologs with the highest predicted solubility were that 
of P. vivax (PVX_123935) and Plasmodium cynomolgi HAD3 (PCYB_145180). We therefore 
obtained gene blocks for these enzymes, codon-optimized for E. coli expression, and cloned 
them into the pKFS expression vector. Again, however, despite fairly robust expression, virtually 




It is not uncommon for recombinantly expressed heterologous proteins to be insoluble. 
The added effort of extra protein production can stress the protein folding machinery and cause 
excess misfolded proteins and aggregation17. This can be compounded by mismatched codon 
availability between the heterologous gene and the expression organism, as well as unavailability 
of eukaryote-specific post-translational modifications when expressing in prokaryotic systems 
like E. coli18. In PfHAD3, there are no predicted post-translational modifications, and codon-
optimization for E. coli expression should have ameliorated most of the problems with 
mismatched codon availability, increasing the %GC content of native HAD3 from 28% to 41%, 
much closer to the ~50% GC content of the E. coli genome.  
 While the exact reason for the insolubility of PfHAD3 remains unclear, several strategies 
can be employed to overcome insolubility. One common method of maximizing protein 
solubility is low growth temperature. At a lower temperature, protein synthesis slows down, 
allowing protein folding machinery more time to correctly fold newly synthesized 
polypeptides18,19. Unfortunately, our attempts to express HAD3 at lower temperatures were not 
successful in preventing insolubility. 
 Another strategy that has been described is to isolate the aggregated insoluble proteins, 
termed inclusion bodies in bacteria, and subject the misfolded proteins to denaturing conditions. 
That denatured protein can then be applied to a wide screen of buffer conditions to allow 
refolding to occur20–22. Additionally, expression in eukaryotic systems, such as mammalian, 
yeast, or insect cells23–25 may be more amenable to maintaining HAD3 as a soluble product.  
 Lastly, we can turn to endogenous HAD3 within parasites. In the last several years, 
genetic modification of P. falciparum parasites has improved immensely, allowing for the 
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tagging, knockout, knockdown, and knock-sideways of native parasite genes, often in an 
inducible manner26. Targeting the endogenous locus of HAD3 would not only help provide a 
phenotypic understanding of HAD3’s role in parasite metabolism and biology, but would also 
allow for immunoprecipitation of tagged HAD3, which could then be used for in vitro 
biochemical assays to validate activity and substrate specificity. 
We propose that future efforts to investigate HAD3 should follow the above strategies of 
endogenous genetic modification, and attempts at recombinant protein expression would be wise 
to utilize a eukaryotic expression system, as mentioned. Deeper understanding of the potential 
role of HAD3 in parasite biology, possibly through flavin metabolism, could prove valuable for 
related efforts to therapeutically target flavin-dependent enzymes in the parasites. Furthermore, 
understanding this sexual-stage expressed enzyme  will deepen our understanding of 
extraerythrocytic parasite metabolism. 
 
B.4 METHODS 
B.4.1 Expression and Purification of PfHAD3 
The native sequence of PfHAD3 was originally cloned from genomic P. falciparum DNA 
using primers SE03 and SE04 (Table 1) and ligation-independent cloning (LIC) was used to 
insert it into the BG1861 vector as previously described. This plasmid was kept stored in a 
frozen glycerol stock of Top10 chemically competent cells for long-term storage, and was 
transformed into BL21(DE3) pLysS cells (ThermoFisher) for protein expression.  
 Codon optimized PfHAD3, pre-cloned into the BG1861 vector, was ordered directly 
from Genewiz. To assist with protein induction, this sequence was cloned out of BG1861 and 
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into the BG1861-derived pKFS vector using primers PMF49 and PMF50 (Table 1). Cloning was 
again performed by LIC.  
 For both the native and codon-optimized PfHAD3 sequences, cultures of BL21(DE3) 
pLysS cells containing the plasmid of interest were grown shaking at 37˚C in LB media until 
they reached mid-log phase. Protein expression was then induced with 1mM IPTG, and cultures 
were grown overnight at 18˚C. Cells were then pelleted, resuspended in Lysis buffer (25 mM Tris 
HCl (pH 7.5), 250 mM NaCl, 1 mM MgCl2, 20 mM imidazole, and cOmplete EDTA-free protease 
inhibitor cocktail), and sonicated. Lysates were then spun to pellet the insoluble fraction, and the 
soluble supernatant was bound to nickel agarose beads (Gold Biotechnology) for 2 hours. Beads 
were washed 3 times in Wash buffer (Lysis buffer without imidazole or protease inhibitors) and 
eluted with 10ml of elution buffer (lysis buffer + 300 mM imidazole). After failing to see 
appreciable quantities of HAD3 in this elution by Coomassie gel, no further purification was 
attempted.  
B.4.2 Expression and Purification of PvHAD3 and PcHAD3 
Gene blocks of PVX_123935 and PCYB_145180, including 5’ and 3’ extensions for LIC 
cloning, were ordered from IdtDNA. These gene blocks were LIC-cloned into the pKFS vector 
and kept in Stellar competent E. coli cells.  
 These plasmids were then transformed into BL21(DE3) pLysS cells for protein 
expression. Cells were grown in just 4 mL of LB until mid-log phase, and induced with 1 mM 
IPTG at 16˚C overnight. Cells were pelleted, and lysed with Lysis Buffer + 1x BugBuster 
Protein Extraction Reagent (Novagen) for 20 minutes at room temperature. Lysates were spun 




Figure 1. Induction of PfHAD3 protein expression.  
PfHAD3 was expressed using either the native sequence cloned from genomic DNA (A) or a 
recodonized sequence that was optimized for E. coli expression (B). In both cases, induction 
appears modest, and it is likely the lower band of the observed doublet, indicated by arrows, that 
represents HAD3. Expected protein size for HAD3 is 37.2 kDa for the native sequence in the 




Figure 2. Lysis and Nickel affinity of PfHAD3.  
Shown is a Coomassie-stained gel of post-sonication crude lysate (Lys), the insoluble pellet 
(Pell), and soluble supernatant (Sup) samples of post-induction pKFS-HAD3 (codon optimized). 
Then, the protein was poured over nickel beads, and the flowthrough (FT) and three washes 
(W1-W3) are shown, as well as the elution off nickel beads (E). The arrow indicates possible 







Figure 3. Expression of HAD3 from P. vivax and P. cynomolgi.  
Coomassie-stained gels of the induction and partial purification of HAD3 from P. vivax (A) and 
P. cynomolgi (B). Expected sizes of PvHAD3 and PcHAD3 are 39.5 kDa and 28.2 kDa, 
respectively, indicated by the arrows. Abbreviations: pre, pre-induction sample; post, post-










Table 1. Primers Used for Cloning 
Name Sequence 
SE03 5’ CTCACCACCACCACCACCATATGTTAAAACACAAATATAACGATTCATGT 3’ 
SE04 5’ ATCCTATCTTACTCACTTAAGAGCGCCTTCCAGATAAAAC 3’ 
PMF49 5’ CTCACCACCACCACCACCATCTGAAACAT 3’ 
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